Benzimidazole modulators of vr1

ABSTRACT

The invention is directed to compounds of Formula (I): 
     
       
         
         
             
             
         
       
     
     to pharmaceutical compositions containing such compounds and to methods of treatment using them.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims the benefits of the filing of U.S. application Ser. No. 11/734,984 filed Apr. 13, 2007, and U.S. Provisional Application No. 60/797,504 filed May 3, 2006. The complete disclosures of the aforementioned related patent applications are hereby incorporated herein by reference for all purposes.

BACKGROUND OF THE INVENTION

Noxious chemical, thermal and mechanical stimuli excite peripheral nerve endings of small diameter sensory neurons (nociceptors) deriving from sensory ganglia (e.g., dorsal root, nodose and trigeminal ganglia) and initiate signals that are perceived as pain. Such nociceptive neurons (i.e., nociceptors) are crucial for the detection of harmful or potentially harmful stimuli (e.g., noxious thermal, chemical, and/or mechanical) that arise from changes in the extracellular environment during inflammatory, ischemic or otherwise traumatic conditions and that cause or have the potential to cause tissue damage (Wall, P. D., and Melzack, R., Textbook of Pain, 1994, New York: Churchill Livingstone).

Nociceptors transduce noxious stimuli into membrane depolarization that leads to an action potential, its subsequent conduction to the CNS, and ultimately to the perception of pain, discomfort, etc. as well as to certain responses thereto. At the molecular level, nociception is carried out by ion channels and/or receptors. Plant-derived vanilloid compounds (e.g., capsaicin and resiniferatoxin) are known to selectively depolarize nociceptors and elicit sensations of burning pain: the sensation that is typically evoked by capsaicin-containing hot chili peppers. Therefore, capsaicin mimics the action of physiological/endogenous stimuli that activate the “nociceptive pathway”. Recent advances in pain biology have identified a receptor, called VR1 (a.k.a. capsaicin receptor or TRPV1) for vanilloids, protons and noxious heat. Because nociceptors are drivers of unwanted pain and inflammatory conditions in human beings and animals, modulation of their function is a validated strategy for palliative and other analgesic therapies.

Compounds that are modulators (competitive and non-competitive agonists or antagonists [with respect to capsaicin and/or its recognition site] and allosteric modulators) at VR1 have broad therapeutic potential, as demonstrated by the clinical usefulness of marketed, VR1-targeted pharmaceutical agents or the efficacy of VR1 modulators in animal models of disease. Furthermore, it is recognized that agonist modulators of VR1 may possess clinical utility deriving from their agonist properties, per se, and/or from their ability to produce an agonist-mediated desensitization, which would indirectly manifest as a functional antagonism. Similarly, antagonist modulators could exhibit direct antagonist (competitive or non-competitive) properties and/or indirect antagonist properties via the aforementioned desensitization mechanism. It is further recognized that positive and negative allosteric modulators may produce any or all of the aforementioned functional consequences and, as such, may also have clinical utility. Accordingly, this invention is directed to each of these types of modulators.

The effective use of VR1 agonists has been demonstrated in inflammatory, neuropathic, and visceral pain states. In an experimental human pain model, dermal capsaicin pretreatment reduced the pain caused by intradermal injection of an acidic solution (Bianco, E. D.; Geppetti, P.; Zippi, P.; (solani, D.; Magini, B.; Cappugi, P. Brit J of Clin Pharmacol 1996, 41, 1-6), suggesting the benefit of VR1 agonists in the treatment of inflammatory pain. A particular role for VR1 agonists has been shown in inflammation and inflammatory pain: for example, resiniferatoxin prevented inflammatory hypersensitivity and edema induction by carrageenan (Kissin, I.; Bright, C. A.; Bradley, E. L., Jr. Anesth Analg 2002, 94, 1253-1258).

Additionally, capsaicin-containing creams (for example, Axcain® and Lidocare®) are marketed for dermal relief of pain related to diabetic neuropathy and postherpetic neuralgia, indicative of the usefulness of VR1 agonists in the treatment of neuropathic pain states. Furthermore, such creams have been shown to reduce postsurgical neuropathic pain (Ellison, N., Loprinzi, C. L., Kugler, J., Hatfield, A. K., Miser, A., Sloan, J. A., Wender, D. B., Rowland, K. M., Molina, R., Cascino, T. L., Vukov, A. M., Dhaliwal, H. S, and Ghosh, C. J. Clin. Oncol. 15:2974-2980, 1997). In cancer patients, capsaicin contained in a taffy vehicle, was shown to substantially reduce oral mucositis pain caused by chemotherapy and radiation therapy (Berger, A., Henderson, M., Naadoolman, W., Duffy, V., Cooper, D., Saberski, L. and Bartoshuk, L. J. Pain Sympt. Mgmt 10:243-248, 1995.

VR1 also plays a role in the physiology of bladder emptying. VR1 is expressed by bladder sensory neurons, where it modulates bladder responsivity to liquid filling. The VR1 agonist resiniferatoxin desensitized bladder afferents in a dose-dependent manner (Avelino, A.; Cruz, F.; Coimbra, A. Eur. J. Pharmacol. 1999, 378, 17-22), supporting its usefulness for the treatment of overactive bladder (Chancellor, M. B.; De Groat, W. C. J. Urol. (Baltimore) 1999, 162, 3-11). Indeed, intravesicular administration of capsaicin or resiniferatoxin inhibited bladder contraction in both normal and spinal cord injured rats (Komiyama, I.; Igawa, Y.; Ishizuka, O.; Nishizawa, O.; Andersson, K.-E. J. Urol. (Baltimore) 1999, 161, 314-319), indicative of the usefulness of VR1 agonists in nerve-injured incontinent patients. The effectiveness of capsaicin or resiniferatoxin treatment on incontinence in spinal cord injured patients was confirmed in a clinical study (de Seze, M.; Wiart, L.; de Seze, M.-P.; Soyeur, L.; Dosque, J.-P.; Blajezewski, S.; Moore, N.; Brochet, B.; Mazaux, J.-M.; Barat, M.; Joseph, P.-A. Journal of Urology (Hagerstown, Md., United States) 2003, 171, 251-255).

The effectiveness of VR1 agonists in the reduction of elevated blood pressure is suggested by capsaicin reduction in blood pressure in SHR and WKY rats (Li, J.; Kaminski, N. E.; Wang, D. H. Hypertension 2003, 41, 757-762.). Capsaicin was also gastroprotective with respect to gastric antral ulcers (Yamamoto, H.; Horie, S.; Uchida, M.; Tsuchiya, S.; Murayama, T.; Watanabe, K. Eur. J. Pharmacol. 2001, 432, 203-210).

VR1 antagonists also may be useful in the treatment of inflammatory, neuropathic and visceral pain. For example, the therapeutic utility of VR1 antagonists has been demonstrated in visceral inflammatory conditions. VR1 is elevated in colonic nerve fibers in patients with inflammatory bowel disease, and VR1 antagonists relieved pain and dysmotility (Yiangou, Y.; Facer, P.; Dyer, N. H.; Chan, C. L.; Knowles, C.; Williams, N. S.; Anand, P. Lancet 2001, 357, 1338-1339). Intestinal inflammation induced by toxin A or dextran sulfate sodium in rodents was attenuated by VR1 antagonists (McVey, D. C.; Schmid, P. C.; Schmid, H. H. O.; Vigna, S. R. J. Pharmacol. Exp. Ther. 2003, 304, 713-722). In addition, a synthetic VR1 antagonist reduced colitis disease scores at several important endpoints, including macroscopic damage, microscopic epithelial damage, myeloperoxidase levels, and diarrhea scores, strongly supporting the therapeutic use of VR1 antagonists in inflammatory bowel diseases (Kimball, E. S.; Wallace, N. H.; Schneider, C. R.; D'Andrea, M. R.; Hornby, P. J. Neurogasteroenterology 2004, 16, 811-818). The VR1 antagonists capsazepine and BCTC reversed mechanical hyperalgesia in models of inflammatory and neuropathic pain in guinea pigs (Walker, K. M.; Urban, L.; Medhurst, S. J.; Patel, S.; Panesar, M.; Fox, A. J.; McIntyre, P. J. Pharmacol. Exp. Ther. 2003, 304, 56-62) and rats (Pomonis, J. D.; Harrison, J. E.; Mark, L.; Bristol, D. R.; Valenzano, K. J.; Walker, K. J. Pharmacol. Exp. Ther. 2003, 306, 387-393).

LPS-induced fever was attenuated in VR1 knock out mice (Lida, T.; Shimizu, I.; Nealen, M. L.; Campbell, A.; Caterina, M. Neurosci. Lett. 2005, 378, 28-33). VR1 agonist-induced rises in core body temperature were suppressed by capsazepine, indicative of the usefulness of VR1 antagonists in the treatment of pyresis (Ohnluki, K.; Haramizu, S.; Watanabe, T.; Yazawa, S.; Fushiki, T. J. Nutr. Sci. Vitaminol. (Tokyo) 2001, 47, 295-298).

VR1 agonists also modulate body temperature and fever. In ferret, rat and mouse, administration of resiniferatoxin-induced hypothermia (Woods, A. J.; Stock, M. J.; Gupta, A. N.; Wong, T. T. L.; Andrews, P. L. R. Eur. J. Pharmacol. 1994, 264, 125-133). Additionally, phase I of LPS (lipopolysaccharide)-induced fever did not occur in animals desensitized with low intraperitoneal doses of capsaicin (Romanovsky, A. A. Frontiers in Bioscience 2004, 9, 494-504).

The therapeutic potential of VR1 antagonists in inflammatory bronchial conditions is demonstrated by the finding that they antagonize capsaicin- and acid-induced bronchoconstriction (Nault, M. A.; Vincent, S. G.; Fisher, J. T. J. Physiol. 1999, 515, 567-578). Related findings demonstrate that the VR1 antagonist capsazepine attenuates anandamide-induced cough in guinea pigs (Jia, Y.; McLeod, R. L.; Wang, X.; Parra, L. E.; Egan, R. W.; Hey, J. A. Brit. J. Pharmacol. 2002, 137, 831-836).

The VR1 antagonist capsazepine was demonstrated to significantly reduce anxiety-like behaviors in rats using the elevated plus maze (Kasckow, J. W.; Mulchahey, J. J.; Geracioti, T. D. Jr. Progress in Neuro-Psychopharmacol. and Biological Psychiatry 2004, 28, 291-295). Thus, VR1 antagonists may have utility in the treatment of anxiety, panic disorders, phobias or other non-adaptive stress responses.

U.S. Pat. No. 6,299,796B1 discloses electroluminescent elements comprising units of the formula:

Thus, there is a need for potent modulators of VR1, and in particular, for novel benzimidazole compounds that exhibit potent binding affinity for the human and rat VR1 ion channel. There is also a need for novel benzimidazole compounds that act as potent functional antagonists and/or agonists of the human and rat VR1 ion channel. Finally, there is a need for novel benzimidazoles that bind with high affinity to VR1 and also act as potent functional antagonists of the human and rat VR1 ion channel.

SUMMARY OF THE INVENTION

The present invention is directed to a compound of Formula (I):

and a form thereof, wherein R₁, R₂, R_(3a), R_(3b), R₄, p, q, r, L and A₁ are as defined herein, and their use as potent modulators of VR₁.

The present invention is also directed to a method for treating a VR₁ ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I). The present invention is further directed to a process for making a compound of Formula (I) and salts thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds of Formula (I):

and a form thereof, wherein:

-   the dashed lines between positions 1, 2 and 3 in Formula (I)     indicate the positions of a tautomeric double bond, -   wherein when a double bond is formed between positions 1 and 2, then     R_(3b) is present, and -   wherein, when a double bond is formed between positions 2 and 3,     then R_(3a) is present; -   p is 1 or 2; -   q is 0 or 1; -   r is 0, 1, 2 or 3; -   L is C₁₋₃alkyl, C₂₋₃alkenyl, C₂₋₃alkynyl or cyclopropyl; -   A₁ is selected from the group consisting of phenyl, biphenyl,     naphthyl, pyridinyl, quinolinyl and indole; -   R₁ is each selected from the group consisting of hydroxy, cyano,     halogen, formyl, carboxy, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy,     haloC₁₋₆alkoxy, C₁₋₆alkylcarbonyl, C₁₋₆alkoxycarbonyl,     C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₃₋₈cycloalkyl,     C₃₋₈cycloalkyl-C₁₋₄alkyl, C₃₋₈cycloalkyl-C₁₋₄alkoxy,     C₃₋₈cycloalkyl-oxy, amino, (C₁₋₆alkyl)₁₋₂-amino,     (C₃₋₈cycloalkyl)₁₋₂-amino, (C₃₋₈cycloalkyl-C₁₋₄alkyl)₁₋₂-amino,     aminocarbonyl, (C₁₋₆alkyl)₁₋₂-aminocarbonyl, C₁₋₆alkylcarbonylamino,     C₁₋₆alkoxycarbonylamino, aminocarbonylamino,     (C₁₋₆alkyl)₁₋₂-aminocarbonylamino, C₁₋₆alkylsulfonylamino,     C₁₋₆alkylsulfinylamino, aminosulfonyl, (C₁₋₄alkyl)₁₋₂-aminosulfonyl,     aminosulfonylamino and (C₁₋₆alkyl)₁₋₂-aminosulfonylamino, -   wherein alkyl is optionally substituted with C₁₋₈alkoxy, amino,     (C₁₋₄alkyl)₁₋₂-amino, C₁₋₆alkylcarbonylamino,     C₁₋₆alkoxycarbonylamino, aminocarbonylamino,     (C₁₋₆alkyl)₁₋₂-aminocarbonylamino, C₁₋₆alkylsulfonylamino,     aminosulfonylamino, (C₁₋₆alkyl)₁₋₂-aminosulfonylamino hydroxy and     phenyl, -   wherein phenyl is optionally substituted with one, two or three     substituents independently selected from the group consisting of     halogen, cyano, nitro, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio and     C₁₋₆alkylsulfonyl, and -   wherein, each instance of alkyl and alkoxy is optionally     perfluorinated; -   R₂ is selected from the group consisting of halogen, C₁₋₄alkyl,     C₁₋₄alkoxy, C₁₋₄alkylsulfonyl, nitro, amino, (C₁₋₄alkyl)₁₋₂-amino     and cyano, wherein each instance of alkyl and alkoxy is optionally     perfluorinated; -   R_(3a) and R_(3b) are each selected from the group consisting of     hydrogen and optionally perfluorinated C₁₋₄alkyl; and -   R₄ is each selected from the group consisting of halogen, nitro,     cyano, carboxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl,     haloC₁₋₆alkoxy, C₁₋₆alkoxy-C₁₋₆alkyl, C₁₋₆alkylcarbonyl,     C₁₋₆alkylthio, haloC₁₋₆alkylthio, C₁₋₆alkylsulfonyl,     haloC₁₋₆alkylsulfonyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₄alkyl,     C₃₋₈cycloalkyl-C₁₋₄alkoxy, C₃₋₈cycloalkyl-oxy, amino,     (C₁₋₆alkyl)₁₋₂-amino, (C₃₋₈cycloalkyl)₁₋₂-amino,     (C₃₋₈cycloalkyl-C₁₋₄alkyl)₁₋₂-amino, aminocarbonyl,     (C₁₋₆alkyl)₁₋₂-aminocarbonyl, C₁₋₆alkylcarbonylamino,     C₁₋₆alkoxycarbonylamino, aminocarbonylamino,     (C₁₋₆alkyl)₁₋₂-aminocarbonylamino, C₁₋₆alkylsulfonylamino,     haloC₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfinylamino, aminosulfonyl     and (C₁₋₄alkyl)₁₋₂-aminosulfonyl, -   wherein each instance of alkyl is optionally substituted with one,     two or three substituents independently selected from the group     consisting of C₁₋₈alkoxy, amino, (C₁₋₄alkyl)₁₋₂-amino,     C₁₋₆alkylcarbonylamino, C₁₋₆alkoxycarbonylamino, aminocarbonylamino,     (C₁₋₆alkyl)₁₋₂-aminocarbonylamino, C₁₋₆alkylsulfonylamino, oxo and     hydroxy, and -   wherein, each instance of alkyl and alkoxy is optionally     perfluorinated.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein q is 0.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein A₁ is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein

-   R₁ is each selected from the group consisting of hydroxy, halogen,     formyl, C₁₋₆alkyl, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, C₁₋₆alkylcarbonyl,     C₁₋₆alkoxycarbonyl, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, amino,     aminocarbonyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkoxycarbonylamino,     C₁₋₆alkylsulfonylamino, aminosulfonyl, (C₁₋₄alkyl)₁₋₂-aminosulfonyl     and aminosulfonylamino, -   wherein alkyl is optionally substituted with amino,     (C₁₋₄alkyl)₁₋₂-amino, aminosulfonylamino or hydroxy, and wherein,     alkyl is optionally perfluorinated.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R₂ is selected from the group consisting of halogen and C₁₋₄alkyl, wherein alkyl is optionally perfluorinated.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R_(3a) and R_(3b) are each selected from the group consisting of hydrogen and C₁₋₄alkyl.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R₄ is each selected from the group consisting of halogen, carboxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, C₁₋₆alkylcarbonyl, haloC₁₋₆alkylthio, C₁₋₆alkylsulfonyl, haloC₁₋₆alkylsulfonyl, (C₁₋₆alkyl)₁₋₂-amino, (C₁₋₆alkyl)₁₋₂-aminocarbonyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkylsulfonylamino and haloC₁₋₆alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein

-   p is 1 or 2; -   q is 0; -   r is 0, 1, 2 or 3; -   L is C₁₋₃alkyl, C₂₋₃alkenyl, C₂₋₃alkynyl or cyclopropyl; -   A₁ is selected from the group consisting of phenyl, biphenyl,     naphthyl, quinolinyl and indole; -   R₁ is each selected from the group consisting of hydroxy, halogen,     formyl, C₁₋₆alkyl, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, C₁₋₆alkylcarbonyl,     C₁₋₆alkoxycarbonyl, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, amino,     aminocarbonyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkoxycarbonylamino,     C₁₋₆alkylsulfonylamino, aminosulfonyl, (C₁₋₄alkyl)₁₋₂-aminosulfonyl     and aminosulfonylamino, -   wherein alkyl is optionally substituted with amino,     (C₁₋₄alkyl)₁₋₂-amino, aminosulfonylamino or hydroxy, and wherein,     alkyl is optionally perfluorinated; -   R₂ is selected from the group consisting of halogen and C₁₋₄alkyl,     wherein alkyl is optionally perfluorinated; -   R_(3a) and R_(3b) are each selected from the group consisting of     hydrogen and C₁₋₄alkyl; and -   R₄ is each selected from the group consisting of halogen, carboxy,     C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy,     C₁₋₆alkylcarbonyl, haloC₁₋₆alkylthio, C₁₋₆alkylsulfonyl,     haloC₁₋₆alkylsulfonyl, (C₁₋₆alkyl)₁₋₂-amino,     (C₁₋₆alkyl)₁₋₂-aminocarbonyl, C₁₋₆alkylcarbonylamino,     C₁₋₆alkylsulfonylamino and haloC₁₋₆alkylsulfonylamino, wherein alkyl     and alkoxy are optionally perfluorinated.

The present invention is further directed to compounds of Formula Ia or Ib:

wherein:

-   R₁ is independently hydroxyl; halogen, C₁₋₆alkanyl; fluorinated     C₁₋₆alkanyl; C₁₋₆alkanyloxy; fluorinated C₁₋₆alkanyloxy;     C₁₋₆alkanylthio; fluorinated C₁₋₆alkanylthio; C₁₋₆alkanylsulfonyl;     fluorinated C₁₋₆alkanylsulfonyl; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyl;     C₁₋₄alkanyl; C₃₋₈cycloalkanyloxy; C₃₋₈cycloalkanyl; C₁₋₄alkanyloxy;     amino; (C₁₋₆alkanyl)₁₋₂-amino; (C₃₋₈cycloalkanyl)₁₋₂-amino;     (C₃₋₈cycloalkanyl; C₁₋₄alkanyl)₁₋₂-amino; cyano; aminocarbonyl;     (C₁₋₆alkanyl)₁₋₂-aminocarbonyl; C₁₋₆alkanylcarbonylamino;     fluorinated C₁₋₆alkanylcarbonylamino; C₁₋₆alkanyloxycarbonylamino;     C₀₋₆alkanylaminocarbonylamino; C₁₋₆alkanylsulfonylamino; fluorinated     C₁₋₆alkanylsulfonylamino; aminosulfonyl;     (C₁₋₈alkanyl)₁₋₂-aminosulfonyl; fluorinated     (C₁₋₈alkanyl)₁₋₂-aminosulfonyl; wherein the alkanyl in any     alkanyl-containing substituent of R₁ is optionally substituted with     1 to 3 substituents independently selected from the group consisting     of amino, (C₁₋₈alkanyl)₁₋₂-amino, C₁₋₆alkanylcarbonylamino;     fluorinated C₁₋₆alkanylcarbonylamino; C₁₋₆alkanyloxycarbonylamino;     C₀₋₆alkanylaminocarbonylamino; C₁₋₆alkanylsulfonylamino; fluorinated     C₁₋₆alkanylsulfonylamino; halogen, oxo, hydroxyl, fluorinated     alkanyl, and C₁₋₈alkanyloxy; -   p is 1 or 2; -   R₂ is independently selected from the group consisting of halogen;     C₁₋₄alkanyl; fluorinated C₁₋₄alkanyl; C₁₋₄alkanyloxy; fluorinated     C₁₋₆alkanyloxy; C₁₋₄alkanylsulfonyl; fluorinated     C₁₋₄alkanylsulfonyl; nitro; (C₁₋₄alkanyl)₁₋₂-amino; cyano; -   n is 0, or 1; -   R₃ is independently selected from the group consisting of hydrogen,     C₁₋₄alkanyl, and fluorinated C₁₋₄alkanyl; -   L is C₂₋₃alkyldiyl, -   A₁ is selected from the group consisting of phenyl and naphthyl; -   R₄ is independently halogen, C₁₋₆alkanyl; fluorinated C₁₋₆alkanyl;     C₁₋₆alkanyloxy; fluorinated C₁₋₆alkanyloxy; C₁₋₆alkanylthio;     fluorinated C₁₋₆alkanylthio; C₁₋₆alkanylsulfonyl; fluorinated     C₁₋₆alkanylsulfonyl; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyl;     C₁₋₄alkanyl; C₃₋₈cycloalkanyloxy; C₃₋₈cycloalkanyl; C₁₋₄alkanyloxy;     amino; (C₁₋₆alkanyl)₁₋₂-amino; (C₃₋₈cycloalkanyl)₁₋₂-amino;     (C₃₋₈cycloalkanyl; C₁₋₄alkanyl)₁₋₂-amino; cyano; aminocarbonyl;     (C₁₋₆alkanyl)₁₋₂-aminocarbonyl; C₀₋₆alkanylcarbonylamino;     fluorinated C₁₋₆alkanylcarbonylamino; C₁₋₆alkanyloxycarbonylamino;     C₀₋₆alkanylaminocarbonylamino; C₁₋₆alkanylsulfonylamino; fluorinated     C₁₋₆alkanylsulfonylamino; aminosulfonyl;     (C₁₋₈alkanyl)₁₋₂-aminosulfonyl; fluorinated     (C₁₋₈alkanyl)₁₋₂-aminosulfonyl; wherein the alkanyl in any     alkanyl-containing substituent of R1 is optionally substituted with     1 to 3 substituents independently selected from the group consisting     of halogen, oxo, hydroxyl, fluorinated alkanyl, and C₁₋₈alkanyloxy;     phenyl optionally substituted with 1 to 3 substituents independently     selected from the group consisting of halogen; C₁₋₄alkanyl;     fluorinated C₁₋₄alkanyl; C₁₋₄alkanyloxy; fluorinated C₁₋₄alkanyloxy;     C₁₋₄alkanylsulfonyl; fluorinated C₁₋₄alkanylsulfonyl; nitro; cyano; -   r is 0, 1 or 2; and -   enantiomers, diastereomers, tautomers, solvates, and     pharmaceutically acceptable salts thereof.

An example of the present invention includes compounds and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof selected from the group consisting of:

As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.

Accordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.

Compound Forms

The term “form” means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof.

The term “isolated form” means, in reference to compounds of the present invention, that such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such isolated forms and mixtures thereof.

Certain compounds of Formula (I) may exist in various stereoisomeric or tautomeric forms and mixtures thereof. The invention encompasses all such compounds and mixtures thereof.

The compounds of the present invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the “pharmaceutically acceptable salts” of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.

Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

Furthermore when the compounds of the present invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

Thus, representative pharmaceutically acceptable salts include the following: acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphorsulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate, trifluoroacetate and the like.

An example of the present invention includes compounds of Formula (I) and a salt form thereof wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.

The invention includes compounds of various isomers and mixtures thereof. The term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers).

The term “optical isomer” means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions. The term “optical activity” means the degree to which an optical isomer rotates the plane of polarized light.

The term “racemate” or “racemic mixture” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.

The term “enantiomer” means an isomer having a nonsuperimposable mirror image. The term “diastereomer” means stereoisomers that are not enantiomers.

The term “chiral” means a molecule, which in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules, which can be superimposed on their mirror images.

The invention is considered to include the tautomeric forms of all compounds of Formula (I). In addition, for chiral embodiments of the invention, the invention is considered to include pure enantiomers, racemic mixtures, as well as mixtures of enantiomers having 0.001% to 99.99% enantiomeric excess. In addition, some of the compounds represented by Formula (I) may be prodrugs, i.e., derivatives of a drug that possess superior delivery capabilities and therapeutic value as compared to the active drug. Prodrugs are transformed into active drugs by in vivo enzymatic or chemical processes.

The two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right handed), abbreviated D, depending on which way they rotate polarized light. The symbols “R” and “S” represent the configuration of groups around a stereogenic carbon atom(s).

An example of an enantiomerically enriched form isolated from a racemic mixture includes a dextrorotatory enantiomer, wherein the mixture is substantially free of the levorotatory isomer. In this context, substantially free means the levorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:

${\% \mspace{14mu} {levorotatory}} = {\frac{\left( {{mass}\mspace{14mu} {levorotatory}} \right)}{\left( {{mass}\mspace{14mu} {dextrorotatory}} \right) + \left( {{mass}\mspace{14mu} {levorotatory}} \right)} \times 100}$

Similarly, an example of an enantiomerically enriched form isolated from a racemic mixture includes a levorotatory enantiomer, wherein the mixture is substantially free of the dextrorotatory isomer. In this context, substantially free means the dextrorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:

${\% \mspace{14mu} {dextrorotatory}} = {\frac{\left( {{mass}\mspace{14mu} {dextrorotatory}} \right)}{\left( {{mass}\mspace{14mu} {dextrorotatory}} \right) + \left( {{mass}\mspace{14mu} {levorotatory}} \right)} \times 100}$

“Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration. In the “E” configuration, the substituents are on opposite sides in relationship to the carbon-carbon double bond. In the “Z” configuration, the substituents are oriented on the same side in relationship to the carbon-carbon double bond. The scope of the present invention is intended to include all such “E” and “Z” isomers.

Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration. In the “cis” configuration, the substituents are on the same side in relationship to the plane of the ring; in the “trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of “cis” and “trans” species are designated “cis/trans”. The scope of the present invention is intended to include all such “cis” and “trans” isomers.

The isomeric descriptors (“R,” “S,” “E,” and “Z”) indicate atom configurations relative to a core molecule and are intended to be used as defined in the literature.

Furthermore, compounds of the present invention may have at least one crystalline, polymorph or amorphous form. The plurality of such forms is included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like). The plurality of such solvates is also intended to be encompassed within the scope of this invention.

Chemical Nomenclature and Definitions

Bond lines drawn into a ring system from a substituent variable indicate that the substituent may be attached to any of the substitutable ring atoms.

As used herein, the following terms are intended to have the following meanings (additional definitions are provided where prophetic throughout the Specification). The definitions herein may specify that a chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term and is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.

Definitions

The term “C₁₋₆alkyl” or “alkyl” means a straight or branched chain hydrocarbon alkyl radical, comprising from 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, tertiary butyl (also referred to as t-butyl or tert-butyl), 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl and the like. The term further includes alkyl groups in any combination thereof (e.g. C₁₋₂, C₁₋₃, C₁₋₄ and the like). An alkyl radical may be attached to a core molecule where allowed by available valences.

The terms “C₂₋₃alkenyl” and “C₂₋₃alkynyl” mean straight or branched carbon chains having 2 to 3 carbon atoms, wherein a C₂₋₃alkenyl chain has at least one double bond in the chain and a C₂₋₃alkynyl chain has at least one triple bond in the chain. An alkenyl and alkynyl radical may be attached to a core molecule where allowed by available valences.

The term “C₁₋₆alkoxy” or “alkoxy” means a straight or branched chain hydrocarbon alkyl radical or alkyldiyl linking group of the formula —O—C₁₋₆alkyl, comprising from 1 to 6 carbon atoms. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term further includes alkoxy groups in any combination thereof (e.g. C₁₋₂, C₁₋₃, C₁₋₄ and the like). An alkoxy radical may be attached to a core molecule where allowed by available valences.

The term “cycloalkyl” refers to a saturated or partially unsaturated, monocyclic, polycyclic or benzofused hydrocarbon ring system composed of from 3 to 14 carbon atoms. Except when specified, the term includes a C₃₋₈cycloalkyl, C₃₋₁₀cycloalkyl, C₅₋₆cycloalkyl, C₅₋₈cycloalkyl, C₅₋₁₂cycloalkyl, C₈₋₁₀cycloalkyl, C₉₋₁₃cycloalkyl, C₃₋₁₄cycloalkyl or benzofused C₃₋₁₄cycloalkyl ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indenyl, indanyl, adamantanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalenyl, acenaphthenyl, bicyclo[2.2.1]heptenyl and the like. C₃₋₁₄cycloalkyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.

The term “benzofused,” used as a prefix for a ring system, means a radical formed by any ring system radical fused with a benzene ring. The benzofused radical may be attached to a core molecule via either ring of the bicyclic system and further substituted on any atom where allowed by available valences.

The term “aryl” refers to monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Examples include phenyl, biphenyl, naphthalene, azulenyl, anthracenyl and the like. Aryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.

The term “aromatic” refers to a cycloalkylic hydrocarbon ring system having an unsaturated, conjugated π electron system.

The term “hetero,” used as a prefix for a ring system, refers to the replacement of at least one ring carbon atom with one or more heteroatoms independently selected from a nitrogen, oxygen or sulfur atom, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include rings wherein 1, 2, 3 or 4 ring members are a nitrogen atom; or, 0, 1, 2 or 3 ring members are nitrogen atoms and 1 member is an oxygen or sulfur atom. When allowed by available valences, up to two adjacent ring members may be heteroatoms; wherein one heteroatom is nitrogen and the other is one heteroatom selected from N, S or O.

The term “heterocyclyl” refers to a nonaromatic (i.e. saturated or partially unsaturated) monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO₂, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 2-imidazolinyl (also referred to as 4,5-dihydro-1H-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, oxazolidinyl, tetrazolinyl, tetrazolidinyl, piperidinyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, azetidinyl, azepanyl, dihydro-pyranyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, tetrahydro-pyridazinyl, hexahydro-1,4-diazepinyl, hexahydro-1,4-oxazepanyl, 1,3-dioxolanyl, 1,4-dioxanyl, 1,3-benzodioxolyl (also referred to as benzo[1,3]dioxolyl), 2,3-dihydro-1,4-benzodioxinyl (also referred to as 2,3-dihydro-benzo[1,4]dioxinyl) and the like. Heterocyclyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.

The term “heteroaryl” means an aromatic monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO₂, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state.

Examples include furanyl, thienyl, pyrrolyl, pyrazolyl, 1H-imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, 1H-tetrazolyl, 2H-tetrazolyl, 1H-[1,2,3]triazolyl, 2H-[1,2,3]triazolyl, 4H-[1,2,4]triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, indolyl, azaindolyl, indazolyl, azaindazolyl, isoindolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl and the like. Heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.

The term “C₁₋₆alkoxy-C₁₋₆alkyl” means a radical of the formula: —C₁₋₆alkyl-O—C₁₋₆alkyl.

The term “C₁₋₆alkoxycarbonyl” means a radical of the formula: —C(O)—O—C₁₋₆alkyl. Examples include C₁₋₄alkoxycarbonyl.

The term “C₁₋₆alkoxycarbonylamino” means a radical of the formula: —NH—C(O)—O—C₁₋₆alkyl. Examples include C₁₋₄alkylcarbonylamino.

The term “(C₁₋₆alkyl)₁₋₂-amino” means a radical of the formula: —NH—C₁₋₆alkyl or —N(C₁₋₆alkyl)₂. Examples include (C₁₋₄alkyl)₁₋₂-amino.

The term “(C₁₋₆alkyl)₁₋₂-amino-C₁₋₆alkyl” means a radical of the formula: —C₁₋₆alkyl-NH—C₁₋₆alkyl or —C₁₋₆alkyl-N(C₁₋₆alkyl)₂. Examples include (C₁₋₄alkyl)₁₋₂-amino-C₁₋₆alkyl.

The term “(C₁₋₆alkyl)₁₋₂-aminocarbonyl” means a radical of the formula: —C(O)—NH—C₁₋₆alkyl or —C(O)—N(C₁₋₆alkyl)₂. Examples include (C₁₋₄alkyl)₁₋₂-aminocarbonyl.

The term “(C₁₋₆alkyl)₁₋₂-aminocarbonylamino” means a radical of the formula: —NH—C(O)—NH—C₁₋₆alkyl or —NH—C(O)—N(C₁₋₆alkyl)₂. Examples include (C₁₋₄alkyl)₁₋₂-aminocarbonylamino.

The term “(C₁₋₄alkyl)₁₋₂-aminosulfonyl” means a radical of the formula: —SO₂—NH—C₁₋₄alkyl or —SO₂—N(C₁₋₄alkyl)₂.

The term “C₁₋₆alkylcarbonyl” means a radical of the formula: —C(O)—C₁₋₆alkyl. Examples include C₁₋₄alkylcarbonyl.

The term “C₁₋₆alkylcarbonylamino” means a radical of the formula: —NH—C(O)—C₁₋₆alkyl. Examples include C₁₋₄alkylcarbonylamino.

The term “C₁₋₆alkylsulfonyl” means a radical of the formula: —SO₂—C₁₋₆alkyl. Examples include C₁₋₄alkylsulfonyl.

The term “C₁₋₆alkylsulfinylamino” means a radical of the formula: —NH—S(O)—C₁₋₆alkyl.

The term “C₁₋₆alkylsulfonylamino” means a radical of the formula: —NH—SO₂—C₁₋₆alkyl.

The term “C₁₋₆alkylthio” means a radical of the formula: —S—C₁₋₆alkyl. Examples include C₁₋₄alkylthio.

The term “amino” means a radical of the formula: —NH₂.

The term “amino-C₁₋₆alkyl” means a radical of the formula: —C₁₋₆alkyl-NH₂.

The term “aminocarbonyl” means a radical of the formula: —C(O)—NH₂.

The term “aminocarbonylamino” means a radical of the formula: —NH—C(O)—NH₂.

The term “aminosulfonyl” means a radical of the formula: —SO₂—NH₂.

The term “aminosulfonylamino” means a radical of the formula: —NH—SO₂—NH₂.

The term “(C₁₋₆alkyl)₁₋₂-aminosulfonylamino” means a radical of the formula: —NH—SO₂—NH—C₁₋₆alkyl or —NH—SO₂—N(C₁₋₆alkyl)₂. Examples include (C₁₋₄alkyl)₁₋₂-aminosulfonylamino.

The term “aminosulfonylamino-C₁₋₆alkyl” means a radical of the formula: —C₁₋₆alkyl-NH—SO₂—NH₂.

The term “(C₁₋₆alkyl)₁₋₂-aminosulfonylamino-C₁₋₆alkyl” means a radical of the formula: —C₁₋₆alkyl-NH—SO₂—NH—C₁₋₆alkyl or —C₁₋₆alkyl-NH—SO₂—N(C₁₋₆alkyl)₂.

The term “carboxy” means a radical of the formula: —C(O)OH.

The term “C₃₋₈cycloalkyl-C₁₋₆alkyl” means a radical of the formula: —C₁₋₆alkyl-C₃₋₈cycloalkyl. Examples include C₃₋₈cycloalkyl-C₁₋₄alkyl.

The term “C₃₋₈cycloalkyl-C₁₋₆alkoxy” means a radical of the formula: —O—C₁₋₆alkyl-C₃₋₈cycloalkyl. Examples include C₃₋₈cycloalkyl-C₁₋₄alkoxy.

The term “C₃₋₈cycloalkyl-oxy” means a radical of the formula: —O—C₃₋₈cycloalkyl.

The term “(C₃₋₈cycloalkyl)₁₋₂-amino” means a radical of the formula: —NH—(C₃₋₈cycloalkyl) or —N(C₃₋₈cycloalkyl)₂.

The term “(C₃₋₈cycloalkyl-C₁₋₄alkyl)₁₋₂-amino” means a radical of the formula: —NH—C₁₋₄alkyl-C₃₋₈cycloalkyl or —N(C₁₋₄alkyl-C₃₋₈cycloalkyl)₂.

The term “formyl” means a radical of the formula: —C(O)H.

The term “oxo” means a radical of the formula: ═O.

The term “halogen” or “halo” means the group chloro, bromo, fluoro or iodo.

The term “haloC₁₋₆alkyl” means a radical of the formula: —C₁₋₆alkyl(halo)_(n), wherein “n” represents that amount of available valences on C₁₋₆alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethyl, trifluoromethyl, trifluoroethyl, chloromethyl and the like.

The term “haloC₁₋₆alkoxy” means a radical of the formula: —O—C₁₋₆alkyl(halo)_(n), wherein “n” represents that amount of available valences on C₁₋₆alkoxy, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethoxy, trifluoromethoxy, trifluoroethoxy, chloromethoxy and the like.

The term “haloC₁₋₆alkylsulfonyl” means a radical of the formula: —SO₂—C₁₋₆alkyl(halo)_(n), wherein “n” represents that amount of available valences on C₁₋₆alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.

The term “haloC₁₋₆alkylsulfonylamino” means a radical of the formula: —NH—SO₂—C₁₋₆alkyl(halo)_(n), wherein “n” represents that amount of available valences on C₁₋₆alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.

The term “haloC₁₋₆alkylthio” means a radical of the formula: —S—C₁₋₆alkyl(halo)_(n), wherein “n” represents that amount of available valences on C₁₋₆alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.

The term “perfluorinated” means a radical that is substituted with fluoro atoms to the extent allowed by available valences while remaining stable.

The term “substituted,” refers to a core molecule on which one or more hydrogen atoms have been replaced with one or more functional radical moieties. The number that is allowed by available valences limits the amount of substituents. Substitution is not limited to the core molecule, but may also occur on a substituent radical, whereby the substituent radical becomes a linking group.

Therapeutic Use

As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.

Accordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.

The term “VR1 ion channel mediated disease” refers to chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.

An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use in the manufacture of a medicament for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.

An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use as a medicine for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.

The term “prodrug” means a compound of Formula (I) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions.

Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.

The term “metabolite” means a form of a compound of Formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a derivative of said compound.

The term “subject” as used herein, refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a disease that has or will result in VR1 ion channel mediated chronic or acute pain, wherein the pain caused by the disease is inflammatory pain, burning pain or post-operative pain.

The term “effective amount” refers to that amount of a compound of Formula (I) or a form, pharmaceutical composition, medicine or medicament thereof that elicits the biological or medicinal response (such as inhibiting, preventing or ameliorating VR1 ion channel mediated chronic or acute pain) in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the inflammatory pain, burning pain or post-operative pain being treated.

The effective amount of a compound of Formula (I) or a form thereof is from about 0.001 mg/kg/day to about 300 mg/kg/day.

The term “pharmaceutical composition” refers to a product containing a compound of Formula (I) or a form thereof, such as a product comprising the specified ingredients in the specified amounts, as well as any product that results, directly or indirectly, from such combinations of the specified ingredients in the specified amounts.

The term “medicament” or “medicine” refers to a product containing a compound of Formula (I) or a form thereof. The present invention includes use of such a medicament for treating VR1 ion channel mediated chronic or acute pain.

The term “pharmaceutically acceptable” refers to molecular entities and compositions that are of sufficient purity and quality for use in the formulation of a pharmaceutical composition, medicine or medicament of the present invention. Since both human use (clinical and over-the-counter) and veterinary use are equally included within the scope of the present invention, a pharmaceutically acceptable formulation would include a pharmaceutical composition, medicine or medicament for either human or veterinary use.

The term “treating” refers, without limitation, inhibiting, ameliorating, facilitating the eradication of, inhibiting the progression of or promoting the stasis of VR1 ion channel mediated chronic or acute pain.

For oral administration, the pharmaceutical composition, medicine or medicament is preferably in the form of a tablet containing, e.g., 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of a compound of formula (I) or a form thereof for the symptomatic adjustment of the dosage to the patient to be treated. Optimal dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet and time of administration), the severity of the condition being treated, the particular compound being used, the mode of administration and the strength of the preparation. The use of either daily administration or post-periodic dosing may be employed.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd Name 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone, 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide, 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide, 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- carbamic acid tert-butyl ester, 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 19 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide, 26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone, 28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 29 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol, 30 2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole, 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide, 38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide, 44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide, 45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanol, 46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol, 48 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-phenol, 49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-phenol, 50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-acetamide, 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol, 52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl- 1H-benzimidazole, 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-benzamide, 54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-carbamic acid tert-butyl ester, 55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol, 59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide, 65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 86 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-ethanone, 94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-ethanol, 95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-methanesulfonamide, 96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-propan-2-ol, 97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- methanesulfonamide, 118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)- phenyl]-methanesulfonamide, 119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2- yl}-vinyl)-phenyl]-methanesulfonamide, 121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, 126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)- 1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 132 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanone, 154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanol, 155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-methanesulfonamide, 156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-propan-2-ol, 157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol- 5-yl)-benzenesulfonamide, 164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)- methanesulfonamide, 178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)- phenyl]-methanesulfonamide, 179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- ethyl)-phenyl]-methanesulfonamide, 181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2- yl}-ethyl)-phenyl]-methanesulfonamide, 185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide, 186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide, 187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanone, 208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanol, 209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-benzenesulfonamide, 212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-ethanone, 214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-ethanol, 215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-propan-2-ol, 217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5- yl)-benzenesulfonamide, 218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- methanesulfonamide, 238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)- phenyl]-methanesulfonamide, 239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- cyclopropyl)-phenyl]-methanesulfonamide, 241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2- yl}-cyclopropyl)-phenyl]-methanesulfonamide, 245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide, 246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide, 247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)- cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}- methanesulfonamide, 298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}- phenyl)-methanesulfonamide, 299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- phenyl}-methanesulfonamide, 300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide, 306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide, 307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5- yl]-benzenesulfonamide, 308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)- 1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide, 309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 389 2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 400 N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 408 (E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide, 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 443 (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide, 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- vinyl)-phenyl]-ethanone, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]- vinyl}-benzamide, 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- phenyl)-acetamide, 453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- benzoic acid, 454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)- vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide, 460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-propionamide, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester, 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenylamine, 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester, 467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazole, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenol, 473 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester, 474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 477 (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide, 478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-acetamide, 479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester, 480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl- phenyl)-1H-benzimidazole, 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzyl)-amine, 484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzaldehyde, 485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzyl)-amine, 486 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzylamine, 487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl- phenyl)-vinyl]-1H-benzimidazole, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide, 499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]- 1H-benzimidazole, 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, and 508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd Name 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- carbamic acid tert-butyl ester, 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 19 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 29 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol, 30 2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole, 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide, 38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide, 44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide, 45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanol, 46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol, 48 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-phenol, 49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-phenol, 50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-acetamide, 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol, 52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl- 1H-benzimidazole, 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-benzamide, 54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-carbamic acid tert-butyl ester, 55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol, 59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide, 65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-methanesulfonamide, 101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 389 2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 400 N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 408 (E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide, 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 443 (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide, 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- vinyl)-phenyl]-ethanone, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]- vinyl}-benzamide, 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- phenyl)-acetamide, 453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- benzoic acid, 454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)- vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide, 460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-propionamide, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester, 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenylamine, 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester, 467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazole, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenol, 473 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester, 474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 477 (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide, 478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-acetamide, 479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester, 480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl- phenyl)-1H-benzimidazole, 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzyl)-amine, 484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzaldehyde, 485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzyl)-amine, 486 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzylamine, 487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl- phenyl)-vinyl]-1H-benzimidazole, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide, 499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]- 1H-benzimidazole, 40333774 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 40334255 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, and 508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd Name 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- carbamic acid tert-butyl ester, 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide, 45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanol, 46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol, 50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-acetamide, 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol, 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-benzamide, 56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol, 59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-methanesulfonamide, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide, 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- vinyl)-phenyl]-ethanone, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester, 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenylamine, 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester, 467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazole, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl- phenyl)-vinyl]-1H-benzimidazole, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide, 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]- 1H-benzimidazole, 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, and 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd Name 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanol, 46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol, 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol, 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-benzamide, 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol, 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide, 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- vinyl)-phenyl]-ethanone, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester, 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazole, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl- phenyl)-vinyl]-1H-benzimidazole, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide, 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]- 1H-benzimidazole, 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, and 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd Name 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, and 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol.

A representative prophetic compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd Name 72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 86 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-ethanone, 94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-ethanol, 96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-propan-2-ol, 97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- methanesulfonamide, 118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)- phenyl]-methanesulfonamide, 119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2- yl}-vinyl)-phenyl]-methanesulfonamide, 121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, 126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)- 1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, 132 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanone, 154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanol, 155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-methanesulfonamide, 156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-propan-2-ol, 157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol- 5-yl)-benzenesulfonamide, 164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)- methanesulfonamide, 178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)- phenyl]-methanesulfonamide, 179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- ethyl)-phenyl]-methanesulfonamide, 181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2- yl}-ethyl)-phenyl]-methanesulfonamide, 185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide, 186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide, 187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanone, 208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanol, 209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-benzenesulfonamide, 212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-ethanone, 214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-ethanol, 215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-propan-2-ol, 217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5- yl)-benzenesulfonamide, 218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- methanesulfonamide, 238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)- phenyl]-methanesulfonamide, 239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- cyclopropyl)-phenyl]-methanesulfonamide, 241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2- yl}-cyclopropyl)-phenyl]-methanesulfonamide, 245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide, 246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide, 247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)- cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}- methanesulfonamide, 298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}- phenyl)-methanesulfonamide, 299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- phenyl}-methanesulfonamide, 300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide, 306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide, 307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5- yl]-benzenesulfonamide, and 308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)- 1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.

General Synthetic Methods

Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.

Compounds of the present invention can be synthesized using the methods described in the schemes that follow.

The terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations and formulas have the indicated meanings:

Abbreviation Meaning Boc tert-butoxycarbonyl BOP benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate AcOH acetic acid Cpd compound DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCM dichloromethane DIEA N,N-diisopropyl ethyl amine DME ethylene glycol dimethyl ether DMF N,N-dimethylformamide DMSO dimethyl sulfoxide EtOAc ethyl acetate EtOH ethanol HPLC high performance liquid chromatography LiOH lithium hydroxide min minute(s) n-BuLi n-butyl lithium h/hr/hrs hour(s) mCPBA m-chloroperbenzoic acid MeOH methanol MTBE methyl-t-butyl ether PdCl₂(dppf) or [1,1′-bis-(diphenylphosphino)ferroceno] Pd(dppf)Cl₂CH₂Cl₂ dichloropalladium (II) dichloromethane complex Pd(PPh₃)₄ palladium tetrakistriphenylphosphine RT or rt room temperature TBAB tetrabutylammonium bromide TBSOTf t-butyldimethylsilyl trifluoromethane sulfonate Et₃N triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TLC thin layer chromatography

Reaction Scheme AA

Scheme AA illustrates a general synthesis of benzimidazoles of formula AA5, representative of a compound of Formula (I).

Typically, a solution of 4-bromobenzene-1,2-diamine AA1 and a suitable carboxylic acid AA2 in phosphorous oxychloride (POCl₃) is heated at reflux to obtain bromobenzimidazole AA3.

Alternatively, the acid can be converted to an acid chloride using oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.

The acid chloride AA2 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give AA3. A suitably substituted phenyl group can be appended to AA3 by a variety of coupling reactions (Suzuki, Stille) that are well known to those versed in the art. A particularly useful substitution method employs a palladium catalyzed cross-coupling Suzuki reaction (Huff, B. et. al. Org. Syn. 1997, 75: 53-60; and, Goodson, F. E. et. al. Org. Synth. 1997, 75: 61-68).

As an example, a mixture of bromobenzimidazole AA3 is reacted with a suitable phenyl boronic acid AA4 in the presence of a reagent such as cesium carbonate and a catalytic amount of a palladium catalyst such as PdCl₂dppf in a solvent such as a mixture of dioxane and ethanol at elevated temperatures to give AA5. The reaction times can be reduced by carrying out this procedure at similar (about 100° C.) or lower temperatures in a microwave synthesizer. Other palladium catalysts suitable for this type of reaction include Pd(PPh₃)₄.

Reaction Scheme BB

Cinnamic acids, as required, can be synthesized via procedures described in reaction Scheme BB.

A solution of arylaldehyde BB1 and (carbethoxymethylene)triphenyl phosphorane in a solvent such as toluene or benzene in the presence of a base such as NaOH is stirred usually at elevated temperatures to give the corresponding cinnamate ester. The ester is hydrolyzed under standard conditions to provide the corresponding cinnamic acid BB2.

Phenylpropionic acid BB3, as required, can be synthesized from cinnamic acid BB2 by hydrogenation using a variety of standard procedures. As shown above, a mixture of BB2 in ethanol with a catalytic amount of palladium on carbon (10%) is stirred at room temperature in an atmosphere of hydrogen (50 psi) to provide acid BB3.

Reaction Scheme BB′

Reaction Scheme BB′ is a variation of Reaction Scheme BB.

Reaction of aldehyde BB1 with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures produces cinnamic acid BB2 in high yield.

Acid BB2 is converted to the acid chloride by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride. The acid chloride is then heated with AA1 in acetic acid to give BB′1, which is further elaborated in place of AA3 as described in reaction Scheme AA.

Reaction Scheme CC

Reaction Scheme CC provides a method to prepare substituted 4-bromobenzene-1,2-diamine intermediates.

As an example, to a solution of a suitably substituted 4-bromoaniline CC1 in trifluoroacetic anhydride is added KNO₃ portionwise at a suitable temperature. The reaction mixture may then be warmed to room temperature for optimal conversion to nitroamide CC2.

Sequentially, using standard procedures, the amide is hydrolyzed and the nitro group is reduced to give bromodiamine CC3. Intermediate CC3 is further elaborated as described in reaction Scheme AA.

Reaction Scheme DD

An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme DD.

A substituted bromobenzimidazole DD1 (representative of AA3 in Scheme AA) is protected (using a protecting group such as Boc), then converted to a pinicolboronate ester DD2 under standard Suzuki coupling conditions (Prieto, M. et. al., J. Org. Chem. 2004, 69: 6812-6820; McDonald, D. et. al., Bioorg. Med. Chem. Lett. 2005, 15: 5241-5246; and, Poon, S. F. et. al. Bioorg. Med. Chem. Lett. 2004, 14, 5477-5480).

In a typical procedure, a mixture of bromo-benzimidazole DD1, bis-(pinacolato)diboron, potassium carbonate and a catalytic amount of a palladium catalyst such as PdCl₂dppf in DMF is heated at elevated temperatures to give boronate ester DD2. Frequently, the reaction durations can be reduced by carrying out this procedure at similar or lower temperatures in a microwave irradiation apparatus.

Boronate ester DD2 can be converted to compounds of the present invention (Boc protected DD3) by Suzuki coupling with a phenyl halide, mesylate or triflate (R₁)_(p)Ph-X. In this instance, borane DD2 is reacted with a suitable aryl halide, tetrakis (triphenylphosphine) palladium (0) and tri-tert-butylphosphonium tetrafluoroborate in 2M aqueous potassium carbonate in toluene at 100° C. to give the protected form of DD3. Deprotection with an acid such as TFA gives DD3.

Reaction Scheme EE

Reaction Scheme EE describes methods to prepare representative compounds of the present invention.

Aniline EE1 can be converted to a variety of amides, carbamates or ureas EE2 by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of EE1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of EE2. As a further example, reaction of EE1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of EE2.

EE1 can be converted to sulfonamides by utilizing various sulfonylation conditions. For instance, reaction of EE1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide EE3. EE1 can be selectively, and successively substituted to give EE3. An efficient method of achieving this is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. J. Org. Chem. 1990, 55, 2552-2554) and references cited therein]. In this procedure, equal amounts of EE1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine EE3.

Reaction Scheme FF

A synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme FF.

Reaction of cinnamate ester FF1, in this case a methyl ester, with trimethylsulfonium iodide methylide in a solvent such as DMSO and sodium hydride (as exemplified by Burger, A. et. al. J. Med. Chem. 1970, 13, 33-35), gives cyclopropyl ester FF2. Hydrolysis of FF2 gives acid FF3, which is further elaborated into the benzimidazoles described in Scheme AA.

Reaction Scheme GG

Reaction Scheme GG describes an alternative method to prepare cyclopropyl acid intermediates.

Cinnamic acids are converted to the corresponding Weinreb amide, by conversion to the acid chloride as described in Reaction Scheme AA and BB′. The acid chloride is reacted with N,N-dimethylhydroxylamine hydrochloride and a base such as triethylamine in methylene chloride to give amide GG2.

Amide GG2 is converted to cyclopropyl amide GG3 as described in Scheme FF. The amide GG3 is then hydrolyzed to give acid GG4, typically by reaction with potassium tertiary butoxide in THF.

Reaction Scheme HH

A synthetic sequence to produce compounds of the present invention wherein R₁Ar is benzenesulfonamide is described in reaction Scheme HH.

Coupling by Suzuki reaction of boronate ester DD2 from reaction Scheme DD and bromobenzene-t-butylsulfonamide HH1 followed by deprotection with TFA gives the product HH2.

Reaction Scheme II

A synthetic sequence to produce compounds of the present invention wherein R is an ether group is described in reaction Scheme II.

An ester of commercially available 4-hydroxycinnamic acid II1 can be converted to ether analogs by a number of routes including the Williamson reaction. In this well-known procedure, II1 and an alkyl halide is reacted with a base such as cesium carbonate in a solvent such as acetonitrile to give the product II2.

More effective electrophiles can be derivatives of alcohols such as mesylates, p-toluene sulfonates or trifluoromethanesulfonates (triflates). An effective alternative method is the conversion of II1 to ether analogs II2 via the Mitsunobu reaction (as reviewed by Mitsunobu, O., Synthesis, 1981, 1-28).

Ether analogs II2 can be further reduced to acid II3 using standard techniques.

Reaction Scheme JJ

Reaction Scheme JJ describes methods to prepare cinnamic acids that contain substituted amino groups.

Cinnamate ester JJ1 can be converted to a variety of amides, carbamates or ureas JJ2 by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of JJ1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of JJ2. As a further example, reaction of JJ1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of JJ2. JJ1 can be converted to sulfonamides by utilizing various sulfonylation conditions.

For instance, reaction of JJ1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide JJ3. JJ1 can be selectively, and successively substituted to give JJ4. An efficient method of substitution is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. J. Org. Chem., 1990, 55, 2552-2554 and references cited therein). In this procedure, equal amounts of JJ1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine JJ4.

Reaction Scheme KK

A synthetic sequence to prepare compounds of the present invention wherein L is acetylene is described in Reaction Scheme KK.

When not commercially available, propiolic acids KK2 are prepared by reaction of acetylenes KK1 with n-butyl lithium in THF at −78° C. warming to 0° C. for 30 min. The mixture is cooled to −78° C., and transferred to a saturated solution of carbon dioxide in THF at −78° C. The reaction is slowly warmed to rt to give the corresponding propiolic acid KK2.

Reaction of the propiolic acid KK2 with 4-bromobenzene-1,2-diamine dihydrochloride KK3 in refluxing ethylene glycol gives chlorovinylbenzimidazole KK4.

Reaction of KK3 with a phenyl boronic acid under Suzuki conditions in a microwave synthesizer and thermal conditions as described in Reaction Scheme AA gives acetylene compounds KK4.

Reaction Scheme LL

An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme LL.

Protected bromodiamine LL1 is coupled with a suitable boronic acid via Suzuki coupling as described in previous reaction schemes to give the diamine LL2.

LL2 is then reacted with an acid or acid chloride to give LL3 (as described in reaction Schemes AA or BB′).

Reaction Scheme MM

A synthetic sequence to produce compounds of the present invention wherein L is vinyl or ethyl that may be used as an alternative to Scheme BB′ is described in reaction Scheme MM.

A solution of AA1 and dichloroimine MM1 (as described in McElvain, S. M. et. al. J. Am. Chem. Soc. 1942, 64, 1825) in ethanol is heated to give chloromethyl benzimidazole MM2 (as described in Komoriya et. al. Bioorg. Med. Chem., 2004, 12, 2099-2114).

Heating in dichloroethane with triphenylphosphine converts MM2 to the phosphonium salt MM3.

Reaction of MM3 with various aldehydes or ketones in a solution of anhydrous THF and EtOH with a base such as DBU (1,8-diazabicyclo[4.5.0]undec-7-ene) gives bromobenzimidazole BB′1, which is further elaborated as described in reaction Scheme AA.

Reaction Scheme NN

An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme NN.

The biaryldiamine LL2 is reacted with dichloroimine MM1 as described in reaction Scheme MM to give NN1.

As described in reaction Scheme MM, NN1 is carried forward to give NN2.

Reaction Scheme OO

Compounds of the present invention wherein L is ethylene can be prepared by the alternate route described in Reaction Scheme OO.

Compounds of the present invention such as NN3, wherein L is vinyl, are dissolved in a solvent such as methanol, and are hydrogenated using a catalyst such as 10% Pd on carbon to give 001.

Reaction Scheme PP

A synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme PP.

Reaction of olefin PP1 with an alkyl diazoacetate, such as ethyl diazoacetate, in the presence of a catalyst, such as copper(I) trifluoromethane sulfonate and Evans' chiral ligand (Evans, D. A.; Woerpel, K. A.; Hinman, M. M.; Faul, M. M. J. Am. Chem. Soc. 1991, 113, 726-728) in a solvent such as chloroform, gives a cyclopropyl ester enantiomer PP2.

The (R,R)-cyclopropyl ester PP2 enantiomer is obtained when a chiral ligand such as 2,2-bis-[2-((4S)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38b is used. The (S,S)-cyclopropyl ester enantiomer is obtained when the chiral ligand 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38a is used. The configurations of the cyclopropyl moiety were predicted based on Evans' J. Am. Chem. Soc. 1991 report. Hydrolysis of the ester PP2 gives acid PP3, which is further elaborated into the benzimidazoles of Scheme AA.

To determine the enantiomeric excess of the asymmetric cyclopropanation products PP2, acid PP3 is reacted with N,O-dimethylhydroxylamine in the presence of a base such as diisopropylethylamine, and an amide coupling reagent such as BOP, in a solvent such as DMF to produce the methoxy methyl amide PP4.

The resulting ¹H NMR of amide PP4 in the presence of an appropriate amount of chiral shifting agent, such as (R)-(−)-2,2,2-trifluoro-1-(9-anthryl)ethanol, gives base line resolution of the resulting methoxy singlets. The ratio of the integration of the methoxy singlets gives the ee value. Thus, the NMR showed methoxy singlets around 3.47 and 3.45 ppm. The integration of the singlets was 1 and 99, respectively; thus providing an ee value of 99%.

Reaction Scheme QQ

A synthetic sequence to produce compounds of the present invention wherein R₁ is an alcohol is described in reaction Scheme QQ.

As elaborated in Scheme BB′, the aldehyde QQ1 is reacted with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures to provide an acid QQ2. Acid QQ2 is converted to an acid chloride QQ3 by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.

As elaborated in Scheme AA, the acid chloride QQ3 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give a bromobenzimidazole QQ4.

As elaborated in Scheme AA, a suitably substituted phenyl boronic acid is reacted with benzimidazole QQ4 in the presence of a reagent and a catalytic amount of a palladium catalyst in a solvent to give an alcohol substituted benzimidazole QQ5, representative of a compound of Formula (I).

Example 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 1) Step A. (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazole

To a solution of 3-(4-tert-butyl-phenyl)-acrylic acid (12 g, 58.7 mmol) in POCl₃ (200 mL), was slowly added 4-bromo-benzene-1,2-diamine (10 g, 53.4 mmol). The solution was heated at reflux for 18 h. The solution was concentrated, and the residual POCl₃ was azeotropically removed with toluene. The residue was partitioned between EtOAc and 10% Na₂CO₃. The organic layer was washed with brine, dried over Na₂SO₄, filtered, and the filtrate was concentrated. The residue was purified by chromatography (silica, EtOAc: hexanes, 3:7) to give the title Compound Ia (7.1 g, 31% yield). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.64 (d, 1H, J=13.9 Hz) 7.62 (s, 1H) 7.41 (d, 2H, J=8.4 Hz) 7.36 (d, 1H, J=8.5 Hz) 7.33 (d, 2H, J=8.4 Hz) 7.28 (s, 1H) 7.22 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.02 (d, 1H, J=16.5 Hz) 1.25 (s, 9H).

Step B. (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone

A solution of Compound 1a (0.106 g, 0.30 mmol), 2-acetylbenzeneboronic acid (136 mg; 0.76 mmol), PdCl₂dppf (0.06 mmol) and Cs₂CO₃ (0.244 g, 0.75 mmol) in 1,4-dioxane:EtOH 5:1 was heated to 115° C. After 18 h, the solution was cooled and concentrated. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7) to give the title Compound 1 (0.0146 g). ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.54 (m, 11H) 7.23 (dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.15 (d, 1H, J=16.5 Hz) 2.02 (s, 3H) 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 395.3 (M+1).

Using the procedures described in Example 1 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.0048 g) was prepared from 2-hydroxybenzeneboronic acid (0.0345 g, 0.25 mmol) and Compound 1a (0.029 g, 0.1 mmol). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.56 (s, 1H) 7.31 (dd, 2H, J = 12.2 Hz, J = 24.1 Hz) 7.10 (m, 8H) 6.86 (t, 1H, J = 7.3 Hz) 6.78 (d, 1H, J = 16.4 Hz) 1.19 (s, 9H). MS (ESI, pos. ion) m/z: 368.3 (M + 1). 4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide The title compound (0.001 g) was prepared from 2-N-acetyl-benzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.44 (m, 4H) 7.24 (m, 6H) 6.91 (d, 1H, J = 12.4 Hz) 6.47 (d, 1H, J = 12.4 Hz) 1.86 (s, 1H) 1.20 (s, 9H). MS (ESI, pos. ion) m/z: 410.2 (M + 1). 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.001 g) was prepared from 2-aminocarbonyl benzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.48 (m, 6H) 7.37 (m, 5H) 7.26 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz) 7.04 (d, 1H, J = 16.5 Hz) 1.26 (s, 9H). MS (ESI, pos. ion) m/z: 396.1 (M + 1). 6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.001 g) was prepared from 3-aminocarbonylbenzene boronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). ¹H- NMR (400 MHz, CD₃OD) δ (ppm) 8.22 (t, 1H, J = 1.7 Hz) 7.88 (m, 3H) 7.62 (m, 6H) 7.51 (m, 2H) 7.17 (d, 1H, J = 16.5 Hz) 1.38 (s, 9H). MS (ESI, pos. ion) m/z: 396.1 (M + 1). 7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.002 g) was prepared from 4-aminocarbonylbenzene boronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). ¹H- NMR (400 MHz, CD₃OD) δ (ppm) 7.97 (m, 2H) 7.77 (m, 4H) 7.60 (m, 4H) 7.47 (d, 2H, J = 8.4 Hz) 7.13 (d, 1H, J = 16.5 Hz) 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 410.2 (M + 1). 8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide The title compound 0.0038 g) was prepared from 4-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol) to give the title compound (0.0038 g). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.73 (m, 2H) 7.61 (m, 7H) 7.49 (m, 3H) 7.12 (d, 1H, J = 16.5 Hz) 2.17 (s, 3H) 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 410.2 (M + 1). 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide The title compound (0.0045 g) was prepared from 2-methanesulfonamide benzeneboronic acid (0.163 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.62 (m, 6H) 7.50 (d, 2H, J = 8.5 Hz) 7.41 (m, 2H) 7.34 (m, 2H) 7.17 (d, 1H, J = 16.5 Hz) 2.75 (s, 3H) 1.37 (s, 9H). MS (ESI, pos. ion) m/z: 446.2 (M + 1). 10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- carbamic acid tert-butyl ester The title compound (0.0016 g) was prepared from 2-N-Boc-benzeneboronic acid (0.180 g, 0.76 mmol) and (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H- aminobenzimidazole Compound 1b (0.106 g, 0.3 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.62 (m, 5H) 7.50 (m, 2H) 7.33 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz) 7.14 (m, 3H) 6.83 (m, 2H) 3.37 (s, 9H) 1.37 (s, 9H). MS (ESI, pos. ion) m/z: 468.1 (M + 1). 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine A solution of (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester (0.005 g, 0.01 mmol) in methylene chloride (1 mL) was treated with trifluoroacetic acid (0.5 mL). The solution was stirred at room temperature for 4 h, then concentrated to give the title compound (0.003 g). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 8.03 (d, 1H, J = 16.5 Hz) 7.90 (d, 1H, J = 8.5 Hz) 7.85 (s, 1H) 7.74 (d, 2H, J = 8.4 Hz) 7.65 (dd, 1H, J = 1.5 Hz, J = 8.5 Hz) 7.59 (d, 2H, J = 8.4 Hz) 7.43 (m, 5H) 1.39 (s, 9H). MS (ESI, pos. ion) m/z: 368.1 (M + 1). 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol The title compound (0.0046 g) was prepared from 2-hydroxymethylbenzene boronic acid (0.102 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). ¹H- NMR (400 MHz, CD₃OD) δ (ppm) 7.59 (m, 5H) 7.49 (d, 2H, J = 8.4 Hz) 7.40 (m, 2H) 7.34 (m, 2H) 7.27 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz) 7.16 (d, 1H, J = 16.6 Hz) 4.58 (s, 2H) 1.37 (s, 9H). MS (ESI, pos. ion) m/z: 383.2 (M + 1). 24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide Using the procedure of Example 1, Step B, the title compound (0.001 g) was prepared from 2-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and (E)-5- bromo-2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazole Compound 1c (0.10 g, 0.30 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.61 (m, 5H) 7.39 (m, 6H) 7.18 (d, 1H, J = 16.5 Hz) 1.99 (s, 3H). MS (ESI, pos. ion) m/z: 390.2 (M + 1). 25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide The title compound (0.0102 g) was prepared from 3-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.78 (d, 1H, J = 0.9 Hz) 7.63 (s, 1H) 7.44 (m, 5H) 7.26 (m, 4H) 7.01 (d, 1H, J = 16.5 Hz) 2.06 (s, 3H). MS (ESI, pos. ion) m/z: 390.1 (M + 1). 26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.0031 g) was prepared from 2-aminocarbonylbenzene boronic acid (0.125 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). ¹H- NMR (400 MHz, CDCl₃ + CD₃OD) δ (ppm) 7.62 (s, 1H) 7.40 (m, 9H) 7.18 (td, 1H, J = 8.4 Hz, J = 10.1 Hz) 7.01 (d, 1H, J = 16.5 Hz). MS (ESI, pos. ion) m/z: 376.2 (M + 1). 27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.125 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.49 (m, 5H) 7.37 (m, 4H) 7.23 (td, 1H, J = 8.4 Hz, J = 10.3 Hz) 7.14 (dd, 1H, J = 1.7 Hz, J = 8.3 Hz) 7.06 (d, 1H, J = 16.5 Hz) 1.91 (s, 3H). MS (ESI, pos. ion) m/z: 375.2 (M + 1). 28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide The title compound (0.0021 g) was prepared from 2-methylsulfonylamino benzeneboronic acid (0.163 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.50 (m, 5H) 7.36 (m, 1H) 7.26 (m, 5H) 7.07 (d, 1H, J = 16.5 Hz) 2.64 (s, 3H). MS (ESI, pos. ion) m/z: 426.1 (M + 1). 30 (E)-2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole The title compound (0.0182 g) was prepared from 3-methylphenylbenzene boronic acid (0.052 g, 0.38 mmol) and 5-bromo-2-[3-(4-tert-butyl-phenyl)- propyl]-1H-benzimidazole Compound 5a (0.055 g, 0.15 mmol). ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.33 (m, 3H) 7.18 (m, 5H) 7.03 (d, 1H, J = 7.4 Hz) 6.95 (d, 2H, J = 8.3 Hz) 2.85 (m, 2H) 2.57 (t, 2H, J = 7.5 Hz) 2.30 (s, 3H) 2.06 (m, 2H) 1.17 (s, 9H). MS (ESI, pos. ion) m/z: 383.2 (M + 1).

Example 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 2)

A solution of (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone Cpd 1 (0.005 g, 0.01 mmol) in ethanol (0.5 mL) was treated with NaBH₄ (0.003 g, 0.08 mmol). After 3 h, the reaction mixture was applied to a preparative TLC plate (2000 microns, silica gel, 20×20) and developed using EtOAc: hexanes, 1:1. The desired band was extracted and concentrated to give the title compound (0.002 g). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.69 (m, 1H) 7.62 (m, 3H) 7.50 (m, 3H) 7.41 (ddd, 2H, J=2.5 Hz, J=10.1 Hz, J=14.1 Hz) 7.32 (dt, 1H, J=1.4 Hz, J=7.5 Hz) 7.23 (m, 2H) 7.17 (d, 1H, J=16.5 Hz) 4.99 (q, 1H, J=6.3 Hz) 1.38 (s, 9H) 1.35 (d, 1.5H, J=6.1 Hz) 1.33 (d, 1.5H, J=6.1 Hz). MS (ESI, pos. ion) m/z: 397.2 (M+1).

Example 3 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide (Cpd 13) Step A. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

Using the procedure of Example 1, Step A, the title Compound 10c (0.910 g) was prepared from 3-(4-trifluoromethyl-phenyl)-acrylic acid Compound 10a (1.5 g, 6.9 mmol) and 4-bromo-benzene-1,2-diamine (1.3 g, 6.9 mmol). ¹H-NMR (400 MHz, CDCl₃+DMSO(d6)) δ (ppm) 7.78 (d, 1H, J=16.5 Hz) 7.73 (d, 1H, J=1.7 Hz) 7.66 (m, 4H) 7.48 (d, 2H, J=8.0 Hz) 7.33 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.23 (d, 1H, J=16.5 Hz).

Step B. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide

Using the procedure of Example 1, Step B, the title compound (0.001 g) was prepared from 2-carboxamidophenylbenzeneboronic acid (0.120 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.74 (d, 2H, J=8.2 Hz) 7.63 (m, 3H) 7.57 (s, 1H) 7.40 (m, 6H) 7.22 (d, 1H, J=16.5 Hz). MS (ESI, pos. ion) m/z: 408.1 (M+1).

Using the procedures described in Example 3 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.001 g) was prepared from 2-hydroxybenzeneboronic acid (0.105 g, 0.38 mmol) and Compound 10c (0.110 g, 0.30 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.74 (d, 2H, J = 8.3 Hz) 7.63 (dd, 3H, J = 8.7 Hz, J = 17.1 Hz) 7.56 (s, 1H) 7.50 (d, 1H, J = 8.3 Hz) 7.38 (dd, 1H, J = 1.5 Hz, J = 8.4 Hz) 7.22 (m, 2H) 7.06 (m, 1H) 6.82 (m, 2H). MS (ESI, pos. ion) m/z: 381.3 (M + 1). 15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.125 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.75 (d, 2H, J = 8.2 Hz) 7.60 (m, 4H) 7.48 (m, 2H) 7.38 (m, 3H) 7.23 (d, 1H, J = 16.6 Hz) 7.16 (dd, 1H, J = 1.7 Hz, J = 8.3 Hz) 1.92 (s, 3H). MS (ESI, pos. ion) m/z: 407.3 (M + 1). 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol A solution of (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone Compound 15 (0.005 g, 0.01 mmol) in ethanol (0.5 mL) was treated with NaBH₄ (0.003 g, 0.08 mmol). After 3 h, the solution was applied to a preparative TLC plate (2000 microns, silica gel, 20 × 20) and developed using EtOAc: hexanes, 1:1. The desired band was extracted and concentrated to give the title compound (0.001 g). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.87 (d, 1H, J = 8.2 Hz) 7.76 (d, 1H, J = 8.0 Hz) 7.67 (m, 1H) 7.51 (s, 1H) 7.42 (m, 1H) 7.32 (m, 1H) 7.25 (m, 1H) 4.98 (q, 1H, J = 6.4 Hz) 1.35 (d, 1H, J = 6.4 Hz). MS (ESI, pos. ion) m/z: 409.2 (M + 1). 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide The title compound (0094 g) was prepared from 2-methylsulfonyl aminobenzeneboronic acid (0.163 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). ¹H-NMR (400 MHz, DMSO(d6)) δ (ppm) 12.82 (s, 1H) 8.89 (s, 1H) 7.91 (d, 2H, J = 8.1 Hz) 7.80 (m, 2H) 7.75 (s, 1H) 7.70 (m, 1H) 7.58 (d, 1H, J = 6.9 Hz) 7.37 (m, 6H) 2.73 (d, 3H, J = 28.8 Hz). MS (ESI, pos. ion) m/z: 458.2 (M + 1). 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide Using the procedure of Example 1, Step A., 5-bromo-2-[2-(4-trifluoroethyl- phenyl)-ethyl]-1H-benzimidazole Compound 3b was prepared from 3-(4- trifluoromethyl-phenyl)-propionic acid (1.04 g, 5.04 mmol) and 4-bromo- benzene-1,2-diamine (0.946 g, 5.06 mmol). Using the procedure of Example 1, Step B., the title compound was prepared from 2-methylsulfonylaminobenzeneboronic acid (0.367 g, 1.7 mmol) and Compound 3b (0.188 g, 0.51 mmol). ¹H-NMR (400 MHz, (CD₃OD) δ (ppm) 7.64-7.50 (m, 5H), 7.47-7.34 (m, 4H), 7.34-7.27 (m, 2H), 3.27 (s, 4H), 2.71 (s, 3H). MS (ESI, pos. ion) m/z: 460.16 (M + 1).

Example 4 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide (Cpd 19) Step A. 3-(4-trifluoromethoxy-phenyl)-acrylic acid

A solution of 4-trifluoromethoxybenzaldehyde (26.3 mmol), malonic acid (5.6 g, 53.8 mmol) and piperidine (0.265 mL, 2.7 mmol) in pyridine (15 mL) was heated to 70° C. for 18 h. Water (200 mL) was added to the reaction solution. The mixture was acidified to pH 4 using concentrated hydrochloric acid. The solution was filtered. The solid was washed with water. The solid was dried in vacuo to give the title Compound 4a (1.2 g). ¹H-NMR (d6-DMSO) δ (ppm): 6.80 (d, J=16.02 Hz, 1H), 6.72 (m, 2H), 6.38 (m, 2H), 5.55 (d, J=16.00 Hz, 1H).

Step B. 3-(4-trifluoromethoxy-phenyl)-acryloyl chloride

A solution of Compound 4a (1.2 g, 5.2 mmol) in methylene chloride (20 mL) was treated with oxalyl chloride (7.8 mL, 3.6 mmol). To the solution was added DMF (0.02 mL). The reaction solution was stirred at room temperature for 2 h. The reaction solution was concentrated. The residue was dried in vacuo to provide Compound 4b, which was used without further purification in the next step.

Step C. (E)-5-bromo-2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazole

A solution of Compound 4b (1 g, 4 mmol) in acetic acid (10 mL) was added slowly to a solution of 4-bromo-benzene-1,2-diamine (0.744 g, 4 mmol) in acetic acid (10 mL). The solution was heated to 100° C. for 18 h. The solution was cooled to room temperature. To the solution was added ethyl acetate:hexanes 3:7 (100 mL). The solution was filtered. The solid was dried in vacuo to give the title Compound 4c (1.1 g). ¹H-NMR (400 MHz, DMSO d6) ppm 8.12 (d, J=16.60 Hz, 1H), 7.98 (m, 1H), 7.87 (m, 2H), 7.82-7.68 (m, 1H), 7.67-7.37 (m, 4H), 7.34 (d, J=16.58 Hz, 1H). MS (ESI pos. ion) m/z: 383.2 and 385.2.

Step D. (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide

Using the procedure of Example 1, Step B, the title Compound 19 was prepared from 2-carboxamido-phenylbenzene boronic acid and Compound 4c.

Using the procedures described in Example 4 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.280 g, 1.7 mmol) and Compound 4c (0.195 g, 0.51 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.66 (d, J = 8.72 Hz, 2H), 7.61-7.43 (m, 4H), 7.43-7.32 (m, 3H), 7.24 (d, J = 8.19 Hz, 2H), 7.19-7.06 (m, 2H), 1.96-1.86 (m, 3H). MS (ESI, pos. ion) m/z: 423.14 (M + 1). 21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol Using the procedure of Example 2, the title compound was prepared from Compound 20. ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.76-7.80 (d, J = 8.84 Hz, 2H) 7.60-7.70 (m, 3H) 7.50 (bs, 1H) 7.40-7.44 (ddd, J = 1.26, 7.32 Hz, 1H) 7.29-7.37 (m, 3H) 7.20-7.25 (m, 3H) 4.96-5.02 (q, J = 6.57 Hz, 1H) 1.34-1.36 (d, J = 6.32 Hz, 3H). MS (ESI, pos. ion) m/z: 425.2 (M + 1). 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide The title compound (0.05 g) was prepared from 2-methylsulfonyl aminobenzeneboronic acid (0.521 g, 2.4 mmol) and Compound 4c (0.463 g, 1.2 mmol). ¹H-NMR (400 MHz, DMSO(d6)) δ (ppm) 12.76 (d, J = 5.43 Hz, 1H), 8.90 (d, J = 4.68 Hz, 1H), 7.83 (d, J = 8.72 Hz, 2H), 7.65 (m, 1H), 7.50-7.22 (m, 8H), 2.76 (s, 1.5H), 2.69 (s, 1.5H). MS (ESI, pos. ion) m/z: 474.2 (M + 1).

Example 5 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol (Cpd 29) Step A. 5-bromo-2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazole

Using the procedure of Example 1, Step A, the title Compound 5a (0.512 g) was prepared from 4-(4-tert-butyl-phenyl)-butyric acid (2.0 g, 10.7 mmol) and 4-bromo-benzene-1,2-diamine (2.0 g, 10.7 mmol). ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.73 (d, 1H, J=1.6 Hz) 7.45 (d, 1H, J=8.5 Hz) 7.38 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.32 (m, 3H) 7.12 (d, 2H, J=8.3 Hz) 2.97 (m, 2H) 2.73 (t, 2H, J=7.4 Hz) 2.23 (m, 2H) 1.33 (s, 9H).

Step B. 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol

Using the procedure outlined in Example 1, Step B, the title Compound 29 (0.0083 g) was prepared from 2-hydroxybenzeneboronic acid (0.07 g, 0.5 mmol) and Compound 5a (0.074 g, 0.2 mmol). ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.51 (s, 1H) 7.39 (d, 1H, J=8.1 Hz) 7.16 (m, 6H) 6.95 (d, 3H, J=8.2 Hz) 6.88 (t, 1H, J=7.4 Hz) 2.73 (t, 2H, J=7.5 Hz) 2.52 (t, 2H, J=7.3 Hz) 2.00 (m, 2H) 1.20 (s, 9H). MS (ESI, pos. ion) m/z: 385.3 (M+1).

Example 6 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol (Cpd 32) Step A. 3-(4-tert-butyl-phenyl)-propionic acid

A mixture of 3-(4-tert-butyl-phenyl)-acrylic acid (12.28 g, 60.1 mmol) and 10% palladium on carbon (0.6 g) in ethanol was hydrogenated at 50 psi hydrogen for 2 hours. The reaction mixture was filtered over a pad of celite, a nylon disk, and the solvents were removed in vacuo to yield the title Compound 6a (12.36 g, 59.9 mmol) as a white crystalline powder. ¹H-NMR (d6-DMSO) δ (ppm): 12.10 (s, 1H), 7.29 (d, 2H), 7.12 (d, 2H), 2.88 (t, 2H), 2.50 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 228.9 (M+Na⁺)

Step B. 5-bromo-2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazole

To a solution of Compound 6a (1.04 g, 5.04 mmol), in 25 mL of POCl₃ was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 2.5 h then concentrated in vacuo. The residue was treated with 25 mL benzene and evaporated in vacuo. The residue was partitioned between 50 mL EtOAc and 50 mL saturated NaHCO₃. The organic fractions were washed with 50 mL of saturated NaHCO₃ and with 50 mL brine. The organic fraction was dried with Na₂SO₄, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, EtOAc:Heptane, 2:8-4:6)) to yield the title Compound 6b (0.726 g, 2.03 mmol) as a tan powder. ¹H-NMR (d6-DMSO) δ (ppm): 12.48-12.32 (m, 1H), 7.74-7.58 (m, 1H), 7.51-7.38 (m, 1H), 7.33-7.22 (m, 3H), 7.17 (d, 2H), 3.10 (m, 4H), 1.27 (s, 9H).

MS (ESI pos. ion) m/z: 357.1/359.1 (M+H⁺).

Step C. 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol

A mixture of Compound 6b, (0.036 g, 0.10 mmol), 2-hydroxy phenyl boronic acid (0.022 g, 0.16 mmol), Cs₂CO₃ (0.074 g, 0.23 mmol), and PdCl₂(dppf) (0.008 g, 0.01 mmol) in 2 mL 5:1 dioxane/EtOH in a sealed tube was heated at 100° C. for 15 minutes in a microwave synthesizer. More 2-hydroxy phenyl boronic acid (0.024 g, 0.17 mmol) and more PdCl₂(dppf) (0.010 g, 0.01 mmol) were added and the reaction was heated at 120° C. for 20 minutes. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was evaporated, and the residue was purified by chromatography. (reverse-phase, acetonitrile:water+0.1% TFA, 25:75-95:5). The relevant fractions were frozen and lyophilized to give the product Compound 32 (0.013 g, 0.04 mmol) as a tan powder. ¹H-NMR (d6-DMSO) δ (ppm): 14.55 (br s, 1H), 9.69 (s, 1H), 7.87 (s, 1H), 7.77 (d, 1H), 7.65 (d, 1H), 7.36-7.30 (m, 3H), 7.24-7.15 (m, 3H), 6.98 (d, 1H), 6.92 (t, 1H), 3.40 (t, 2H), 3.17 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 371.2 (M+H⁺).

Using the procedures described in Example 6 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.016 g) was prepared from 3-hydroxy phenyl boronic acid (0.037 g) and Compound 6b (0.036 g). ¹H-NMR (d6-DMSO) δ (ppm): 14.62 (br s, 1H), 9.62 (s, 1H), 7.88 (s, 1H), 7.81 (d, 1H), 7.71 (dd, 1H), 7.36-7.27 (m, 3H), 7.18 (d, 2H), 7.13 (d, 1H), 7.08 (t, 1H), 6.82 (dd, 1H), 3.40 (t, 2H), 3.16 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion): 371.2 (M + H⁺). 34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.022 g) was prepared from 4-hydroxy phenyl boronic acid (0.032 g) and Compound 6b (0.036 g). ¹H-NMR (d6-DMSO) δ (ppm): 14.61 (br s, 1H), 9.65 (s, 1H), 7.85 (s, 1H), 7.78 (d, 1H), 7.71 (dd, 1H), 7.56 (d, 2H), 7.33 (d, 2H), 7.18 (d, 2H), 6.89 (d, 2H), 3.39 (t, 2H), 3.16 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 371.2 (M + H⁺).

Example 7 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol (Cpd 35) Step A. (E)-3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid ethyl ester

To a solution of 4-trifluoromethylsulfanyl-benzaldehyde (15.46 g, 75.0 mmol) in 350 mL of benzene was added (carbethoxymethylene)triphenyl-phosphorane (26.14 g, 75.0 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 6 hours. The solvents were removed in vacuo and the resulting material was triturated with 350 mL of diethyl ether and filtered. The filtrate was concentrated in vacuo and triturated once more with 50 mL diethyl ether and filtered. The filtrate was evaporated in vacuo and purified by chromatography (silica, EtOAc:heptane, 0:10-1:9) to obtain the title Compound 7a (15.8 g, 57.3 mmol) as a white solid. ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89 (d, 2H), 7.75 (d, 2H), 7.70 (d, 1H), 6.77 (d, 1H), 4.21 (q, 2H), 1.27 (t, 3H). MS (ESI pos. ion) m/z: 277.0 (M+H⁺).

Step B. (E)-3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid

To a solution of Compound 7a (10.31 g, 37.3 mmol), in 300 mL of ethanol was added 3N aqueous NaOH solution (13.0 mL, 39.0 mmol). The reaction mixture was stirred for 21 hours, then evaporated in vacuo. The residue was dissolved in 250 mL water, and to it was added 1N aqueous HCl (45 mL, 45 mmol). The resulting precipitate was filtered, rinsed with water and dried under a stream of air to yield the title Compound 7b (8.967 g, 36.1 mmol) as a white powder. ¹H-NMR (400M Hz, d6-DMSO) δ (ppm): 12.58 (s, 1H), 7.85 (d, 2H), 7.74 (d, 2H), 7.63 (d, 1H), 6.66 (d, 1H).

Step C. (E)-5-bromo-2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazole

To a suspension of Compound 7b (1.240 g, 5.00 mmol) in 100 mL of CH₃CN was added POCl₃ (2.3 mL, 25.1 mmol) and 4-bromo-benzene-1,2-diamine (0.938 g, 5.01 mmol). The reaction mixture was heated at reflux under a nitrogen atmosphere for 18 hours, cooled slightly then additional 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. Refluxing was continued for 6 hours, then a final amount of 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. After heating for an additional 15 hours, the reaction mixture was concentrated in vacuo. The residue was purified by chromatography (silica, NH₃ in MeOH (2M):CH₂Cl₂, 1:99-5:95) then a second time (EtOAc:heptane, 1:9-1:1)) to afford the title Compound 7c (1.255 g, 3.14 mmol) as a tan powder. ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 12.96-12.83 (br d, 1H), 7.87-7.68 (m, 6H), 7.60-7.45 (m, 1H), 7.39-7.29 (m, 2H). MS (ESI pos. ion) m/z: 398.9/400.9 (M+H⁺).

Step D. (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol

To a solution of Compound 7c (0.040 g, 0.10 mmol) and 2-hydroxymethyl phenyl boronic acid (0.029 g, 0.19 mmol) in 3 mL dioxane in a small pressure tube was added aqueous Na₂CO₃ solution (0.13 mL, 2M, 0.26 mmol) followed by PdCl₂(dppf) (0.008 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120° C. for 1 hour. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fractions were dried with Na₂SO₄, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase, acetonitrile:water+0.1% TFA, 1:3-95:5). The relevant fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound 35 (0.027 g, 0.063 mmol) as a yellow powder. ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89-7.78 (m, 5H), 7.71-7.57 (m, 3H), 7.44-7.28 (m, 5H), 4.44 (s, 2H). MS (ESI pos. ion) m/z: 426.7 (M+H⁺).

Using the procedures described in Example 7 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol The title compound (0.029 g) was prepared from 2-hydroxy phenyl boronic acid (0.028 g) and Compound 7c (0.040 g). ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.61 (s, 1H), 7.90-7.79 (m, 6H), 7.70 (d, 1H), 7.54 (d, 1H), 7.42 (d, 1H), 7.33 (dd, 1H), 7.19 (dt, 1H), 6.98 (d, 1H), 6.91 (dt, 1H). MS (ESI pos. ion) m/z: 412.8 (M + H⁺). 37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide The title compound (0.016 g) was prepared from N-[2-(4,4,5,5-tetramethyl- [1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.052 g) and Compound 7c (0.040 g). ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.24 (s, 1H), 7.86 (d, 2H), 7.82-7.75 (m, 3H), 7.67 (d, 1H), 7.57 (s, 1H), 7.51 (d, 1H), 7.44-7.24 (m, 5H), 1.89 (s, 3H). MS (ESI pos. ion) m/z: 453.8 (M + H⁺). 38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide The title compound (0.031 g) was prepared from 2-benzamido boronic acid (0.034 g) and Compound 7c (0.040 g). ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.91-7.79 (m, 5H), 7.73-7.66 (m, 3H), 7.54-7.38 (m, 6H), 7.31 (s, 1H). MS (ESI pos. ion) m/z: 439.8 (M + H⁺). 39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone The title compound (0.027 g) was prepared from 2-acetyl phenyl boronic acid (0.034 g) and Compound 7c (0.040 g). ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.87 (d, 2H), 7.84-7.77 (m, 3H), 7.69 (d, 1H), 7.55-7.47 (m, 2H), 7.64-7.58 (m, 3H), 7.40 (d, 1H), 7.21 (dd, 1H), 2.09 (s, 3H). MS (ESI pos. ion) m/z: 438.7 (M + H⁺).

Example 8 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 40) Step A. (E)-3-(4-trifluoromethanesulfonyl-phenyl)-acrylic acid

To a suspension of Compound 7b (2.483 g, 10.01 mmol), in 50 mL of TFA was added 30% H₂O₂ solution (8 mL, 83 mmol). The reaction mixture was stirred for 21 h, then poured into 250 mL of ice water. The resulting precipitate was filtered off, rinsed with water and dried under vacuum at 50° C. to yield the title Compound 8a (2.281 g, 8.14 mmol) as a white powder. ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 12.80 (s, 1H), 8.15 (s, 4H), 7.73 (d, 1H), 6.83 (d, 1H). MS (ESI pos. ion) m/z: 278.9 (M−H⁺).

Step B. (E)-5-bromo-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazole

To a suspension of Compound 8a (1.405 g, 5.01 mmol) in 100 mL of acetonitrile was added POCl₃ (2.3 mL, 25.1 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 30 minutes, then cooled slightly. To this reaction mixture was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol) and the reaction was refluxed for 2 h before additional 4-bromo-benzene-1,2-diamine (0.942 g, 5.04 mmol) was added. After an hour of heating, the reaction mixture was cooled and filtered over a pad of celite. The filter cake was rinsed with acetonitrile, ethyl acetate, and methanol. The filtrate was stirred with aqueous NaHCO₃/EtOAc. The organic fraction was evaporated, and partitioned between 100 mL EtOAc and 100 mL saturated NaHCO₃. The organic fraction was dried with Na₂SO₄, filtered, and the filtrate was evaporated. The residue was purified by chromatography (silica gel, EtOAc:heptane, 1:4-1:1)) to yield the title Compound 8b (1.595 g, 3.70 mmol) as a tan powder. ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 13.00 (d, 1H), 8.14 (q, 4H), 7.87-7.73 (m, 2H), 7.63-7.50 (m, 2H), 7.40-7.33 (m, 1H). MS (ESI pos. ion) m/z: 430.8/432.8 (M+H⁺).

Step C. (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone

A solution of Compound 8b (0.043 g, 0.10 mmol), and 2-acetyl phenyl boronic acid (0.035 g, 0.21 mmol) in 3 mL dioxane was stirred in a small pressure tube. Aqueous Na₂CO₃ solution (0.13 mL, 2M, 0.26 mmol) was added followed by PdCl₂(dppf) (0.007 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120° C. for 1 h. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was dried with Na₂SO₄, filtered, and the filtrate was evaporated. The residue was flushed over a plug of silica gel with 100% EtOAc then evaporated. The crude material was purified by chromatography (reverse-phase, acetonitrile/water+0.1% TFA, 1:3-95:5). The appropriate fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound 40 (0.022 g, 0.047 mmol) as a yellow powder. ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.87 (d, 1H), 7.70 (d, 1H), 7.64-7.56 (m, 3H), 7.55-7.47 (m, 3H), 7.21 (d, 1H), 2.09 (s, 3H). MS (ESI pos. ion): 471.0 (M+H⁺).

Using the procedures described in Example 8 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol The title compound (0.024 g) was prepared from 2-hydroxy phenyl boronic acid (0.029 g) and Compound 8b (0.043 g). ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.53 (s, 1H), 8.16 (q, 4H), 7.85 (d, 1H), 7.77 (s, 1H), 7.65 (d, 1H), 7.58 (d, 1H), 7.47 (d, 1H), 7.33 (d, 1H), 7.17 (dt, 1H), 6.97 (d, 1H), 6.90 (dt, 1H). MS (ESI pos. ion) m/z: 445.0 (M + H⁺). 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol The title compound (0.030 g) was prepared from 2-hydroxymethyl phenyl boronic acid (0.027 g) and Compound 8b (0.043 g). ¹H-NMR (400 MHz, d6- DMSO) δ (ppm): 8.16 (q, 4H), 7.89 (d, 1H), 7.69 (d, 1H), 7.62 (d, 2H), 7.58 (d, 1H), 7.43-7.33 (m, 2H), 7.30 (dd, 2H), 4.44 (s, 2H). MS (ESI pos. ion) m/z: 459.0 (M + H⁺). 43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide The title compound (0.011 g) was prepared from N-[2-(4,4,5,5-tetramethyl- [1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.053 g) and Compound 8b (0.043 g). ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.23 (s, 1H), 8.15 (q, 4H), 7.85 (d, 1H), 7.67 (d, 1H), 7.62-7.55 (m, 2H), 7.51 (d, 1H), 7.42-7.23 (m, 4H), 1.89 (s, 3H). MS (ESI pos. ion) m/z: 486.1 (M + H⁺). 44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide The title compound (0.018 g) was prepared from 2-benzamido boronic acid (0.034 g) and Compound 8b (0.043 g). ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.88 (d, 1H), 7.70-7.64 (m, 3H), 7.59 (d, 1H), 7.54-7.39 (m, 4H), 7.36 (dd, 1H), 7.30 (s, 1H). MS (ESI pos. ion) m/z: 472.0 (M + H⁺).

Example 9 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 45) 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 46)

To a solution of Compound 40 (0.047 g, 0.10 mmol) in 5 mL EtOH was added NaBH₄ (0.028 g, 0.74 mmol). After 1 h, an additional amount of NaBH₄ (0.024 g, 0.63 mmol) was added. After an additional 4.5 h, the reaction was diluted into 25 mL EtOAc and washed twice with 25 mL water/brine. The organic fractions were dried with Na₂SO₄, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase (acetonitrile/water with 0.1% TFA, 1:3-95:5). The two products were isolated, frozen and lyophilized to give the products Compound 45 (0.024 g, 0.051 mmol) as a yellow powder and Compound 46 (0.020 g, 0.042 mmol) as a white powder.

Compound 45: ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.18 (dd, 4H), 7.93 (d, 1H), 7.74 (d, 1H), 7.67 (d, 1H), 7.64-7.57 (m, 2H), 7.43 (dt, 1H), 7.35-7.27 (m, 2H), 7.21 (dd, 1H), 4.80 (q, 1H), 1.22 (d, 3H). MS (ESI pos. ion) m/z: 472.8 (M+H⁺).

Compound 46: ¹H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.12 (d, 2H), 7.82-7.74 (m, 3H), 7.70-7.63 (m, 2H), 7.47-7.37 (m, 2H), 7.32 (dt, 1H), 7.18 (dd, 1H), 4.72 (q, 1H), 3.47 (t, 2H), 3.40 (t, 2H), 1.19 (d, 3H). MS (ESI pos. ion) m/z: 474.8 (M+H⁺).

Example 10 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol(Cpd 18)

Step A. 3-(4-trifluoromethyl-phenyl)-acrylic acid

A solution of 4-trifluoromethylbenzaldehyde (7.7 mL, 57.7 mmol), malonic acid (12.0 g, 115.4 mmol), 0.567 μL piperidine (5.75 mmol) in 30 mL of pyridine was stirred at 70° C. for 18 h. The reaction solution was cooled to room temperature. Water (300 mL) was added and the resulting mixture was acidified to pH 4 (litmus) using concentrated hydrochloric acid to give a precipitate. The solid was filtered, and washed with water until the filtrate was neutral. The solid product was dried in vacuo to give the title Compound 10a as a white powder (11.2 g, 90%). ¹HNMR (400 MHz, DMSO-d₆) δ (ppm): 12.60 (bs, 1H), 7.92 (d, 2H, J=8.2 Hz), 7.77 (d, 2H, J=8.2 Hz), 7.66 (d, 1H, J=16.0 Hz), 6.70 (d, 1H, J=16.0 Hz).

Step B. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

A solution of Compound 10a (20.6 g, 95.4 mmol) in anhydrous methylene chloride (200 mL) was treated with oxalyl chloride (16.6 mL, 190 mmol) and “3 drops” of anhydrous dimethylformamide. The resulting solution was stirred at room temperature under an argon atmosphere for 18 h. The solvent was concentrated to give 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound 10b as a solid, which was used without further purification in the next step.

To a solution of 4-bromo-benzene-1,2-diamine (16.1 g, 86.7 mmol) in acetic acid (100 mL) was added dropwise a solution of Compound 10b (assumed 95.4 mmol) in acetic acid (100 mL). The reaction mixture was stirred at 100° C. for 18 h. The reaction mixture was cooled to room temperature, and a mixture of ethyl acetate and hexanes 3:7 (500 mL) was added. The mixture was triturated at room temperature for 3 h to give a precipitate. The solid was filtered, and dried in vacuo to give the title Compound 10c (23.2 g, 73%). ¹H NMR (400 MHz, DMSO-d₆/CDCl₃) δ (ppm): 8.45 (d, 1H, J=16.7 Hz), 7.84-7.90 (m, 1H), 7.74 (d, 2H, J=8.3 Hz), 7.56-7.62 (m, 3H), 7.50-7.52 (m, 1H), 7.34 (d, 1H, 16.7 Hz).

Step C. 2-(2-bromo-phenyl)-propan-2-ol

To a solution of methyl 2-bromobenzoate (20.76 g, 96 mmol) in 120 mL of anhydrous ether under Argon at 0° C. was slowly added methylmagnesium bromide (77 mL, 3.26 M) at a rate that the internal temperature of the mixture was below 20° C. A white suspension resulted, and the mixture was stirred at room temperature for 2 h. The mixture was cooled in an ice-water bath. To the reaction mixture was very slowly added hydrochloric acid (400 mL, 0.5 M). The pH of the final mixture was adjusted to less than about 6 with few drops of 2M hydrochloric acid. The layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined and dried over magnesium sulfate. The organic fraction was filtered, and the filtrate was concentrated to yield the title compound as a pale yellow liquid, which was distilled under vacuum to afford the title Compound 10d as a colorless liquid (16.9 g, 82%, b.p. about 65-70° C./0.3 mmHg). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.67 (dd, 1H, J=1.7, 7.9 Hz), 7.58 (dd, 1H, J=1.3, 7.9 Hz), 7.30 (ddd, 1H, J=1.4, 7.4, 7.9 Hz), 7.10 (ddd, 1H, J=1.7, 7.4, 7.8 Hz), 2.77 (br s, 1H), 1.76 (s, 6H).

Step D. 3,3-dimethyl-3H-benzo[c][1,2]oxaborol-1-ol

To a solution of n-BuLi (166 mL, 2.6 M, 432 mmol) in 200 mL of THF at −78° C. under argon was slowly added a solution of Compound 10d (42.2 g, 196 mmol) in 60 mL of THF at a rate that the internal temperature remained below −70° C. The mixture was stirred at −75° C. for 2 h. To the reaction mixture was then added triisopropylborate (59 mL, 255 mmol) in three portions. The mixture was allowed to warm slowly to room temperature overnight. The mixture was then cooled to 0° C., and was carefully quenched with dilute hydrochloric acid (250 mL, 2N). The mixture was then stirred at room temperature for 1 h. The pH of the mixture was checked and adjusted to acidic using additional 2N HCl if prophetic. The two layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined, and dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to yield a pale yellow oil. The residue was then diluted with ethyl acetate (400 mL) and, washed with 1N sodium hydroxide solution (150 mL×3). The basic aqueous layers were combined and acidified with 2N HCl. The clear solution turned cloudy when the acid was added. The mixture was extracted with ether (150 mL×3). The organic layers were combined and dried with magnesium sulfate. The solution was filtered, and the filtrate was concentrated under reduced pressure to yield the title Compound 10e as a colorless oil (26.2 g, 82%) which was used without further purification in the next step. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.00 (s, 1H), 7.66 (dm, 1H, J=7.3 Hz), 7.45 (dt, 1H, J=1.1, 7.7 Hz), 7.40 (dm, 1H, J=7.6 Hz), 7.31 (dt, 1H, J=1.2, 7.1 Hz), 1.44 (s, 6H).

Step E. (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol

To a mixture of Compound 10e (11.7 g, 71 mmol), Compound 10c (19.9 g, 54 mmol), sodium carbonate (46 g, 435 mmol) and PdCl₂(dppf).CH₂Cl₂ (8.9 g, 11 mmol) in a 1 L round bottom flask equipped with water condenser was added 400 mL of anhydrous DME and 200 mL of water. The mixture was evacuated and filled with Argon three times. The mixture was heated to 100° C. for 20 h. The mixture was then cooled to room temperature. The biphasic system was transferred to a 1 L separatory funnel and the two layers were separated. The organic layer was washed with brine (2×300 mL). The aqueous layers were combined and extracted with ethyl acetate once (about 300 mL). The organic layers were combined, dried with sodium sulfate, and filtered. The volume of the filtrate was reduced to about 170 mL under reduced pressure. The mixture was then filtered through a pad of silica gel and the pad was washed with ethyl acetate until the filtrate did not contain any product. After concentration, a light pink/beige solid was obtained. The solid was triturated with 50 mL ethyl acetate, and the mixture was heated to 85° C. for 5 min. The mixture was slowly cooled to r.t., then cooled at 0° C. for 0.5 h. The mixture was filtered, and the solid was washed with cold ethyl acetate twice, and dried under vacuum at 40° C. to yield the title Compound 18 as a light beige solid (7.58 g, 33%). RP-HPLC 95% pure. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 12.73 (m, 1H,), 7.90 (d, 2H, J=8.2 Hz), 7.85 (dd, 1H, J=8.0, 0.6 Hz), 7.78 (d, 2H, J=8.4 Hz), 7.74 (d, 1H, J=16.8 Hz), 7.59-7.47 (m, 1H), 7.41 (s, 1H), 7.37-7.32 (m, 2H), 7.21 (dt, 1H, J=1.2, 7.4 Hz), 7.06 (s, 1H), 7.02 (d, 1H, J=7.4 Hz), 4.85 (s, 1H), 1.21 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₅H₂₁F₃N₂O: 423.2 (M+H), Found 423.3. m.p. (uncorr.) 250-251° C.

Using the procedures described in Example 10 and corresponding reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.84 (dd, J = 1.26, 8.084 Hz, 1H) 7.75-7.85 (m, 2H) 7.66 (d, J = 16.4 Hz) 7.53-7.58 (m, 1H) 7.45 (bs, 1H) 7.34-7.38 (m, 3H) 7.17-7.26 (m, 3H) 7.09 (dd, J = 1.58, 7.58 Hz, 1H) 1.36 (s, 6H). MS (ESI, pos. ion) m/z: 439.2 (M + 1). 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.07 (d, 2H, J = 8.6 Hz), 7.98 (d, 2H, J = 8.6 Hz), 7.78 (dd, 1H, J = 1.1, 8.1 Hz), 7.69 (d, 1H, J = 16.5 Hz), 7.54 (d, 1H, J = 8.2 Hz), 7.44 (d, 1H, J = 16.5 Hz), 7.42 (br s, 1H), 7.31 (ddd, 1H, J = 1.5, 7.8, 8.1 Hz), 7.18 (dt, 1H, J = 1.3, 7.4 Hz), 7.16 (dd, 1H, J = 1.5, 8.3 Hz), 7.03 (dd, 1H, J = 1.4, 7.5 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₅H₂₁F₃N₂O₃S: 487.1 (M + H), Found 487.1. 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.79 (dd, 1H, J = 8.1, 1.1 Hz), 7.63-7.54 (m, 3H), 7.51 (br d, 1H, J = 9.7, 7.4 Hz), 7.40-7.38 (m, 3H), 7.31 (m, 1H), 7.19 (dt, 1H, J = 1.4, 7.4 Hz), 7.15 (d, 1H, J = 16.5 Hz), 7.13 (dd, 1H, J = 7.9, 1.8 Hz), 7.04 (dd, 1H, J = 7.5, 1.4 Hz), 1.30 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₄H₂₁ClN₂O: 389.1 (M + H), Found 389.3. 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.00 (d, J = 8 Hz, 2H), 7.91 (d, J = 8 Hz, 2H), 7.82 (dd, J = 1.6, 8 Hz, 1H), 7.70 (d, J = 16.4 Hz, 2H), 7.41 (s, 1H), 7.36 (dt, J = 1.6, 8 Hz, 1H), 7.34 (s, 1H), 7.23 (dt, J = 1.6, 8 Hz, 1H), 7.19 (dd, J = 1.6, 8 Hz, 1H), 7.07 (dd, J = 1.6, 8 Hz, 1H), 3.16 (s, 3H), 1.26 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₅H₂₄N₂O₃S: 433.1 (M + H), Found 433.4. 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.89-7.87 (m, 2H), 7.79 (dd, 1H, J = 8.1, 1.1 Hz), 7.67-7.56 (m, 3H), 7.52 (m, 1H), 7.40 (br s, 1H), 7.31 (m, 1H), 7.27 (d, 1H, J = 16.6 Hz), 7.18 (dt, 1H, J = 1.3, 7.4 Hz), 7.14 (dd, 1H, J = 8.3, 1.4 Hz, 1H), 7.04 (dd, 1H, J = 7.52, 1.38 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₅H₂₁F₃N₂O: 423.2 (M + H), Found 423.3. 458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide. The title compound (0.0195 g) was prepared from Compound 465 (0.10 g, 0.26 mmol) and trifluoroacetylimidazolide (0.047 g, 0.29 mmol). ¹H-NMR (400 MHz, DMSO d6) δ (ppm): 12.7-12.9 (bs, 1H) 11.0 (s, 1H) 7.90-7.94 (d, J = 8.59 Hz, 2H)) 7.78-7.81 (d, J = 8.59 Hz, 2H) 7.37-7.76 (m, 7H) 7.20 (d, J = 9.34 Hz, 1H) MS (ESI, pos. ion) m/z: 476.2 (M + 1). 459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)- vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide The title compound (0.0015 g) was prepared from Compound 465 (0.034 g, 0.09 mmol) and trifluoromethylsulfonylchloride (0.018 g, 0.10 mmol). ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 12.75-12.82 (bs, 1H) 9.70-9.80 (bs, 1H) 7.90-7.96 (d, J = 8.08 Hz, 2H) 7.78-7.84 (m, 3H) 7.54-7.77 (m, 2H) 7.40-7.50 (m, 2H) 7.24-7.40 (m, 6H) 4.0 (bs, 2H)MS (ESI, pos. ion) m/z: 526.1 (M + 1). 460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-propionamide The title compound (0.0014 g) was prepared from Compound 465 (0.034 g, 0.09 mmol) and trimethylacetylchloride (0.012 mL, 0.036 mmol). ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.80-7.84 (m, 3H) 7.58-7.78 (m, 6H) 7.38-7.42 (m, 2H) 7.24-7.35 (m, 3H) 1.20 (s, 9H) MS (ESI, pos. ion) m/z: 464.3 (M + 1). 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide The title compound (0.0018 g) was prepared from Compound 465 (0.10 g, 0.26 mmol) and ethylsulfonyl chloride (0.027 mL, 0.29 mmol). ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 12.88 (d, J = 9.1 Hz, 1H) 8.92 (d, J = 7.3 Hz, 1H) 7.78 (d, J = 8.08 Hz, 2H)) 7.85 (d, J = 8.08 Hz, 2H) 7.72-7.82 (m, 3H) 7.63-7.68 (m, 1H) 7.30-7.53 (m, 6H) 2.78-2.92 (qq, J = 7.33 Hz, 2H) 1.00 (tt, J = 7.33 Hz, 3H). MS (ESI, pos. ion) m/z: 472.1 (M + 1). 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester The title compound (0.0056 g) was prepared from Compound 465 (0.10 g, 0.26 mmol) and chloromethylformate (0.022 mL, 0.29 mmol). ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (d, J = 8.59 Hz, 2H) 7.76-7.78 (d, J = 8.59 Hz, 2H) 7.62-7.70 (m, 3H) 7.59 (bs, 1H) 7.36-7.41 (m, 3H) 7.24-7.34 (m, 3H). MS (ESI, pos. ion) m/z: 438.4 (M + 1). 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (m, 1H) 7.35-7.64 (m, 8H) 7.10-7.30 (m, 4H) 1.38 (s, 15H). MS (ESI, pos. ion) m/z: 411.3 (M + 1). 465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenylamine The title compound was prepared from Compound 479 by stirring in TFA with heating. ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 12.78 (s, 0.5H) 12.75 (s, 0.5H) 7.91 (d, J = 8.08 Hz, 2H) 7.78-7.81 (m, 3H) 7.74 (d, J = 4.55 Hz, 1H) 7.68 (d, J = 8.08 Hz, 1H) 7.56-7.62 (m, 1H) 7.52 (bs, 1H) 7.41 (d, J = 16.4 Hz, 1H) 7.20-7.29 (m, 1H) 7.05 (t, J = 7.6 Hz, 2H) 6.78 (d, J = 8.34 Hz, 1H) 6.65 (t, J = 6.8 Hz, 1H) 4.81 (s, 1H) 4.74 (s, 1H)MS (ESI, pos. ion) m/z: 526.1 (M + 1). 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (d, J = 8.59 Hz, 2H) 7.76-7.78 (d, J = 8.59 Hz, 2H) 7.62-7.70 (m, 3H) 7.59 (bs, 1H) 7.36-7.41 (m, 3H) 7.24-7.34 (m, 3H). MS (ESI, pos. ion) m/z: 438.4 (M + 1). 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 8.18 (bs, 2H) 7.70 (m, 3H) 7.44 (m, 3H) 7.30 (m, 3H) 7.22 (m, 2H) 7.19 (m, 1H) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 412.2 (M + 1). 470 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)sulfamide The title compound (0.0023 g) was prepared from Compound 465 (0.0175 g, 0.046 mmol) and sulfamide (0.5 g, 5.2 mmol). ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.86 (d, J = 8.61 Hz, 2H) 7.62-7.78 (m, 6H) 7.31-7.41 (m, 4H) 7.21-7.25 (m, 1H). MS (ESI, pos. ion) m/z: 459.2 (M + 1). 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.83 (d, J = 8.59 Hz, 2H) 7.77 (d, J = 8.34 Hz, 2H)7.56-7.74 (m, 5H)7.24-7.42 (m, 5H) 4.56 (s, 2H)MS (ESI, pos. ion) m/z: 395.1 (M + 1). 478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-acetamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.80-7.84 (m, 3H) 7.56-7.78 (m, 5H) 7.30-7.44 (m, 5H) 1.97 (s, 3H). MS (ESI, pos. ion) m/z: 422.3 (M + 1). 479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.76-8.00 (d, J = 8.1 Hz, 2H) 7.82-7.90 (d, J = 8.8 Hz, 2H) 7.68-7.79 (m, 4H) 7.36-7.48 (5H) 1.44 (s, 9H). MS (ESI, pos. ion) m/z: 480.2 (M + 1). 480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.84-7.87 (d, J = 8.1 Hz, 2H) 7.56-7.78 (m, 5H) 7.20-7.40 (m, 6H). MS (ESI, pos. ion) m/z: 411.2 (M + 1). 481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl- phenyl)-1H-benzimidazole ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.10 (d, 2H, J = 8.5 Hz, 1H), 8.02 (d, 2H, J = 8.5 Hz), 7.77 (d, 1H, J = 7.8 Hz, 1H), 7.73 (d, 1H, J = 16.5 Hz), 7.64 (d, 1H, J = 7.4 Hz), 7.60 (d, 1H, J = 8.4 Hz), 7.54 (d, 1H, J = 7.7 Hz), 7.50 (s, 1H), 7.46 (d, 1H, J = 16.5 Hz), 7.42 (d, 1H, J = 7.6 Hz), 7.22 (dd, 1H, J = 8.4, 1.0 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₃H₁₄F₆N₂O₂S: 497.1 (M + H), Found 497.1. 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.00-7.94 (m, 2H), 7.79 (dd, 1H, J = 8.1, 1.1 Hz), 7.73 (d, 1H, J = 7.9 Hz), 7.66 (t, 1H, J = 7.7 Hz), 7.53 (br s, 1H), 7.50 (t, 1H, J = 7.67, 7.67 Hz), 7.41 (br s, 1H), 7.31 (m, 1H), 7.21-7.13 (m, 3H), 7.04 (dd, 1H, J = 7.5, 1.4 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₅H₂₁F₃N₂O: 423.2 (M + H), Found 423.3. 483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzyl)-amine To a solution of Compound 484 (20.7 mg, 0.053 mmol) in DMF (10 mL) was added dimethylamine 2.0 M in THF (66 μL, 0.132 mmol). The mixture was stirred for 45 min and sodium triacetoxyborohydride (17 mg, 0.080 mmol) was added. The mixture was stirred at rt for 2.5 d and then concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20 × 20 cm, 2000 microns, EtOAc:hexanes:methanol 5:5:1) to give the title compound (18.2 mg, 81%). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.81 (d, 2H, J = 8.2 Hz), 7.70 (d, 2H, J = 8.0 Hz), 7.67 (d, 1H, J = 16.3 Hz), 7.60 (d, 1H, J = 8.2 Hz), 7.55-7.47 (m, 2H), 7.40-7.26 (m, 4H), 7.19 (dd, 1H, J = 8.3, 1.5 Hz), 3.58 (s, 2H), 2.14 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₅H₂₂F₃N₃: 422.2 (M + H), Found 422.1. 484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzaldehyde ¹H NMR (400 MHz, DMSO-d6) δ (ppm): 12.93 (d, 1H, J = 12.5 Hz), 9.93 (s, 1H), 7.93 (d, 3H, J = 8.4 Hz), 7.82-7.56 (m, 8H), 7.44 (d, 1H, J = 16.5 Hz), 7.28 (dd, 1H, J = 10.1, 9.3 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₃H₁₅F₃N₂O: 393.1 (M + H), Found 393.3. 485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzyl)-amine The title compound was prepared according to the procedure used for Compound 483, with the exception that methylamine was used. ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.82 (d, 2H, J = 8.3 Hz, 1H), 7.71 (d, 2H, J = 8.3 Hz), 7.69 (d, 1H, J = 16.6 Hz), 7.63 (d, 1H, J = 8.1 Hz), 7.52-7.47 (m, 2H), 7.39 (tdd, 2H, J = 9.1, 7.2, 3.6, 3.6 Hz), 7.35-7.29 (m, 2H), 7.23 (dd, 1H, J = 8.3, 1.6 Hz), 3.86 (s, 2H), 2.30 (s, 3H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₄H₂₀F₃N₃: 408.2 (M + H), Found 408.1. 487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.80 (d, 2H, J = 8.2 Hz), 7.76 (d, 1H, J = 7.9 Hz), 7.70-7.60 (m, 4H), 7.57 (d, 1H, J = 8.3 Hz), 7.52 (t, 1H, J = 7.7 Hz), 7.47 (s, 1H), 7.40 (d, 1H, J = 7.6 Hz), 7.29 (d, 1H, J = 16.6 Hz), 7.19 (dd, 1H, J = 8.3, 1.0 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₃H₁₄F₆N₂: 433.1 (M + H), Found 433.3. 488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.78 (d, 2H, J = 8.3 Hz), 7.68-7.66 (m, 3H), 7.63-7.58 (m, 2H), 7.50 (m, 1H), 7.43-7.35 (m, 3H), 7.33 (dd, 1H, J = 8.4, 1.6 Hz), 7.27 (d, 1H, J = 16.6 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₃H₁₄F₆N₂O: 449.1 (M + H), Found 449.3.

Example 10.1 Scale Up Preparation of (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 18) Step A. 3-(4-trifluoromethyl-phenyl)-acrylic acid

A 2-L 4-neck round bottom flask equipped with an air condenser/argon inlet, mechanical stirrer, thermocouple and a stopper was charged with 4-(trifluoromethyl)benzaldehyde (250 g, 196.2 mL, 1.44 mol), malonic acid (302.6 g, 2.87 mol), and pyridine (750 mL). An exotherm developed (about 38-40° C.), which was maintained for 30 min. Piperidine (14.202 mL, 143.58 mmol) was then added to the reaction and a second exotherm developed (T_(max) about 42° C. after about 10 min.). The reaction was stirred for 30 min and then heated to 60° C. for 18 h (overnight). The reaction appeared to be complete by TLC, and was cooled to about 40° C., diluted into water (2 L; done to prevent reaction freezing), cooled to room temperature, and further diluted with water (4 L, 6 L total). The slurry was acidified to pH=2.0-3.0 with concentrated hydrochloric acid (about 675-700 mL). The material was stirred for 30 min., and a white solid was collected by filtration. The filter cake was washed with water until the filtrate was neutral (pH about 5.5-6, 2.5 L), air-dried in a Buchner funnel for 2 h, and then further dried in a vacuum oven at 60° C. overnight to provide 300.5 g (96%) of the title Compound 10a as a white solid.

Step B. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

To a 5-L 4-neck round bottom flask equipped with a magnetic stirrer, argon inlet-argon outlet to a carbonate scrub, two stoppers, and a room temperature water bath was charged with 4-(trifluoromethyl)cinnamic acid (315 g, 1.46 mol) and dichloromethane (3.15 L) to give a slurry. To the slurry was added oxalyl chloride (151.71 mL, 1.75 mol) and DMF (1.13 mL, 14.57 mmol). Upon addition of DMF, gas evolution commenced, and the reaction was continued for about 3 h during which time a solution developed. When the reaction was complete (LC-MS), it was concentrated to dryness to give 342.4 g of 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound 10b (>100%) as a yellow oily solid.

A 5-L 4-neck round bottom flask equipped with mechanical stirrer, thermocouple, air condenser with argon inlet, and a stopper was charged with 4-bromo-benzene-1,2-diamine (244 g, 1.27 mol) and acetic acid (2.13 L). To this solution was added a solution of Compound 10b (327 g, 1.39 mol) in toluene (237 mL). After this addition, the temperature spiked to 45° C. in about 30 seconds and then subsided. The reaction was then heated to 90° C. for 16 h (overnight). The reaction was cooled to 40° C., and poured into a mixed solution of EtOAc and heptane (about 1:3, 5.75 L) and a precipitate occurred. The resulting slurry was stirred for 3 h, and the solid was collected by filtration, washed with EtOAc: heptane (1:3, 3 L), and then dried in a vacuum oven (60° C.) to give 324.3 g (65%) of the title Compound 10c as a partial acetate salt.

Step C. 2-(2-bromo-phenyl)-propan-2-ol

A 12-Liter 4-neck flask equipped with a thermocouple, condenser, septum, addition funnel and overhead mechanical stirrer under argon was charged with methyl-2-bromobenzoate (226.5 g, 1.05 mol) and THF (1.6 L, 19.66 mol). The mixture was cooled to a temperature between 2 and 5° C. with stirring and held for 30 min. To the solution was slowly added methyl magnesium bromide in diethyl ether (3M, 1.05 L; 3.15 mol) via the addition funnel at a rate to maintain the reaction temperature below 15° C. An exotherm was observed during the addition, the reaction temperature warmed from 3 to 15° C. The addition of 1.05 L Grignard was complete in 4 h (approximate feed rate was 4.17 mL/min). The reaction mixture appeared to be off-white/yellow slurry. The reaction was allowed to warm to room temperature and stirred overnight (15 h). The reaction was sampled by HPLC/TLC and showed no starting material present. The ice bath was again applied to the reaction flask and a 0.5 M HCl solution (4.5 L; 2.25 mol) was slowly added over a period of 2 h. The temperature increased dramatically from 0 to 15° C. After the quench was complete, the reaction was stirred at room temperature for 30 min. Additional 2 N HCl (500 mL; 1.00 mol) was slowly added to maintain a pH less than 6. MTBE (1 L) was added to help with the phase split. The reaction was stirred at room temperature for 1 to 2 h to dissolve the solid material into the aqueous phase (most likely Mg(OH)₂ which is very basic). The pH must be checked and adjusted with additional acid when necessary. The phases were separated and the aqueous layer was washed with an additional 1 L MTBE (2×500 mL). The organic phases were combined, washed with NaHCO₃ solution (2×300 mL), dried over MgSO₄, filtered and the filtrate was concentrated under vacuum to yield the title Compound 10d (220.83 g, 97.48% yield) as a clear yellow oil.

Step D. 3,3-dimethyl-3H-benzo[c][1,2]oxaborol-1-ol

A 12-Liter 4-neck round bottom flask equipped with a thermocouple, condenser, addition funnel and overhead mechanical stirrer under dry Argon was charged with anhydrous THF, (3 L) and chilled to −70 to −78° C. via a dry ice/acetone bath. n-Butyl lithium (2.5N in hexanes, 860 mL, 2.15 mol) was slowly added via addition funnel. An exotherm was observed as the temperature rose from −78 to −70° C. To the addition funnel was added a solution of Compound 10d (220 g, 979.97 mmol) in anhydrous THF (1 L). The 2-(2-bromophenyl)propan-2-ol solution was slowly added to the n-BuLi solution. The addition took 90 min in order to maintain a reaction temperature below −70° C. After the addition was complete, the reaction mixture was stirred at −70 to −75° C. for 30 min. The triethylborate (230 mL, 1.35 mol) was quickly added in 3 portions at −70° C. An exotherm was observed, the batch temperature rose from −70 to −64° C. The reaction was stirred at −70° C. and slowly warmed to room temperature over night. After the reaction was cooled to 0-5° C., the reaction was slowly quenched with 2 M HCl (1 L, 2.00 mol) added via the addition funnel while maintaining the batch temperature 0-5° C. The reaction mixture was stirred for 1 h. The aqueous phase pH was 9-10. The pH was then adjusted to acidic (4-5) with 2 M HCl (200 mL). The two phases were separated and the aqueous layer was extracted with MTBE (2×500 mL). The combined organic phases were dried with anhydrous magnesium sulfate. The solution was filtered and concentrated to yield a yellow oil. The yellow oil was diluted with MTBE (1.5 L) and washed with 1M NaOH (3×500 mL). The product containing basic aqueous phases were combined and acidified with 2 M HCl (800 mL) (the clear solution turns turbid with the addition of acid). After stirring the turbid solution for 15 min (pH=4-5) (Note 1), it was extracted with MTBE (2×500 mL). The organic phases were combined and dried over MgSO₄. The solution was filtered and the filtrate was concentrated to yield the title Compound 10e as a clear yellow oil (121.78 grams, 77% yield).

Step E. (E)-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol

A 5-L 4-neck flask equipped with a thermocouple controller, condenser, overhead mechanical stirrer, Firestone valve® and a nitrogen inlet/outlet was charged with dimethoxyethane (2 L), DI water (1 L) and sodium carbonate (230.9 g, 2.18 mol). The solution was degassed and purged with N₂ three times. Compound 10e (71.7 g, 0.35 mol) and Compound 10c (100.0 g, 0.27 mol) were added to the degassed solution. The solution was degassed and purged with N_(2 three times. PdCl) ₂(dppf) (44.48 g, 54.4 mmol) was added to the solution, and the solution was degassed and purged with N₂ three times. The resulting two-phase suspension was heated to reflux for 18 h, and then cooled to room temperature. The reaction mixture was transferred to a 12-L separatory funnel, and the layers were separated. The organic layer was washed with brine (1 L). The two aqueous layers were combined and extracted with EtOAc (1 L). The combined organic layers were dried (Na₂SO₄), filtered, and the filtrate was concentrated to an oil. Two separate 100 g coupling reactions were combined and purified by chromatography in 10 successive chromatography runs on an ISCO preparative chromatography system (10×1.5 Kg SiO₂, 5 column volumes of EtOAc, 250 mL/min flow rate). The combined fractions were transferred to two 22 L 4-neck round bottom flasks, and Silicycle Si-thiol functionalized silica gel (2 g) was added to each solution. The solutions were warmed to 40° C. and aged for 1 h. The solutions were filtered thru a medium glass funnel and washed with EtOAc (4 L) and combined. The filtrate was evaporated to a semi solid, which was transferred to a 2 L round bottom flask, to which EtOAc (0.4 L) was added. The resulting white precipitate slurry was cooled to −5° C. and stirred for 1 h. The slurry was filtered and washed twice with cold EtOAc (100 mL). The solids were dried in a vacuum oven at 40° C. for 40 h to afford 84.0 g (36.5% yield, 98.8 area % purity) of the title Compound 18 as a white solid. Anal. Calcd for C₂₅H₂₁N₂OF₃ 0.04% H₂O 0.15 mol MeOH: C, 70.48; H, 5.14: N, 6.42; F, 13.06 Found: C, 70.54; H, 4.83: N, 6.18; F, 13.33

Example 10.2 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt (Cpd 18)

A 5-L 4-neck flask equipped with a thermocouple controller, an overhead mechanical stirrer, and a nitrogen inlet/outlet was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound 18 (125.0 g, 0.510 mol) and MeOH (1.25 L). A solution of sodium methoxide in methanol (0.5 M, 592 mL, 0.3 mol) was added. The reaction was heated to 65° C. for 30 min and all solids dissolved. The solution was cooled and evaporated to dryness. The foam was collected by scraping it out of the flask. The solids were placed in vacuum oven for 24 h at 40° C. to afford 139 g (about 100% isolated yield) of the title Compound 18 monosodium salt as a yellowish solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.80-7.84 (m, 3H), 7.74 (d, 2H, J=8.59 Hz), 7.65 (d, 1H, J=16.4 Hz), 7.40-7.44 (m, 2H), 7.25-7.37 (m, 2H), 7.16-7.20 (m, 1H), 7.01-7.05 (m, 1H), 6.84-6.87 (m, 1H), 1.23 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₅H₂₁F₃N₂O: 423.2 (M+H), Found 423.3. m.p. (uncorr.) 258-259° C.

Example 10.3 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol hydrochloride salt (Cpd 18)

A 250-mL separatory funnel was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound 18 (1.0 g, 2.4 mmol) and EtOAc (20 mL). Aqueous HCl (1M, 20 mL) was added to the white slurry, and the separatory funnel was shaken. The solid product quickly dissolved, and a white precipitate started to form. The organic layer was transferred to a 100 mL round bottom flask equipped with a magnetic stir bar, and was stirred for 2 h. The thick slurry was filtered, rinsed with EtOAc (2×5 mL), and put into a vacuum oven at 40° C. for 36 h to afford 0.95 g (87.5%) of the title Compound 18 hydrochloride salt.

Example 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol (Cpd 48) Step A. N-(4-bromo-2-nitro-5-trifluoromethyl-phenyl)-2,2,2-trifluoro-acetamide

4-bromo-3-trifluoromethyl aniline (4.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO₃ (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 h, and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL), and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 11 a as a bright yellow solid (6.4 g). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 9.19 (s, 1H) 8.64 (s, 1H) MS (ESI, pos. ion) m/z: 381.4 (M+1).

Step B. 4-bromo-2-nitro-5-trifluoromethyl-phenylamine

Compound 11a (5.7 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K₂CO₃ (15 mL). The reaction mixture was then stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 11b as a yellow solid (2.99 g). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.44 (s, 1H) 7.21 (s, 1H), 6.21 (bs, 2H). MS (ESI, pos. ion) m/z: 285.0 (M+1).

Step C. 4-bromo-5-trifluoromethyl-benzene-1,2-diamine

Compound 11b (2.85 g, 0.01 mol) was dissolved in 30 mL of ethanol. Zinc powder (5.9 g, 0.09 mol) was added in portions followed by the addition of ammonium chloride (1.07 g, 0.02 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (40 mL), washed with 35 mL of brine, dried over Na₂SO₄, and evaporated in vacuo. The residue was purified by chromatography (silica gel, CH₂Cl₂: MeOH, 96:4-94:6)) to provide the title Compound 11c as a bright yellow solid (1.53 g), which was used without further purification in the next step. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 6.99 (s, 1H) 6.92 (s, 1H) MS (ESI, pos. ion) m/z: 254.7 (M+1).

Step D. (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazole

4-t-butyl acrylic acid (1.02 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl₃. To this was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na₂SO₄, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:3-2:3) to provide the title Compound 11d as a light brown solid (0.84 g). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.91 (d, 2H, J=18.5 Hz) 7.69 (d, 1H, J=16.4 Hz), 7.32 (m, 4H) 7.09 (d, 1H, J=16.5 Hz) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 423.7 (M+1).

Step E. (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol

Compound 11d (0.00026 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.00052 mol, 0.072 g, 2.0 equiv) was added followed by aqueous Na₂CO₃ (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was concentrated in vacuo. The residue was taken up in 10 mL of CH₂Cl₂, and washed sequentially with 10 mL of saturated aqueous NaHCO₃ and 10 mL of brine. The organic fractions were dried over Na₂SO₄, filtered, and the filtrate was concentrated in vacuo. The residue purified by chromatography (silica gel, CH₂Cl₂: MeOH, 98:2-95:5) to provide the title Compound 48 as a white solid. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.29-7.56 (m, 8H) 7.15 (d, 1H, J=6.7 Hz) 6.89-7.05 (m, 3H)) 1.34 (s, 9H). MS (ESI, pos. ion) m/z: 437.1 (M+1).

Using the procedures described in Example 11 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenol The title compound was prepared from 3-hydroxyphenyl boronic acid (0.00052 mol, 0.072 g) and Compound 1a (0.00026 mol, 0.10 g). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.25-7.61 (m, 8H) 7.19 (d, 1H, J = 7.0 Hz) 6.90-7.11 (m, 3H)) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 437.1 (M + 1). 50 (E)—N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-acetamide The title compound was prepared from 2-acetamidophenyl boronic acid (0.00052 mol, 0.093 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as an off-white solid. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.15 (d, 2H, J = 8.1 Hz) 7.73-7.76 (m, 2H) 7.35-7.52 (m, 4H) 7.0-7.14 (m, 3H) 6.77 (s, 1 H) 1.45 (s, 9H) 1.35 (s, 3H). MS (ESI, pos. ion) m/z: 478.2 (M + 1). 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.00052 mol, 0.070 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a white solid. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 6.9-7.5 (m, 12H) 4.39 (m, 2H) MS (ESI, pos. ion) m/z: 451.2 (M + 1). 52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl- 1H-benzimidazole The title compound was prepared from 2-fluorophenylboronic acid (0.00052 mol, 0.073 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a beige solid. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.1 (m, 2H) 7.72 (d, 2H, J = 16 5 Hz) 7.42-7.53 (m, 4H) 7.05-7.20 (m, 4H) 1.34 (s, 9H). MS (ESI, pos. ion) m/z: 440.1 (M + 1). 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-benzamide The title compound was prepared from 2-aminocarbonyl phenylboronic acid (0.00052 mol, 0.086 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a yellow solid. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.2-7.8 (m, 9H) 6.91 (d, 2H, J = 5.4 Hz) 6.68 (d, 1H, J = 19.5 Hz) 1.32 (s, 9H). MS (ESI, pos. ion) m/z: 465.25 (M + 1). 54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-carbamic acid tert-butyl ester The title compound was prepared from t-butyl-N-[2-4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl) phenylcarbamate (0.00052 mol, 0.166 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a beige solid. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.0 (s, 1H), 7.89 (s, 1H), 7.62-7.79 (m, 4H), 7.42-7.55 (m, 3H), 7.36-7.41 (m, 2H), 7.15-7.30 (m, 2H))) 1.32 (s, 18H) MS (ESI, pos. ion) m/z: 536.2 (M + 1). 55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide The title compound was prepared from 2-methylsulfonylaminophenyl boronic acid (0.00052 mol, 0.111 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a bright yellow solid. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.0 (s, 1H) 7.79 (d, 1H, J = 16.5 Hz) 7.65 (d, 2H, J = 8.4 Hz) 7.5 (m, 3H) 7.41 (t, 1H, J = 7.7 Hz) 7.23-7.28 (m, 3H) 7.10 (d, 1H, J = 12.1 Hz) 2.5 (s, 3H) 1.31 (s, 9H). MS (ESI, pos. ion) m/z: 514.2 (M + 1).

Example 12 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide (Cpd 56) Step A. (E)-5-bromo-6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

Using the procedure of Example 11, Step D, 4-trifluoromethyl acrylic acid (1.19 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl₃. To this solution was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and then concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na₂SO₄, filtered, and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 3:1-3:2) to provide the title Compound 12a as a light yellow solid (1.02 g). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.92 (d, 2H, J=14.1 Hz) 6.67-7.76 (m, 5H) 7.21 (d, 1H, J=16.5 Hz) MS (ESI, pos. ion) m/z: 368.3 (M+1).

Step B. (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide

Compound 12a (0.00025 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-acetamidophenyl boronic acid (0.0005 mol, 0.089 g, 2.0 equiv) was added followed by aqueous Na₂CO₃ (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the reaction mixture was concentrated in vacuo. The residue was taken up in 10 mL of CH₂Cl₂, and washed sequentially with 10 mL of saturated aqueous NaHCO₃ and 10 mL of brine. The organic fractions were dried over Na₂SO₄, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel CH₂Cl₂: MeOH, 98:2-95:5) to provide the title Compound 56 as a white solid. ¹H-NMR (400M Hz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s, 1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2H, J=4.1 Hz) 1.8 (s, 3H) MS (ESI, pos. ion) m/z: 490.0 (M+1).

Using the procedures described in Example 12 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082 g) and Compound 12a (0.00025 mol, 0.10 g) to give the product as a whitish-yellow solid. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.81-8.0 (m, 8H) 7.42-7.62 (m, 3H) 7.30 (d, 1H, J = 6.8 Hz) 2.49 (s, 3H) MS (ESI, pos. ion) m/z: 475.0 (M + 1). 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g) and Compound 12a (0.00025 mol, 0.10 g) to give the product as a light yellow powder. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.0 (d, 2H, J = 8.1 Hz) 7.8 (d, 2H, J = 8.2 Hz) 7.0-7.59 (m, 8H) 4.91-5.07 (m, 1H) 4.09-4.22 (m, 2H) (s, 9H). MS (ESI, pos. ion) m/z: 463.0 (M + 1).

Example 13 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol (Cpd 59) Step A. N-(4-bromo-5-fluoro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide

4-bromo-3-fluoromethyl aniline (3.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the solution was added KNO₃ (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 h and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 13a as a bright yellow solid (5.42 g). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.66 (d, 1H, J=10.0 Hz) 8.60 (d, 1H, J=11.3 Hz). MS (ESI, pos. ion) m/z: 402.0 (M+Na).

Step B. 4-bromo-5-fluoro-2-nitro-phenylamine

Compound 13a (5.0 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K₂CO₃ (15 mL) and the mixture was stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 13b as a yellow solid (2.5 g). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.39 (d, 1H, J=7.1 Hz) 6.75 (d, 1H, J=9.6 Hz) 6.19 (bs, 2H). MS (ESI, pos. ion) m/z: 236.9 (M+1).

Step C. 4-bromo-5-fluoro-benzene-1,2-diamine

Compound 13b (1.88 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.71 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.86 g, 0.016 mol). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na₂SO₄, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica gel, CH₂Cl₂: MeOH, 96:4-94:6)) to provide the title Compound 13c as a dark yellow solid (1.02 g) that was used immediately in the next reaction. MS (ESI, pos. ion) m/z: 235.7 (M+1).

Step D. (E)-5-bromo-6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl₃. To the solution was added Compound 13c (1.02 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. The reaction mixture was cooled to room temperature and then evaporated in vacuo. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 3:1-3:2) to provide the title

Compound 13d as a light brown solid (0.80 g). ¹H-NMR (400 MHz, DMSO-d₆) δ (ppm): 7.63-8.09 (m, 4H) 7.4 (d, 1H, J=20.7 Hz) 6.69 (d, 1H, J=20.7 Hz) MS (ESI, pos. ion) m/z: 386.0 (M+1).

Step E. (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol

Compound 13d (0.00025 mol, 0.096 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.0005 mol, 0.069 g) was added followed by aqueous Na₂CO₃ (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH₂Cl₂, and washed sequentially with 10 mL of saturated aqueous NaHCO₃ and 10 mL of brine. The organic fractions were dried over Na₂SO₄, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel (CH₂Cl₂: MeOH, 98:2-95:5) to provide the title Compound 59 as a tan solid. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.90 (d, 2H, J=8.0 Hz) 7.79 (d, 2H, J=7.8 Hz) 7.22-7.53 (m, 4H) 6.88-6.96 (m, 4H) MS (ESI, pos. ion) m/z: 399.1 (M+1).

Using the procedures described in Example 13 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol The title compound was prepared from 3-hydroxyphenyl boronic acid (0.0005 mol, 0.069 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as an off-white solid. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.76-8.0 (m, 4H) 7.24-7.64 (m, 5H) 6.96-7.03 (m, 1H) 6.75-6.8 (m, 2H) MS (ESI, pos. ion) m/z: 399.3 (M + 1). 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as a yellowish solid. ¹H-NMR (400 MHz, CD3OD) δ (ppm): 7.83 (d, 2H, J = 8.2 Hz) 7.70-7.73 (m, 2H) 7.64 (t, 2H, J = 7.9, 7.5 Hz)) 7.55 (d, 1H, J = 7.2 Hz) 7.25-7.46 (m, 4H) 7.10 (dd, 1H, J = 1.2 Hz) 4.29 (d, 2H, J = 0.85 Hz) MS (ESI, pos. ion) m/z: 413.1 (M + 1). 62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as a bright yellow solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.75-7.91 (m, 5 H) 7.55-7.68 (m, 4H) 7.41-7.47 (m, 3H) 2.46 (s, 3H) MS (ESI, pos. ion) m/z: 425.1 (M + 1). 63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide The title compound was prepared from 2-aminocarbonyl phenylboronic acid (0.0005 mol, 0.083 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as a sticky tan solid. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.93 (d, 2H, J = 8.6 Hz) 7.83 (d, 2H, J = 8.6 Hz) 7.40-7.71 (m, 8H) MS (ESI, pos. ion) m/z: 426.0 (M + 1). 64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide The title compound was prepared from 2-acetamidophenyl boronic acid (0.0005 mol, 0.089 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as an off-white solid. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s, 1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2H, J = 4.1 Hz) 1.8 (s, 3H) MS (ESI, pos. ion) m/z: 440.1 (M + 1). 65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide The title compound was prepared from 2 methylsulfonylaminophenyl boronic acid (0.0005 mol, 0.108 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as an off-white solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.65 (s, 1 H) 7.59 (d, 1H, J = 6.7 Hz) 7.26-7.48 (m, 10 H) 2.95 (s, 3H) MS (ESI, pos. ion) m/z: 476.1 (M + 1).

Example 14 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol (Cpd 66) Step A. N-(4-bromo-5-chloro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide

4-Bromo-3-chloromethyl aniline (4.1 g, 0.02 mol) was added in portions to a stirred ice cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO₃ (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 hour and then allowed to warm to room temperature overnight.

The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 14a as a pale yellow solid (5.55 g).

Step B. 4-bromo-5-chloro-2-nitro-phenylamine

Compound 14a (5.2 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) saturated aqueous K₂CO₃ (15 mL). The reaction mixture was stirred at room temperature for 10 hours. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 14b as a yellow solid (2.71 g). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.39 (s, 1H) 6.98 (s, 1H) 6.08 (bs, 2H). MS (ESI, pos. ion) m/z: 250.9 (Br, Cl pattern).

Step C. 4-bromo-5-chloro-benzene-1,2-diamine

Compound 14b (2.0 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.7 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.88 g, 0.016 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 hours). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na₂SO₄, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica gel, CH₂Cl₂: MeOH, 96:4-94:6) to provide the title Compound 14c as a dark yellowish-brown solid (1.08 g) and was used immediately in the next reaction. MS (ESI, pos. ion) m/z: 220.9 (Br, Cl pattern).

Step D. (E)-5-bromo-6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl₃. To this solution was added Compound 14c (1.08 g, 0.005 mol), and the reaction mixture was heated to reflux for 6 hours (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and the evaporated in vacuo. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na₂SO₄, filtered and the filtrate was evaporated in vacuo. The residue was purified by chromatography (silica gel hexanes: EtOAc, 3:1-3:2) to provide the title Compound 14d as a light brown solid (0.80 g). ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.57-8.21 (m, 4H) 7.35 (d, 1H, J=19 Hz) 6.72 (d, 1H, J=18.5 Hz). MS (ESI, pos. ion) m/z: 401.0.

Step E. (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol

Compound 14d (0.00025 mol, 0.100 g) was dissolved in 5 mL of dioxane. 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g, 2.0 equiv) was added followed by aqueous Na₂CO₃ (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH₂Cl₂, and washed sequentially with 10 mL of saturated aqueous NaHCO₃ and 10 mL of brine. The organic fractions were dried over Na₂SO₄, filtered and the solvent was evaporated in vacuo. The residue was purified by chromatography (silica gel, CH₂Cl₂: MeOH, 98:2-95:5) to provide the title Compound 66 as a yellow sticky solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.82-7.85 (d, 2H, J=8.4 Hz) 7.72-7.74 (d, 2H, J=8.3 Hz) 7.56-7.66 (m, 3H) 7.26-7.43 (m, 5H) 5.05 (s, 1H) 4.58 (s, 2H). MS (ESI, pos. ion) m/z: 395.3 (—CH₂OH).

Using the procedures described in Example 14 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082 g) and Compound 14d (0.00025 mol, 0.100 g) to give the product as a pale yellow solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.80-7.84 (m, 2H) 7.70-7.74 (m, 2H) 7.67 (s, 1H), 7.50-7.7.64 (m, 2H) 7.27-7.43 (m, 5H), 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 441.1 (M + 1). 68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol The title compound was prepared from 2-hydroxyphenyl boronic acid (0.0005 mol, 0.108 g) and Compound 14d (0.00025 mol, 0.069 g) to give the product as a dark yellow solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 6.2-6.6 (m, 5H) 5.99-6.05 (m, 5H) 5.59-5.66 (2H) 7.80-7.84 (m, 2H). MS (ESI, pos. ion) m/z: 415.0 (M + 1).

Example 15 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 70) (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 309) Step A. (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

A mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (12.4 g, 0.048 mol), Compound 10c (13.6 g, 0.037 mol), Pd(dppf)Cl₂CH₂Cl₂ (3.00 g, 3.70 mmol), TBAB (11.9 g, 0.037 mmol), and Na₂CO₃ (31.4, 0.296 mol) in 750 mL of mixed solvent (DME: water, 4:1) was heated at 90° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:1) to provide the title Compound 309 as a yellow oil. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J=1.6 and 7.6 Hz) 7.84 (d, 2H, J=8.4 Hz) 7.73 (d, 2H, J=8.4 Hz) 7.70-7.62 (m, 4H) 7.54 (dt, 1H, J=1.6 and 8.6 Hz) 7.41 (dd, 1H, J=1.2 and 7.6 Hz) 7.37-7.31 (m, 2H) 1.00 (s, 9H) MS (ESI, pos. ion) m/z: 490.3 (M+1).

Step B. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

A solution of Compound 309 in 60 mL TFA was heated at 70° C. for 2 hours.

The reaction was concentrated, the residue was dissolved in EtOAc, and washed with sat'd NaHCO₃. The organic layer was dried over Na₂SO₄, filtered, and the residue was concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:2) to provide the title Compound 70 as a light brown solid. M.p. 168-170° C. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.16 (dd, 1H, J=1.2 and 8.0 Hz) 7.95-7.91 (m, 3H) 7.82-7.76 (m, 4H) 7.70-7.56 (m, 3H) 7.44 (s, 1H) 7.16 (d, 1H, J=9.6 Hz) MS (ESI, pos. ion) m/z: 444.3 (M+1).

Using the procedures described in Example 15 and reagents, starting materials and conditions known to those skilled in the art, the following compound representative of the present invention was prepared:

Cpd Name and Data 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 8.10 (d, 2H, J = 8.4 Hz) 8.01 (d, 2H, J = 8.4 Hz) 7.71-7.53 (m, 5H) 7.44 (d, 1H, J = 16.4 Hz) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.35 (dd, 1H, J = 1.2 and 8.4 Hz) MS (ESI, pos. ion) m/z: 508.3 (M + 1). 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-N,N-dimethylaminosulfonylphenyl boronic acid and Compound 10c. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.08 (dd, 1H, J = 1.2 and 8.4 Hz) 7.84 (d, 2H, J = 8.4 Hz) 7.73 (d, 2H, J = 8.8 Hz) 7.69-7.56 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.33 (d, 1H, J = 16.4 Hz) 7.28 (dd, 1H, J = 1.6 and 8.4 Hz) 2.34 (s, 6H) MS (ESI, pos. ion) m/z: 472.5 (M + 1). 441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-5- fluorophenylboronic acid and Compound 10c. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.18 (dd, J = 5.6, 8 Hz, 1H), 7.94 (d, J = 5.6, 8 Hz, 1H), 7.84 (d, J = 8 Hz, 2H), 7.73 (s, 1H), 7.71-7.69 (m, 2H), 7.63 (d, J = 8 Hz, 1H), 7.35-7.32 (m, 1H), 7.28-7.22 (m, 2H), 7.14 (dd, J = 2, 9 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₅F₄N₃O₂S: 462.4 (M + H), Found 462.2. 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-5- trifluoromethylphenyl boronic acid and Compound 10c. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.33 (d, J = 8 Hz, 1H), 7.88 (s, 1H), 7.85 (d, J = 8 Hz, 2H), 7.74-7.68 (m, 6H), 7.36-7.32 (m, 1H), 7.34 (d, J = 16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₅F₆N₃O₂S: 512.5 (M + H), Found 512.3. 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-4- trifluoromethylphenyl boronic acid and Compound 10c. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.42 (s, 1H), 7.94 (d, J = 8 Hz, 1H), 7.85 (d, J = 8 Hz, 2H), 7.73 (d, J = 8 Hz, 2H), 7.71 (d, J = 8 Hz, 2H), 7.64 (d, J = 8 Hz, 2H), 7.34 (d, J = 16.4 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₅F₆N₃O₂S: 512.1 (M + H), Found 512.2.

Example 16 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 69) Step A. (5-bromo-2-tert-butoxycarbonylamino-phenyl)-carbamic acid tert-butyl ester

4-bromo-phenylenediamine (25 g, 0.134 mol) was added portionwise to di-t-butyl dicarbonate (175 g, 0.802 mol) at 25° C., and the reaction mixture was stirred for 10 hours. The mixture was purified by chromatography (silica gel, hexanes to hexanes: EtOAc, 1:1) to provide the title Compound 16a as a light brown solid.

¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.76 (brs, 1H) 7.32 (brs, 1H) 7.22 (dd, 1H, J=2.0 and 8.8 Hz) 6.72 (brs, 1H) 6.53 (brs, 1H).

Step B. (3-tert-butoxycarbonylamino-2′-tert-butylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester

A mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (4.7 g, 0.018 mmol), Compound 16a (4.7 g, 0.012 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (0.99 g, 0.0012 mmol), TBAB (3.90 g, 0.012 mmol), and 20 mL of 1M Na₂CO₃ (aq) in 100 mL of DME was heated at 100° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 2:1) to provide the title Compound 16b as a yellow oil.

Step C. 3′,4′-diamino-biphenyl-2-sulfonic acid tert-butylamide

A mixture of Compound 16b in 20 mL of 4M HCl in dioxane was stirred for 3 hours. The reaction mixture was concentrated, diluted with EtOAc and washed with sat'd NaHCO₃ (aq), then dried over Na₂SO₄ and filtered. The filtrate was concentrated to provide the title Compound 16c as a brown oil. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.04 (dd, 1H, J=1.2 and 7.6 Hz) 7.56 (dt, 1H, J=1.2 and 8.2 Hz) 7.44 (dt, 1H, J=1.2 and 8.4 Hz) 7.33 (dd, 1H, J=1.2 and 7.6 Hz) 6.86 (d, 1H, J=1.6 Hz) 6.77 (d, 1H, J=7.6 Hz) 6.73 (dd, 1H, J=2.0 and 8.0 Hz) 0.97 (s, 9H). MS (ESI, pos. ion) m/z: 319.9 (M+1).

Step D. (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

A mixture of Compound 16c (0.120 g, 0.376 mmol), trans 4-(trifluoromethoxy)-cinnamic acid (0.105 g, 0.451 mmol), and 0.4 mL of 4N HCl (aq) in 4 mL of ethylene glycol was heated at 180° C. for 1 hour. The reaction mixture was purified directly by HPLC (YMC ODS-A, H₂O: MeCN, 90:10 to 40:60, over 10 min) to provide the title Compound 69 as an off-white solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 8.0 Hz) 7.75 (d, 2H, J=8.4 Hz) 7.68-7.53 (m, 5H) 7.41 (dd, 1H, J=1.2 and 7.6 Hz) 7.37-7.33 (m, 3H) 7.19 (d, 1H, J=16.8 Hz) MS (ESI, pos. ion) m/z: 460.3 (M+1).

Using the procedures described in Example 16 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.68-7.54 (m, 7H) 7.46-7.40 (m, 3H) 7.38 (dd, 1H, J = 1.2 and 8.4 Hz) 7.19 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 410.4 (M + 1). 85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.99 (d, 2H, J = 8.4 Hz) 7.89 (d, 2H, J = 8.4 Hz) 7.71-7.53 (m, 5H) 7.41 (dd, 1H, J = 1.6 and 7.6 Hz) 7.36 (d, 1H, J = 16.4 Hz) 7.34 (dd, 1H, J = 1.6 and 8.4 Hz) MS (ESI, pos. ion) m/z: 453.4 (M + 1). 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (d, 1H, J = 8.0 Hz) 7.83-7.75 (m, 2H) 7.67-7.53 (m, 4H) 7.38 (t, 2H, J = 9.2 Hz) 7.22 (d, 1H, J = 16.8 Hz) 7.08-7.03 (m, 2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.72-7.55 (m, 6H) 7.48-7.35 (m, 4H) 7.20 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.84 (d, 1H, J = 16.8 Hz) 7.70-7.54 (m, 5H) 7.41 (dd, 2H, J = 1.6 and 8.4 Hz) 7.33 (d, 1H, J = 16.8 Hz) 7.29-7.23 (m, 2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.81 (d, 1H, J = 16.8 Hz) 7.69-7.54 (m, 5H) 7.46-7.38 (m, 2H) 7.33 (d, 1H, J = 16.8 Hz) 7.26-7.14 (m, 2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 8.0 Hz) 7.71-7.55 (m, 5H) 7.42 (td, 2H, J = 1.4 and 8.4 Hz) 7.34-7.28 (m, 3H) 7.04-6.99 (m, 1H) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.37-7.51 (m, 8H) 7.41 (dd, 1H, J = 1.2 and 8.0 Hz) 7.35 (dd, 1H, J = 1.6 and 8.0 Hz) 7.29 (d, 1H, J = 8.8 Hz) 7.25 (d, 1H, J = 16.8 Hz) 7.34 (dd, 1H, J = 1.6 and 8.4 Hz) MS (ESI, pos. ion) m/z: 460.4 (M + 1). 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, 1H, J = 1.2 and 7.6 Hz) 7.93 (d, 1H, J = 1.2 and 7.6 Hz) 7.65-7.47 (m, 6H) 7.42-7.29 (m, 4H) 7.22 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 454.3 (M + 1). 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 8.10 (dd, 1H, J = 2.0 and 16.4 Hz) 8.01 (d, 1H, J = 7.6 Hz) 7.80 (d, 1H, J = 7.6 Hz) 7.75-7.55 (m, 6H) 7.42 (dd, 2H, J = 1.2 and 8.4 Hz) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 444.3 (M + 1). 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.16 (d, 1H, J = 7.6 Hz) 8.13 (s, 1H) 7.90 (d, 1H, J = 9.2 Hz) 7.68 (d, 1H, J = 14.4 Hz) 7.65-7.49 (m, 4H) 7.43-7.38 (m, 4H) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 410.3 (M + 1). 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.35 (d, 1H, J = 16.4 Hz) 8.16 (dd, 1H, J = 1.6 and 8.0 Hz) 7.97 (dd, 1H, J = 1.6 and 7.6 Hz) 7.84 (s, 1H) 7.80 (d, 1H, J = 9.2 Hz) 7.76 (dd, 1H, J = 1.2 and 8.0 Hz) 7.70-7.60 (m, 3H) 7.52 (dt, 1H, J = 1.2 and 8.2 Hz) 7.45-7.39 (m, 2H) 7.32 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 454.3 (M + 1). 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 7.6 Hz) 8.12-8.08 (m, 2H) 7.76-7.41 (m, 8H) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 461.4 (M + 1). 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 8.10 (t, 1H, 7.0 Hz) 7.91 (d, 1H, J = 16.4 Hz) 7.75-7.54 (m, 5H) 7.46-7.34 (m, 4H) MS (ESI, pos. ion) m/z: 461.4 (M + 1). 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.16 (dd, 1H, J = 1.6 and 8.0 Hz) 8.12-8.10 (m, 2H) 7.94 (d, 1H, J = 16.8 Hz) 7.85 (dd, 1H, J = 0.8 and 1.6 Hz) 7.80 (dd, 1H, J = 0.8 and 8.8 Hz) 7.70-7.59 (m, 3H) 7.52 (t, 1H, J = 9.8 Hz) 7.43 (dd, 1H, J = 1.6 and 7.6 Hz) 7.39 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 462.3 (M + 1). 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (d, 1H, J = 8.0 Hz) 7.79 (d, 1H, J = 16.8 Hz) 7.68 (d, 1H, J = 16.0 Hz) 7.64-7.55 (m, 4H) 7.43-7.40 (m, 2H) 7.31 (d, 1H, J = 16.8 Hz) 7.23 (q, 1H, J = 8.1 Hz) MS (ESI, pos. ion) m/z: 430.4 (M + 1). 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.84-7.79 (m, 1H) 7.75 (d, 1H, J = 15.6 Hz) 7.68-7.53 (m, 4H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.37 (dd, 1H, J = 1.6 and 8.4 Hz) 7.33-7.25 (m, 2H) MS (ESI, pos. ion) m/z: 430.3 (M + 1). 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 0.8 and 7.6 Hz) 7.85 (d, 1H, J = 16.8 Hz) 7.70-7.54 (m, 4H) 7.49 (d, 1H, J = 16.8 Hz) 7.46-7.40 (m, 3H) 7.10 (t, 2H, J = 8.8 Hz) MS (ESI, pos. ion) m/z: 412.3 (M + 1). 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.25 (s, 2H) 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.95 (s, 1H) 7.71 (d, 1H, J = 16.8 Hz) 7.68-7.53 (m, 4H) 7.44 (d, 1H, J = 16.8 Hz) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.35 (dd, 1H, J = 1.6 and 8.0 Hz) MS (ESI, pos. ion) m/z: 512.4 (M + 1). 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.36 (s, 1H) 8.24 (dd, 1H, J = 2.0 and 16.4 Hz) 8.16 (dd, 1H, J = 1.2 and 8.0 Hz) 8.06 (d, 1H, J = 8.4 Hz) 7.84 (d, 1H, J = 8.4 Hz) 7.83 (s, 1H) 7.79 (d, 1H, J = 8.8 Hz) 7.69-7.57 (m, 3H) 7.48-7.42 (m, 2H) MS (ESI, pos. ion) m/z: 512.4 (M + 1). 375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.51 (d, 1H, J = 16.0 Hz) 8.16-8.10 (m, 2H) 8.03 (d, 1H, J = 8.4 Hz) 7.82 (dd, 1H, J = 1.6 and 8.0 Hz) 7.75-7.55 (m, 4H) 7.49-7.36 (m, 2H) 7.28 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 488.1 (M + 1). 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (d, 1H, J = 7.6 Hz) 7.89 (s, 1H) 7.74-7.58 (m, 7H) 7.48-7.37 (m, 3H) 7.27 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 454.3 (M). 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 8.0 Hz) 8.04 (d, 1H, J = 2.0 Hz) 7.93 (dd, 1H, J = 2.0 and 8.4 Hz) 7.71-7.54 (m, 6H) 7.43-7.38 (m, 2H) 7.32 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 478.4 (M + 1). 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 8.00 (dd, 1H, J = 2.4 and 6.4 Hz) 7.88 (d, 1H, J = 16.4 Hz) 7.76-7.57 (m, 5H) 7.51 (dd, 1H, J = 1.6 and 8.8 Hz) 7.42 (dd, 1H, J = 1.2 and 8.0 Hz) 7.38 (d, 1H, J = 16.4 Hz) 7.20 (dd, 1H, J = 8.8 and 10.4 Hz) MS (ESI, pos. ion) m/z: 472.3 (M + 1). 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, J = 1.2, 8.2 Hz, 1H), 7.74-7.62 (m, 7H), 7.43-7.34 (m, 3H), 6.64 (d, J = 16.0 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₅F₄N₃O₂S: 462.1 (M + H), Found 462.2. 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8.0 Hz, 1H), 7.99 (t, J = 7.2 Hz, 1H), 7.83 (d, J = 16.8 Hz, 1H), 7.67-7.52 (m, 4H), 7.45 (s, 1H), 7.43-7.40 (m, 3H), 7.34 (dd, J = 1.6, 7.6 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₅F₄N₃O₂S: 462.1 (M + H), Found 462.2. 425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8.0 Hz, 1H), 7.99 (t, J = 7.2 Hz, 1H), 7.57 (d, J = 16 Hz, 1H), 7.67-7.60 (m, 2H), 7.45 (s, 1H), 7.43-7.40 (m, 2H), 7.25 (t, J = 4 Hz, 1H), 7.11 (d, J = 8 Hz, 1H), 7.07-7.08 (m, 1H), 6.92-6.89 (m, 1H), 6.45 (d, J = 16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₂₁N₃O₃S: 420.1 (M + H), Found 420.2. 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide 1H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 7.8 Hz, 1H), 7.66-7.58 (m, 6H), 7.54 (dt, J = 1.6, 7.6 Hz, 1H), 7.44-7.40 (m, 3H), 7.38-7.34 (m, 1H), 7.31 (dd, J = 1.6, 8 Hz, 1H), 7.18 (d, J = 16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₇N₃O₂S: 376.1 (M + H), Found 376.3. 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.82 (s, 1H), 7.65-7.61 (m, 3H), 7.60-7.54 (m, 3H), 7.52 (s, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32 (dd, J = 1.6, 8 Hz, 1H), 7.22 (d, J = 16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅Cl₂N₃O₂S: 444.0 (M + H), Found 444.1. 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.78 (d, J = 8 Hz, 1H), 7.75 (d, J = 8 Hz, 1H), 7.72 (s, 1H), 7.55-7.54 (m, 1H), 7.62 (dd, J = 1.6, 8 Hz, 1H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.34-7.26 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅ClFN₃O₂S: 428.9 (M + H), Found 430.2. 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.65-7.60 (m, 4H), 7.58-7.52 (m, 3H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32-7.29 (m, 3H), 7.13 (d, J = 16.8 Hz, 1H), 2.94 (h, J = 2.4 Hz, 1H), 1.27 (d, J = 8 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₂₃N₃O₂S: 418.1 (M + H), Found 418.4. 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.65-7.58 (m, 5H), 7.53 (d, J = 7.6 Hz, 2H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.30 (dd, J = 1.6, 8 Hz, 1H), 7.23 (d, J = 8 Hz, 2H), 7.11 (d, J = 16.8 Hz, 1H), 2.36 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₉N₃O₂S: 390.1 (M + H), Found 390.5. 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.80 (d, J = 16 Hz, 1H), 7.73 (t, J = 7.2 Hz, 1H), 7.66-7.60 (m, 4H), 7.57-7.52 (m, 1H), 7.51-7.46 (m, 1H), 7.42 (dd, J = 1.6, 8 Hz, 1H), 7.33 (dd, J = 1.6, 8 Hz, 1H), 7.22 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅ClFN₃O₂S: 428.9 (M + H), Found 428.3. 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.80 (dd, J = 2, 7.2 Hz, 1H), 7.65-7.52 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.33-7.28 (m, 2H), 7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅ClFN₃O₂S: 428.9 (M + H), Found 428.3. 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 8.01 (s, 1H), 7.91-7.82 (m, 4H), 7.80 (d, J = 16.8 Hz, 1H), 7.66-7.59 (m, 3H), 7.55 (dd, J = 1.6, 8 Hz, 1H), 7.52-7.48 (m, 2H), 7.42 (dd, J = 2, 7.6 Hz, 1H), 7.32 (dd, J = 1.6, 8 Hz, 1H), 7.30 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₅H₁₉N₃O₂S: 426.5 (M + H), Found 426.3. 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.69-7.66 (m, 2H), 7.65-7.52 (m, 5H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.31 (dd, J = 1.6, 8 Hz, 1H), 7.18-7.10 (m, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₆FN₃O₂S: 394.4 (M + H), Found 394.3. 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.70 (d, J = 8 Hz, 2H), 7.66-7.61 (m, 4H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.42 (dd, J = 1.6, 8 Hz, 1H), 7.32 (d, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 7.15 (d, J = 16 Hz, 1H), 6.89 (s, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₇F₂N₃O₂S: 426.5 (M + H), Found 426.3. 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.78 (s, 1H), 7.73 (dd, J = 1.6, 8 Hz, 1H), 7.66-7.61 (m, 4H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.44 (d, J = 8 Hz, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.33 (d, J = 8 Hz, 1H), 7.34 (d, J = 16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₅F₄N₃O₂S: 461.4 (M + H), Found 462.2. 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.97 (d, J = 16.8 Hz, 1H), 7.84 (d, J = 8 Hz, 1H), 7.66-7.51 (m, 5H), 7.41-7.37 (m, 2H), 7.32 (dd, J = 1.6, 8 Hz, 1H), 7.20 (d, J = 16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅Cl₂N₃O₂S: 445.3 (M + H), Found 446.1. 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.89 (d, J = 16.8 Hz, 1H), 7.66-7.60 (m, 3H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.45 (d, J = 16 Hz, 1H), 7.43 (s, 1H), 7.41-7.32 (m, 3H), 7.24-7.18 (m, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅ClFN₃O₂S: 428.9 (M + H), Found 428.3. 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.94 (dd, J = 1.6, 8 Hz, 1H), 7.68-7.62 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32 (d, J = 1.6, 8 Hz, 1H), 7.28 (t, J = 8 Hz, 1H), 7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅BrFN₃O₂S: 473.3 (M + H), Found 473.2. 440 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.94 (dd, J = 1.6, 8 Hz, 1H), 7.68-7.62 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32 (d, J = 1.6, 8 Hz, 1H), 7.28 (t, J = 8 Hz, 1H), 7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅BrFN₃O₂S: 473.3 (M + H), Found 473.2.

Prophetic Example 17

Using the procedures described in Example 15 or 16 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:

Cpd Name and Data 91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]- vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide, 97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, and 127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide.

Example 18 (E)-N-Methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 310) Step A. N-methylbenzenesulfonamide-2-boronic acid

To a solution of N-methylbenzenesulfonamide (2.00 g, 0.0117 mmol) in 20 mL THF at 0° C. was added dropwise n-butyl lithium (1.6 M in hexanes, 14.6 mL, 0.0234 mmol). After 30 min., triisopropyl borate (3.1 mL, 0.0164 mmol) was added, and the mixture was stirred at 0° C. for 2 hours. The reaction was quenched by addition of 20 mL of 1M HCl (aq). The mixture was extracted with EtOAc, and the organic fractions were washed with brine, dried over Na₂SO₄, filtered, and the filtrate was concentrated to provide the title Compound 18a as a yellow oil. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.81 (d, 1H) 7.62-7.56 (m, 2H) 2.52 (s, 3H).

Step B. (3-tert-butoxycarbonylamino-2′-methylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester

A mixture of the freshly prepared Compound 18a (9.3 g, 0.0434 mol), Compound 16a (11.2 g, 0.289 mol), Pd(dppf)Cl₂CH₂Cl₂ (4.7 g, 6.42 mmol), TBAB (9.3 g, 0.0289 mol), in 120 mL of 1M Na₂CO₃ (aq) and 600 mL DME was heated at 85° C. for 10 hours. The reaction mixture was cooled, and concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 2:1) to provide the title Compound 18b as a yellow oil. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.12 (d, 1H) 7.86 (d, 1H) 7.62-7.46 (m, 3H) 7.22 (d, 1H) 7.14 (d, 1H) 2.62 (d, 3H) 1.55 (s, 9H) 1.44 (s, 9H).

Step C. 3′,4′-diamino-biphenyl-2-sulfonic acid methylamide

A solution of Compound 18b (21.4 g, 0.0995 mol) in 210 mL of 4M HCl in dioxane was stirred for 4 hours. The reaction mixture was concentrated, made basic with 1M NaOH (aq), and extracted with EtOAc. The organic fraction was dried over Na₂SO₄, filtered, and the filtrate was concentrated to provide the title

Compound 18c as a brown oil. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.00 (dd, 1H, J=1.6 and 8.0 Hz) 7.59 (dt, 1H, J=1.6 and 8.4 Hz) 7.48 (dt, 1H, J=1.2 and 8.4 Hz) 7.33 (dd, 1H, J=1.2 and 8.0 Hz) 6.79 (d, 1H, J=2.0 Hz) 6.75 (d, 1H, J=8.4 Hz) 6.68 (d, 1H, J=2.0 and 7.6 Hz) 2.93 (s, 3H) MS (ESI, pos. ion) m/z: 277.9 (M+1).

Step D. (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

A mixture of Compound 18c (0.100 g, 0.361 mmol) and 4-trifluoromethyl cinnamic acid (0.324 mmol) in 2 mL of POCl₃ was heated to 100° C. for 14 hours. Evaporation of the reaction mixture provided a residue, which was then purified by HPLC(H₂O:MeCN, 90:10 to 30:70, over 15 min) to provide the title Compound 310 as a white solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.07 (dd, 1H, J=1.2 and 8.4 Hz) 7.85 (d, 2H, J=8.4 Hz) 7.73 (d, 2H, J=8 Hz) 7.69-7.63 (m, 3H) 7.58 (dt, 2H, J=1.6 and 7.2 Hz) 7.44 (dd, 1H, J=1.2 and 7.2 Hz) 7.34 (d, J=16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 499.2 (M+MeCN+1).

Using the procedures described in Example 18 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.68-7.60 (m, 3H) 7.59-7.55 (m, 6H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.30 (dd, 1H, J = 1.6 and 8.0 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 509.2 (M + MeCN). 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.04 (dd, 1H, J = 1.2 and 8.0 Hz) 7.77 (d, 1H, J = 16.4 Hz) 7.70 (d, 1H, J = 15.2 Hz) 7.66-7.64 (m, 2H) 7.61-7.55 (m, 3H) 7.46 (dd, 1H, J = 1.6 and 8.4 Hz) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.26 (d, 2H, J = 7.6 Hz) 7.15 (d, 1H, J = 16.8 Hz) 2.42 (s, 3H) 2.36 (s, 3H) MS (ESI, pos. ion) m/z: 404.2 (M + 1). 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82-7.73 (m, 4H) 7.70-7.66 (m, 2H) 7.61 (dd, 1H, J = 1.2 and 7.6 Hz) 7.45 (dd, 1H, J = 1.2 and 8.0 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.22 (d, 1H, J = 8.4 Hz) 7.21 (s, 2H) 7.18 (d, 1H, J = 7.6 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 408.3 (M + 1). 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.84 (s, 1H) 7.70-7.66 (m, 2H) 7.64 (d, 1H) 7.60 (d, 2H, J = 7.6 Hz) 7.59 (s, 2H) 7.42 (dt, 2H, J = 1.6 and 9.2 Hz) 7.25 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 408.3 (M + 1). 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.96 (dd, 1H, J = 2 and 5 Hz) 7.69-7.62 (m, 4H) 7.61-7.57 (m, 2H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.39 (dd, 1H, J = 1.6 and 8.0 Hz) 7.29 (t, 1H, J = 8.4 Hz) 7.18 (d, 1H, J = 16.4 Hz) 2.40 (s, 3H) MS (ESI, pos. ion) m/z: 486.2 (M). 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 7.6 Hz) 7.96 (d, 1H, J = 16.4 Hz) 7.73-7.67 (m, 3H) 7.63 (dd, 1H, J = 1.2 and 8.0 Hz) 7.59 (d, 2H, J = 9.2 Hz) 7.52 (dd, 1H, J = 1.6 and 8.4 Hz) 7.44 (dd, 1H, J = 1.6 and 7.6 Hz) 6.90 (d, 1H, J = 16 Hz) 6.81 (d, 2H, J = 8.8 Hz) 3.06 (s, 6H) 2.45 (s, 3H) MS (ESI, pos. ion) m/z: 433.4 (M + 1). 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.4 Hz) 7.77 (q, 1H, J = 5.3 Hz) 7.73-7.63 (m, 5H) 7.60 (dt, 1H, J = 1.6 and 8.4 Hz) 7.51 (dd, 1H, J = 1.6 and 6.4 Hz) 7.43 (d, 2H, J = 8.4 Hz) 7.39 (d, 1H, J = 16.8 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) m/z: 476.3 (M + 1). 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 6.4 Hz) 8.01 (t, 1H, J = 7.8 Hz) 7.90 (d, 1H, J = 16.4 Hz) 7.70-7.65 (m, 3H) 7.61-7.56 (m, 3H) 7.45 (d, 1H, J = 16.8 Hz) 7.28 (dd, 1H, J = 1.2 and 7.2 Hz) 7.40 (d, 1H, J = 1.2 and 7.2 Hz) 2.40 (s, 3H) MS (ESI, pos. ion) m/z: 476.3 (M + 1). 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.0 Hz) 7.86 (t, 1H, J = 2.0 and 6.2 Hz) 7.73-7.65 (m, 5H) 7.61 (dd, 1H, J = 1.6 and 7.6 Hz) 7.46 (dd, 1H, J = 1.6 and 8.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (t, 1H, J = 8.8 Hz) 7.22 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 442.3 (M + 1). 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.0 Hz) 7.86 (t, 1H, J = 2.0 and 6.2 Hz) 7.73-7.65 (m, 5H) 7.61 (dd, 1H, J = 1.6 and 7.6 Hz) 7.46 (dd, 1H, J = 1.6 and 8.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (t, 1H, J = 8.8 Hz) 7.22 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 442.3 (M + 1). 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (d, 1H, J = 7.6 Hz) 7.75 (d, 1H, J = 16.8 Hz) 7.68-7.56 (m, 5H) 7.43 (d, 1H, J = 3.2 Hz) 7.34 (d, 1H, J = 1.2 and 8.0 Hz) 7.33 (d, 1H, J = 4.0 Hz) 7.22 (q, 1H, J = 8.8 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 444.4 (M + 1). 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 7.87-7.82 (m, 2H) 7.72-7.58 (m, 5H) 7.46-7.42 (m, 2H) 7.31 (d, 1H, J = 16.4 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) m/z: 444.4 (M + 1). 325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.95 (d, 1H, J = 16.8 Hz) 7.74-7.66 (m, 3H) 7.63-7.59 (m, 2H) 7.47 (dd, 1H, J = 1.6 and 8.0 Hz) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.39 (d, 1H, J = 16.8 Hz) 7.34-7.70 (m, 2H) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82 (d, 1H, J = 16.4 Hz) 7.69-7.64 (m, 3H) 7.61-7.55 (m, 2H) 7.43 (dd, 1H, J = 1.6 and 7.6 Hz) 7.37 (dd, 1H, J = 1.6 and 8.8 Hz) 7.33 (d, 1H, J = 16.8 Hz) 7.26-7.15 (m, 2H) 2.39 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.90 (d, 1H, J = 16.8 Hz) 7.71-7.58 (m, 4H) 7.51 (d, 1H, J = 16.8 Hz) 7.46-7.43 (m, 3H) 7.12 (t, 2H, J = 9.0 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 7.68-7.56 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.36 (dd, 1H, J = 1.6 and 8.8 Hz) 7.31-7.25 (m, 3H) 6.99-6.96 (m, 1H) 2.39 (s, 3H) MS (ESI, pos. ion) m/z: 426.3 (M + 1). 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.66-7.56 (m, 6H) 7.48-7.42 (m, 2H) 7.36-7.32 (m, 2H) 7.17 (d, 1H, J = 16.8 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.25 (dd, 1H, J = 1.6 and 16.4 Hz) 8.16 (dd, 1H, J = 1.2 and 9.2 Hz) 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 8.4 (d, 1H, J = 1.2 Hz) 8.25 (dd, 1H, J = 0.8 and 8.0 Hz) 7.73-7.56 (m, 5H) 7.46 (dd, 1H, J = 1.6 and 8.0 Hz) 7.65 (d, 1H, J = 16.4 Hz) 2.46 (s, 3H) MS (ESI, pos. ion) m/z: 476.4 (M + 1). 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02-7.98 (m, 2H) 7.18-7.56 (m, 4H) 7.45-7.40 (m, 2H) 7.38 (dd, 1H, J = 1.6 and 8.4 Hz) 7.26 (d, 1H, J = 16.8 Hz) 2.39 (s, 3H) MS (ESI, pos. ion) m/z: 476.4 (M + 1). 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.10-8.05 (m, 2H) 7.84 (d, 1H, J = 16.8 Hz) 7.71-7.55 (m, 5H) 7.43 (dd, 1H, J = 1.6 and 7.2 Hz) 7.37 (d, 1H, J = 16.8 Hz) 7.32 (dd, 1H, J = 1.2 and 8.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 476.5 (M + 1). 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.24 (s, 2H) 7.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.94 (s, 1H) 7.73-7.55 (m, 5H) 7.45-7.40 (m, 2H) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 526.4 (M + 1). 334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.27 (s, 1H) 8.08-7.92 (m, 3H) 8.87 (d, 1H, J = 8.4 Hz) 7.69-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.36-7.32 (m, 2H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 526.4 (M + 1). 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (d, 1H, J = 8.4 Hz) 7.93 (d, 1H, J = 8.0 Hz) 7.81 (d, 1H, J = 16.4 Hz) 7.74-7.56 (m, 4H) 7.50-7.23 (m, 5H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 442.4 (M + 1). 336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.89 (d, 1H, J = 16.8 Hz) 7.68-7.55 (m, 4H) 7.45 (d, 1H, J = 16.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.6 Hz) 7.38-7.31 (m, 3H) 7.23-7.18 (m, 1H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 442.4 (M + 1). 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 8.51 (d, 1H, J = 16.8 Hz) 7.88 (d, 1H, J = 8.0 Hz) 7.68-7.56 (m, 5H) 7.45-7.41 (m, 2H) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 7.24 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 458.3 (M + 1). 338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82 (t, 1H, J = 1.8 Hz) 7.68-7.49 (m, 7H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.35 (d, 1H, J = 7.6 Hz) 7.30 (dd, 1H, J = 0.8 and 8.0 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 468.3 (M + 1). 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.40 (d, 1H, J = 16.4 Hz) 8.08-8.06 (m, 2H) 8.01 (d, 1H, J = 8.4 Hz) 7.89 (dd, 1H, J = 2.4 and 8.4 Hz) 7.80-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.33 (dd, 1H, J = 1.6 and 7.2 Hz) 7.26 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 442.3 (M + 1). 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-N-methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.76-7.72 (m, 2H) 7.66-7.54 (m, 4H) 7.42 (dd, 1H, J = 0.8 and 7.2 Hz) 7.32-7.26 (m, 4H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 502.3 (M + 1). 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylthio-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (d, 2H, J = 8.8 Hz) 8.06 (dd, 1H, J = 1.2 and 8.4 Hz) 8.06 (d, 2H, J = 8.8 Hz) 7.75-7.56 (m, 5H) 7.47 (d, 1H, J = 16.4 Hz) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (dd, 1H, J = 1.2 and 8.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 522.3 (M + 1). 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.4 Hz) 7.75 (q, 4H, J = 10.6 Hz) 7.44-7.55 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.6 Hz) 7.33-7.28 (m, 2H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 490.3 (M + 1). 343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (dd, 1H, J = 12.0 and 16.0 Hz) 7.98 (d, 1H, J = 8.0 Hz) 7.77 (d, 1H, J = 8.4 Hz) 7.72-7.62 (m, 4H) 7.57 (dt, 1H, J = 1.6 and 8.4 Hz) 7.54 (t, 1H, J = 7.6 Hz) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 458.4 (M + 1). 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.62 (m, 4H) 7.60-7.54 (m, 3H) 7.51 (d, 1H, J = 8.0 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.31 (dd, 1H, J = 1.2 and 8.0 Hz) 7.28 (d, 1H, J = 8.4 Hz) 7.25 (d, 1H, J = 16.8 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 474.4 (M + 1). 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.75 (d, 2H, J = 8.4 Hz) 7.69-7.64 (m, 3H) 7.61 (d, 1H, J = 8.0 Hz) 7.57 (dt, 1H, J = 1.2 and 8.4 Hz) 7.42 (dd, 1H, J = 1.6 and 8.4 Hz) 7.33 (d, 3H, J = 10.0 Hz) 7.20 (d, 1H, J = 16.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 474.4 (M + 1). 346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.03-8.05 (m, 2H) 7.87 (dd, 2H, J = 1.68 and 7.6 Hz) 7.66-7.55 (m, 4H) 7.45 (dd, 1H, J = 1.6 and 7.6 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.38-7.30 (m, 3H) 7.22 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 425.3 (M + 1). 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.36-7.63 (m, 4H) 7.62-7.55 (m, 3H) 7.44 (d, 3H, J = 8.0 Hz) 7.31 (dd, 1H, J = 1.6 and 8.0 Hz) 7.19 (d, 1H, J = 16.4 Hz) 2.36 (s, 3H) MS (ESI, pos. ion) m/z: 425.3 (M + 1). 348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (d, 1H, J = 16.4 Hz) 7.84 (dd, 1H, J = 1.6 and 8.4 Hz) 7.68-7.55 (m, 5H) 7.44-7.40 (m, 2H) 7.31 (dd, 1H, J = 1.2 and 6.8 Hz) 7.02 (dt, 1H, J = 1.6 and 8.4 Hz) 7.17 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 469.5 (M + 1). 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.80 (q, 1H, J = 8.0 Hz) 7.74 (d, 1H, J = 16.8 Hz) 7.67-7.54 (m, 5H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 7.23 (d, 1H, J = 16.8 Hz) 7.05 (t, 1H, J = 8.8 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.01 (d, 2H, J = 8.4 Hz) 7.90 (d, 2H, J = 8.8 Hz) 7.72 (d, 1H, J = 16.4 Hz) 7.67-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.6 and 7.2 Hz) 7.38 (d, 1H, J = 16.4 Hz) 7.33 (dd, 1H, J = 1.6 and 8.4 Hz) 3.15 (s, 3H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 468.4 (M + 1).

Example 19 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 414) Step A. (3-tert-butoxycarbonylamino-2′-methanesulfonylamino-biphenyl-4-yl)-carbamic acid tert-butyl ester

To a solution of Compound 16a (2.0 g, 5.1 mmol), 2-methylsulfonylphenyl boronic acid (1.1 g, 5.1 mmol), and K₂CO₃ (2.1 g, 15.3 mmol) in 1,4-dioxane:water (4:1, 120 mL), was added Pd(dppf)Cl₂CH₂Cl₂ (0.42 g, 0.51 mmol) under an argon atmosphere. The mixture was heated at 95° C. for 12 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc: hexanes, 3:7) to provide the title Compound 19a as a yellow solid (1.7 g, 70% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.64 (d, J=8.4 Hz, 1H), 7.57 (d, J=14.4 Hz, 1H), 7.34 (t, J=8.4 Hz, 1H), 7.26-7.15 (m, 3H), 7.07 (s, 1H), 7.04 (d, J=8 Hz, 1H), 6.87 (s, 1H), 6.63 (s, 1H), 2.90 (s, 3H), 1.51 (s, 9H), 1.49 (s, 9H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₃₁N₃O₆S: 478.19 (M+H), Found 478.0.

Step B. N-(3′,4′-diamino-biphenyl-2-yl)-methanesulfonamide

A solution of Compound 19a (1.0 g, 2.1 mmol) in a mixture of 4M HCl in 1,4-dioxane (10 mL) was heated at 70° C. for 2 h. After concentration of the reaction, the residue was dissolved in dichloromethane (20 mL), and to the solution was added K₂CO₃ (0.5 g) and the mixture was stirred at room temperature for 20 min. After filtration and removal of solvents, the residue was dried to provide the title Compound 19b as a brown solid (0.58 g, quantitative yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.47 (d, J=8.4 Hz, 1H), 7.40-7.35 (m, 1H), 7.32-7.29 (m, 2H), 7.16-7.09 (m, 3H), 2.80 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₁₃H₁₅N₃O₂S: 278.09 (M+H), Found 278.1.

Step C. (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide

A solution of Compound 19b (50 mg, 0.18 mmol) and commercially available 3-(4-ethoxy-phenyl)-acrylic acid (34.6 mg, 0.18 mmol) in POCl₃ (1.5 mL) was heated to 100° C. for 12 h. The reaction was cooled, the excess POCl₃ was removed under reduced pressure, and the residue was purified by HPLC (Gilson, C-18 column, CH₃CN: H₂O (gradient of CH₃CN: 5%-80%)) to provide the title Compound 414 as an off-white solid (25 mg, 32% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm):7.62-7.59 (m, 4H), 7.54-7.52 (m, 1H), 7.41-7.37 (m, 2H), 7.35-7.30 (m, 2H), 7.03 (d, J=16.8 Hz, 2H), 6.97 (d, J=12 Hz, 2H), 4.09 (q, J=7.2 Hz, 2H), 2.72 (s, 3H), 1.41 (t, J=7.2 Hz, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₂₃N₃O₃S: 434.1 (M+H), Found 434.1.

Using the procedures described in Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.40-7.56 (m, 6H) 7.24-7.33 (m, 4H) 7.19-7.22 (m, 2H) 7.05 (d, J = 16.4 Hz, 1H) 2.61 (s, 3H). MS (ESI, pos. ion) m/z: 424.1 (M + 1)., 83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.99-7.96 (m, 2H), 7.89-7.86 (m, 4H), 7.78 (dd, J = 6.4, 15.8 Hz, 2H), 7.60 (dd, J = 1.2, 8.2 Hz, 1H), 7.46-7.39 (m, 2H), 7.33 (dt, J = 1.6, 8.2 Hz, 2H), 6.99 (dd, J = 6.4, 15.8 Hz, 2H), 3.10 (s, 3H), 3.09 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₂₁N₃O₄S₂: 468.1 (M + H), Found 468.0., 95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-methanesulfonamide ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.67-7.62 (m, 5H), 7.54-7.52, (m, 1H), 7.42-7.33 (m, 4H), 7.09 (d, J = 16.4 Hz, 2H), 7.08 (d, J = 12 Hz, 1H), 4.60 (q, J = 8.4 Hz, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₂₀F₃N₃O₃S: 488.1 (M + H), Found 488.3, 101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.65-7.60 (m, 5H), 7.54-7.52 (m, 1H), 7.41-7.37 (m, 2H), 7.34-7.30 (m, 2H), 7.10-7.06 (m, 3H), 4.68 (t, J = 12.8 Hz, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₅H₂₀F₅N₃O₃S: 538.1 (M + H), Found 538.2., 113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD3OD) δ (ppm) 7.90-7.96 (m, 2H) 7.54-7.76 (m, 6H) 7.26-7.42 (m, 5H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 458.1 (M + 1)., 406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.87-7.80 (m, 2H), 7.58-7.30 (m, 9H), 2.85 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₈BrN₃O₂S: 468.0 (M + H), Found 469.1., 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.67-7.52) (m, 6H), 7.14 (d, J = 16.4 Hz, 1H), 3.13-3.12 (m, 1H), 2.72 (s, 3H), 1.27 (d, J = 6.8 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₅H₂₅N₃O₂S: 432.2 (M + H), Found 432.2., 408 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.82 (dd, J = 2.4, 7.2 Hz, 1H) 7.66-7.60 (m, 4H), 7.56-7.52 (m, 2H), 7.41-7.39 (m, 6H), 7.18 (d, J = 16.4 Hz, 1H), 2.73 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₇ClFN₃O₂S: 442.1 (M + H), Found 442.3., 409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.95 (dd, J-2.4, 6.8 Hz, 1H), 7.69-7.68 (m, 1H), 7.67-7.63 (m, 2H), 7.58 (d, J = 16.4 Hz, 1H), 7.53-7.51 (m, 1H), 7.40-7.26 (m, 5H), 7.18 (d, J = 16.4 Hz, 1H), 2.72 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₇BrFN₃O₂S: 486.0 (M + H), Found 486.3., 410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.73 (d, J = 12.8 Hz, 2H), 7.54-7.52 (m, 1H), 7.48-7.45 (m, 1H), 7.41-7.39 (m, 2H), 7.34-7.30 (m, 2H), 7.21 (d, J = 8.8 Hz, 2H), 7.16 (d, J = 17.2 Hz, 1H), 6.90 (s, 1H), 2.73 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₉F₂N₃O₃S: 456.1 (M + H), Found 456.1., 411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.77 (s, 1H), 7.75 (d, J = 12 Hz, 1H), 7.68 (s, 1H), 7.67-7.64 (m, 2H), 7.52 (d, J = 12 Hz, 1H), 7.46 (d, J = 12 Hz, 1H), 7.40-7.25 (m, 5H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₇F₄N₃O₂S: 476.1 (M + H), Found 476.2, 412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.65-7.60 (m, 3H), 7.41-7.36 (m, 3H), 7.41-7.36 (m, 2H), 7.33-7.30 (m, 2H), 7.26 (d, J = 10 Hz, 2H), 7.18 (d, J = 20 Hz, 1H), 2.74 (s, 3H), 2.39 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₂₁N₃O₂S: 404.1 (M + H), Found 404.3, 413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.69-7.61 (m, 2H) 7.57-7.51 (m, 2H), 7.46-7.39 (m, 3H), 7.29 (d, J = 16.2 Hz, 2H), 7.05 (d, J = 12 Hz, 1H), 6.67 (d, J = 16.2 Hz, 2H), 6.33 (d, J = 12 Hz, 1H), 3.01 (s, 3H), 2.97 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₂₄N₄O₂S: 433.2 (M + H), Found 433.3, 415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.09 (s, 1H), 7.96-7.88, (m, 4H), 7.74-7.72 (m, 2H), 7.57-7.52 (m, 3H), 7.51-7.33 (m, 6H), 2.80 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₆H₂₁N₃O₂S: 440.1 (M + H), Found 440.3, 416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.03-8.00 (m, 1H), 7.93 (s, 1H), 7.77 (s, 1H), 7.74 (d, J = 11.2 Hz, 1H), 7.69 (s, 1H), 7.57-7.52 (m, 2H), 7.47 (d, J = 8 Hz, 1H), 7.44 (d, J = 7.6 Hz, 2H), 7.40-7.36 (m, 1H), 7.32 (d, J = 17.2 Hz, 1H), 2.84 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₇Cl₂N₃O₂S: 458.0 (M + H), Found 458.2., 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.03-8.00 (m, 1H), 7.76 (t, J = 8.0 Hz, 1H), 7.71-7.67 (m, 3H), 7.63 (d, J = 8.4 Hz, 1H), 7.54-7.52 (m, 1H), 7.78-7.44 (m, 1H), 7.43-7.38 (m, 3H), 7.38-7.32 (m, 1H), 2.77 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₇F₄N₃O₂S: 476.1 (M + H), Found 476.2., 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.00 (t, J = 8.4 Hz, 1H), 7.84 (d, J = 17.2 Hz, 1H), 7.62-7.58 (m, 2H), 7.55-7.52 (m, 2H), 7.46 (s, 1H), 7.44-7.38 (m, 3H), 7.38-7.32 (m, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₇F₄N₃O₂S: 476.1 (M + H), Found 476.2, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.44-7.65 (m, 10H) 7.22-7.40 (m, 5H) 7.10-7.20 (m, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 466.2 (M + 1).,

Prophetic Example 20

Using the procedures described in Example 19, or using the procedures in Example 1 and the corresponding bromobenzimidazole and boronic acid or boronate ester, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:

Cpd Name and Data 89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]- methanesulfonamide, 107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino- phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- methanesulfonamide,

Prophetic Example 21

Using the procedures described in Example 1 or Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:

Cpd Name and Data 72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide. 75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide. 81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanone, 88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanol, 90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- phenyl]-ethanone, 94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- phenyl]-ethanol, 96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- phenyl]-propan-2-ol, 98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, and 104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide. 105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide. 117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- methanesulfonamide, 118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)- phenyl]-methanesulfonamide, 120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2- yl}-vinyl)-phenyl]-methanesulfonamide, 122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, and 128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)- 1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide.

Example 22 2-{2-[2-(2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 401)

A mixture of (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Cpd 364 (0.020 g, 0.045 mmol) and 10% palladium on charcoal (0.005 g, 0.0045 mmol) in 2 mL MeOH was hydrogenated under H₂ gas (1 atm) for 1 hour. The catalyst was removed by filtration, the filtrate was concentrated to dryness, and the residue was purified by chromatography (silica gel, MeOH: CH₂Cl₂=10:1) to give the title compound as a white solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 7.6 Hz) 7.74-7.53 (m, 4H) 7.60-7.56 (m, 2H) 7.51-7.40 (m, 4H) 3.41 (m, 4H) MS (ESI, pos. ion) m/z: 446.5 (M+1).

Using the procedures described in Example 22 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:

Cpd Name and Data 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, 1.2 and 8.0 Hz) 7.65-7.54 (m, 4H) 7.44-7.31 (m, 4H) 7.20 (d, 2H, J = 8.8 Hz) 3.26-3.23 (m, 4H) MS (ESI, pos. ion) m/z: 462.4 (M + 1). 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (dd, 1H, J = 1.2 and 8.4 Hz) 7.64-7.51 (m, 6H) 7.42 (d, 2H, J = 8.0 Hz) 7.39 (dd, 1H, J = 1.2 and 7.6 Hz) 7.27 (dd, 1H, J = 1.6 and 8.4 Hz) 3.24 (m, 4H) MS (ESI, pos. ion) m/z: 446.4 (M + 1). 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (d, 2H, J = 8.8 Hz) 7.70-7.55 (m, 7H) 7.42 (dd, 1H, J = 1.6 and 7.2 Hz) 7.36 (dd, 1H, J = 1.6 and 8.4 Hz) 3.41-3.48 (m, 4H) MS (ESI, pos. ion) m/z: 510.2 (M + 1). 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.64-7.59 (m, 2H) 7.55-7.51 (m, 2H) 7.39 (dd, 1H, J = 0.8 and 7.6 Hz) 7.32-7.14 (m, 5H) 3.20-3.13 (m, 4H) MS (ESI, pos. ion) m/z: 412.3 (M + 1). 145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, 1.2 and 7.6 Hz) 7.87 (d, 2H, J = 8.4 Hz) 7.66-7.50 (m, 6H) 7.41 (dd, 1H, J = 1.2 and 8.0 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 3.10 (m, 4H) MS (ESI, pos. ion) m/z: 456.3 (M + 1). 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.13 (dd, 1H, J = 1.2 and 7.6 Hz) 7.70-7.48 (m, 8H) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.39 (dd, 1H, J = 1.2 and 7.2 Hz) 3.40-3.30 (m, 4H) MS (ESI, pos. ion) m/z: 446.4 (M + 1). 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.02 (dd, 1H, J = 1.2 and 8.0 Hz) 7.52-7.49 (m, 2H) 7.45-7.41 (m, 4H) 7.31-7.26 (m, 1H) 7.18 (dd, 1H, J = 1.2 and 8.0 Hz) 7.13 (t, 1H, J = 7.2 Hz) 3.20-3.15 (m, 4H) MS (ESI, pos. ion) m/z: 446.4 (M + 1). 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.6 and 7.6 Hz) 7.29 (dd, 1H, J = 1.6 and 8.4 Hz) 7.04-6.99 (m, 2H) 3.24 (m, 4H) MS (ESI, pos. ion) m/z: 432.5 (M + 1). 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.4 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 7.26-7.10 (m, 2H) 3.23-3.20 (m, 4H) MS (ESI, pos. ion) m/z: 432.3 (M + 1). 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.31-7.25 (m, 2H) 6.97-6.93 (m, 2H) 3.26-3.19 (m, 4H) MS (ESI, pos. ion) m/z: 414.3 (M + 1). 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.92 (dd, 1H, 1.2 and 8.4 Hz) 7.80 (s, 1H) 7.64-7.51 (m, 4H) 7.40-7.33 (m, 2H) 7.28 (dd, 1H, J = 1.6 and 8.0 Hz) 3.38-3.25 (m, 4H) MS (ESI, pos. ion) m/z: 514.4 (M + 1). 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 7.6 Hz) 7.94 (d, 1H, J = 8.0 Hz) 7.76-7.72 (m, 2H) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.33 (dd, 1H, J = 1.6 and 8.4 Hz) 3.50-3.45 (m, 2H) 3.31-3.26 (m, 2H) MS (ESI, pos. ion) m/z: 514.5 (M + 1). 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.54-7.60 (m, 3H) 7.54 (dd, 1H, J = 1.2 and 8.0 Hz) 7.52-7.48 (m, 2H) 7.43 (dd, 1H, J = 2.0 and 8.4 Hz) 7.39 (dd, 1H, J = 1.6 and 7.2 Hz) 7.27 (d, 1H, J = 8.0 Hz) 3.23 (m, 4H) MS (ESI, pos. ion) m/z: 480.4 (M + 1). 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, 1.2 and 8.0 Hz) 7.65-7.54 (m, 4H) 7.43-7.37 (m, 2H) 7.33 (dd, 1H, J = 2.0 and 8.0 Hz) 7.26 (d, 1H, J = 8.8 Hz) 7.17 (s, 1H) 7.13 (d, 1H, J = 9.6 Hz) 3.26 (m, 4H) MS (ESI, pos. ion) m/z: 462.4 (M + 1). 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, 1.6 and 6.4 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, 1.6 and 8.0 Hz) 7.30 (dd, 1H, J = 1.2 and 6.8 Hz) 7.28-7.23 (m, 1H) 6.96-6.85 (m, 2H) 3.22 (m, 4H) MS (ESI, pos. ion) m/z: 414.2 (M + 1). 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, 1.2 and 7.6 Hz) 7.65-7.53 (m, 4H) 7.42 (dd, 1H, 1.2 and 7.2 Hz) 7.32 (dd, 1H, J = 1.2 and 8.4 Hz) 7.22-7.13 (m, 2H) 7.04-7.01 (m, 1H) 3.22 (m, 4H) MS (ESI, pos. ion) m/z: 414.4 (M + 1). 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, 1.6 and 8.0 Hz) 7.68-7.53 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.32 (dd, 1H, J = 1.6 and 8.0 Hz) 7.15-7.01 (m, 3H) 3.28 (m, 4H) MS (ESI, pos. ion) m/z: 414.3 (M + 1). 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, 2.4 and 7.6 Hz) 7.67-7.53 (m, 4H) 7.43-7.39 (m, 1H) 7.33-7.29 (m, 1H) 7.12-6.94 (m, 3H) 3.26 (m, 4H) MS (ESI, pos. ion) m/z: 414.4 (M + 1). 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, 2.0 and 8.0 Hz) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.36 (dd, 1H, 1.6 and 8.4 Hz) 6.91-6.77 (m, 3H) 3.26-3.20 (m, 4H) MS (ESI, pos. ion) m/z: 414.6 (M + 1). 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, 1.6 and 7.6 Hz) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.30-7.17 (m, 7H) 3.25-3.06 (m, 4H) MS (ESI, pos. ion) m/z: 378.3 (M + 1). 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound 398. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 7.65 (dt, 1H, J = 1.6 and 8.2 Hz) 7.58-7.53 (m, 5H) 7.41-7.38 (m, 3H) 7.20 (dd, 1H, J = 1.6 and 8.4 Hz) 3.25 (m, 4H) 2.27 (s, 6H) MS (ESI, pos. ion) m/z: 474.4 (M + 1). 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (d, 1H) 7.64-7.52 (m, 4H) 7.41-7.38 (m, 2H) 7.26-7.19 (m, 4H) 3.22-3.18 (m, 4H) MS (ESI, pos. ion) m/z: 412.3 (M + 1). 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (dd, 1H, J = 1.6 and 8.0 Hz) 7.64-7.60 (m, 2H) 7.56-7.51 (m, 2H) 7.46-7.38 (m, 3H) 7.30-7.27 (m, 2H) 3.33-3.30 (m, 2H) 3.35-3.32 (m, 2H) MS (ESI, pos. ion) m/z: 464.4 (M + 1). 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.62 (m, 2H) 7.59-7.50 (m, 4H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.31 (dd, 1H, J = 1.6 and 8.0 Hz) 7.26-7.21 (m, 1H) 3.26 (m, 4H) MS (ESI, pos. ion) m/z: 464.3 (M + 1). 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (d, J = 8.0 Hz, 1H), 7.71 (s, 1H), 7.68-7.64 (m, 2H), 7.60-7.57 (m, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.29-7.24 (m, 2H), 7.12-7.06 (m, 2H), 3.41 (t, J = 8.0 Hz, 2H), 3.28 (t, J = 8.0 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₈FN₃O₂S: 396.1 (M + H), Found 396.3. 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, J = 1.6, 8.0 Hz, 1H), 7.73 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.65 (dd, J = 1.6, 8.0 Hz, 1H), 7.58 (dt, J = 1.6, 8.0 Hz, 1H), 7.51 (d, J = 1.6, 8.0 Hz, 1H), 7.40 (dd, J = 1.2, 7.2 Hz, 1H), 7.27-7.24 (m, 2H), 7.04-7.00 (m, 2H), 3.42 (t, J = 8.0 Hz, 2H), 3.23 (t, J = 8.0 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₈FN₃O₂S: 396.1 (M + H), Found 396.3. 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (d, J = 8.0 Hz, 1H), 7.64-7.60 (m, 2H), 7.56-7.51 (m, 2H), 7.40-7.36 (m, 2H), 7.32-7.29 (m, 3H), 3.27-3.25 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₇F₄N₃O₂S: 464.1 (M + H), Found 464.3. 442 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.12 (dd, J = 1.6, 8 Hz, 1H), 8.01 (d, J = 1.6, 8 Hz, 1H), 7.65-7.60 (m, 3H), 7.58-7.53 (m, 3H), 7.48-7.44 (m, 1H), 7.40 (dd, J = 1.6, 8 Hz, 1H), 7.33 (dd, J = 1.6, 8 Hz, 1H), 3.13 (m, 1H), 2.86 (t, J = 7.6 Hz, 2H), 2.83 (t, J = 7.6 Hz, 2H), 1.21 (d, J = 7.6 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₂₅N₃O₂S: 420.5 (M + H), Found 420.4. 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound 444. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.33 (d, J = 8 Hz, 1H), 7.83 (dd, J = 2, 8 Hz, 1H), 7.63 (d, J = 8 Hz, 2H), 7.58-7.54 (m, 3H), 7.42 (d, J = 8 Hz, 2H), 7.29 (dd, J = 2, 8 Hz, 1H), 3.28-3.24 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₇F₆N₃O₂S: 514.5 (M + H), Found 514.3. 447 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound 446. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.42 (s, 1H), 7.94 (d, J = 8 Hz, 1H), 7.63-7.56 (m, 5H), 7.42 (d, J = 8 Hz, 2H), 7.29 (d, J = 1.6, 8 Hz, 1H), 3.27-3.25 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₇F₆N₃O₂S: 514.1 (M + H), Found 514.2.

Example 23 N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 400)

Using the procedure of Example 18, the title compound was prepared from Compound 18c and 4-trifluoromethylphenyl propionic acid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.04 (dd, 1H, J=1.2 and 8.0 Hz) 7.66-7.53 (m, 6H) 7.42-7.38 (m, 3H) 7.29 (dd, 1H, J=1.6 and 8.4 Hz) 3.27 (m, 4H) MS (ESI, pos. ion) m/z: 460.4 (M+1).

Example 24 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 350)

Using the procedure of Example 18, the title compound was prepared from Compound 18c and 3-trifluoromethylphenyl propionic acid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.05 (dd, 1H, J=1.2 and 7.6 Hz) 7.64 (td, 1H, 1.2 and 8.2 Hz) 7.58-7.53 (m, 4H) 7.50-7.44 (m, 3H) 7.40 (dd, 1H, J=1.2 and 7.2 Hz) 7.25 (dd, 1H, J=1.6 and 8.0 Hz) 3.26-3.22 (m, 4H) MS (ESI, pos. ion) m/z: 460.4 (M+1).

Example 25 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 464)

Using the procedure of Example 10, the title Compound 464 (0.013 g) was prepared from 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazole Compound 25a (0.048 g, 0.13 mmol) and Compound 10e (0.032 g, 0.20 mmol).

¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.26, 8.08 Hz, 1H) 7.45 (d, J=7.8 Hz, 2H) 7.37 (d, J=8.34 Hz, 1H) 7.31 (d, J=8.08 Hz, 2H) 7.20-7.26 (m, 2H) 7.10 (ddd, J=1.51, 7.33, 7.58 Hz, 1H) 6.93-7.20 (m, 2H) 3.14 (m, 4H) 1.21 (s, 6H).

MS (ESI, pos. ion) m/z: 425.1 (M+1).

Using the procedures described in Example 25 and Compound 25a, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:

Cpd Name and Data 457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.50-7.60 (m, 5H) 7.32-7.44 (m, 5H) 7.22-7.26 (d, J = 8.6 Hz, 1H) 3.24-3.30 (s, 4H) 1.96 (s, 3H). MS (ESI, pos. ion) m/z: 424.2 (M + 1).

Prophetic Example 26

Using the procedures of Examples 22, 23, 24 or 25, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.

Cpd Name and Data 133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, 140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanone, 154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanol, 155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-methanesulfonamide, 156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-propan-2-ol, 157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)- methanesulfonamide, 178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)- phenyl]-methanesulfonamide, 179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- ethyl)-phenyl]-methanesulfonamide, 181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol- 2-yl}-ethyl)-phenyl]-methanesulfonamide, 185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide, 186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide, 187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, and 188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)- ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.

Example 27 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 190) Step A. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methyl ester

To a solution of trimethylsulfonium iodide (0.53 g, 2.39 mmol) in 8 mL of DMSO was added sodium hydride (0.06 g, 2.39 mmol) at 25° C. After stirring for one hour, a solution of methyl 4-trifluoromethylcinnamate (0.50 g, 2.17 mmol) in 4 mL DMSO was added. The reaction mixture was stirred for six hours, when it was quenched by sat'd NH₄Cl solution. The resulting mixture was extracted with CH₂Cl₂, the organic layer was dried over Na₂SO₄, filtered and the filtrate was concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 2:1) to provide the title Compound 27a as a solid.

Step B. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid

A solution of Compound 27a in 10 mL MeOH and 4 mL of 1N LiOH (aq) was heated at 70° C. for 4 h. The mixture was then acidified by 4N HCl (aq) and extracted with EtOAc. The organic layer was washed with brine, dried over Na₂SO₄, filtered, and filtrate was concentrated to provide the title Compound 27b. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.56 (d, 2H) 7.25 (d, 2H) 2.39 (m, 1H) 1.80 (m, 1H) 1.47 (m, 1H) 1.18 (m, 1H).

Step C. 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

To a solution of Compound 16c (0.140 g, 0.438 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride Compound 27c (0.060 g, 0.313 mmol) in 4 mL acetonitrile at rt was slowly added a solution of Compound 27b (0.072 g, 0.313 mmol) in 2 mL of acetonitrile. After stirring for 2 hours, the mixture was passed through a short column (silica gel, hexanes: EtOAc, 2:1). The collected eluent was concentrated, and the residue was dissolved in AcOH. The reaction was heated at 80° C. for 3 h. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 2:1). This material was dissolved in TFA, and the mixture was heated at 60° C. for 2 h. The reaction was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:1) to provide the title Compound 190 as a solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 7.6 Hz) 7.74-7.63 (m, 6H) 7.60-7.47 (m, 5H) 7.40 (dd, 1H, J=1.6 and 7.2 Hz) 2.97-2.92 (m, 1H) 2.76-2.71 (m, 1H) 2.12-2.00 (m, 2H) MS (ESI, pos. ion) m/z: 458.3 (M+1).

Example 28 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 471) Step A. N-methoxy-N-methyl-3-(4-trifluoromethyl-phenyl)-acrylamide

To a solution of 4-trifluoromethyl cinnamic acid (3.6 g, 16.7 mmol) in anhydrous methylene chloride (40 mL) was slowly added oxalyl chloride (1.7 mL, 19.5 mmol). To the solution was added anhydrous dimethylformamide (10 μL) and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, the reaction was concentrated. A solution of the residue Compound 10b (16.7 mmol) in methylene chloride (40 mL) was added dropwise to a solution of N,N-dimethylhydroxylamine hydrochloride (1.6 g, 16.7 mmol) and triethylamine (5.8 mL, 41.7 mmol) in methylene chloride (40 mL) at 0° C. The reaction mixture was stirred at 0° C. for 30 min, then warmed to room temperature. After 6 h, the reaction was successively washed with sodium carbonate (10% in water), water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated. The compound was purified by chromatography (silica, EtOAc: hexanes, 1:1) to provide the title Compound 28a (2.2 g, 50% over two steps) ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (d, J=8.3 Hz, 2H) 7.78 (d, J=8.08 Hz, 2H) 7.64 (d, J=15.9 Hz, 1H) 7.24 (d, J=15.9 Hz, 1H) 3.77 (s, 3H) 3.23 (s, 3H).

Step B. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide

Anhydrous dimethylsulfoxide (8 mL) was added dropwise under an argon atmosphere to a mixture of sodium hydride (60% suspension in oil, 0.369 g, 9.2 mmol) and trimethylsulfoxonium iodide (2 g, 9.1 mmol). To the solution was added dropwise Compound 28a (1.2 g, 4.6 mmol) in DMSO (8 mL). The reaction mixture was stirred at room temperature for 18 h. The reaction was poured into ethyl ether:water (1:1, 50 mL). The organic layer was separated and washed successively with water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound 28b (1.9 g, 90%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.55 (d, J=8.08 Hz, 2H) 7.25 (d, J=8.3 Hz, 2H) 3.72 (s, 3H) 3.26 (s, 3H) 2.54-2.59 (m, 1H) 2.43-2.52 (m, 1H) 1.68-1.74 (m, 1H) 1.33-1.38 (m, 1H).

Step C. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid

To a solution of Compound 28b (3.6 g, 13.2 mmol) in tetrahydrofuran (45 mL) was added a solution of potassium-t-butoxide (1M in tetrahydrofuran, 50 mL, 50 mmol). To the reaction was added water (1.5 mL, 83.3 mmol), and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, ice was added to the reaction until it became homogeneous. To the solution was added ethyl ether, and the layers were separated. The aqueous layer was cooled and acidified with 1 M HCl until the pH was 4. The aqueous layer was extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound 28c (2.2 g, 73%). ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 12.4 (s, 1H) 7.62 (d, J=8.08 Hz, 2H) 7.40 (d, J=8.08 Hz, 2H) 2.46-2.54 (m, 1H) 1.88-1.96 (m, 1H) 1.46-1.52 (m, 1H) 1.38-1.44 (m, 1H).

Step D. 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole

Using the procedure of Example 1, the title Compound 28d was prepared from Compound 28c and 4-bromobenzene-1,2-diamine. ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (s, 1H) 7.68-7.75 (m, 3H) 7.60-7.64 (dd, J=1.5, 8.6 Hz, 1H) 7.46-7.56 (m, 4H) 7.10-7.14 (d, J=8.4 Hz, 2H) 2.96-3.02 (m, 1H) 2.70-2.78 (m, 1H) 2.10-2.16 (m, 1H) 2.00-2.08 (m, 1H).

Step E. 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol

Using the procedure of Example 10, the title Compound 471 was prepared from Compound 28d and Compound 10e. ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 12.4 (s, 0.5H) 12.32 (s, 0.5H) 7.88 (m, 1H) 7.65 (d, 2H, J=8.084 Hz) 7.46 (m, 2H) 7.35 (m, 2H) 7.20 (m, 1H) 6.95 (m, 2H) 4.85 (s, 1H) 2.70 (m, 1H) 2.46 (m, 1H) 1.90 (m, 1H) 1.70 (m, 1H) 1.20 (d, 6H). MS (ESI, pos. ion) m/z: 437.2 (M+1).

Using the procedures described in Example 28 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:

Cpd Name and Data 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.83-7.86 (m, 1H) 7.44-7.49 (bs, 1H) 7.31-7.36 (m, 4H) 7.21-7.26 (m, 3H) 7.055-7.13 (m, 2H) 2.60-2.65 (m, 1H) 2.40-2.44 (m, 1H) 1.84-1.90 (m, 1H) 1.62-1.70 (m, 1H) 1.32 (s, 6H). MS (ESI, pos. ion) m/z: 403.2 (M + 1). 234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-propan-2-ol ¹H-NMR (400 MHz, CD3OD) δ (ppm) 7.71-7.74 (dd, J = 1.01, 8.08 Hz, 1H) 7.40-7.45 (m, 4H) 7.33-7.38 (d, J = 8.34 Hz) 7.21-7.26 (m, 2H) 7.08-7.13 (ddd, J = 1.52, 7.58 Hz, 1H) 6.99-7.02 (dd, J = 1.52, 8.34 Hz) 6.93-6.97 (dd, J = 1.52, 7.58 Hz, 1H) 2.60-2.66 (m, 1H) 2.37-2.42 (m, 1H) 1.78-1.84 (m, 1H) 1.59-1.65 (m, 1H) 1.22 (s, 6H). MS (ESI, pos. ion) m/z: 437.3 (M + 1). 467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.52-7.62 (m, 5H) 7.33-7.41 (m, 4H) 7.24-7.32 (m, 2H) 2.70 (m, 4H) 2.48-2.53 (m, 1H) 1.90-1.96 (m, 1H) 1.69-1.75 (m, 1H). MS (ESI, pos. ion) m/z: 472.2 (M + 1), 472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenol ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.70 (bs, 1H) 7.61 (d, 2H, J = 8.34 Hz) 7.51 (m, 3H) 7.42 (m, 3H) 7.30 (m, 1H) 7.15 (m, 1H) 6.93 (m, 2H) 2.72 (m, 1H) 2.50 (m, 1H) 1.93 (m, 1H) 1.74 (m, 1H). MS (ESI, pos. ion) m/z: 395.2 (M + 1), 474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanol ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.62 (m, 3H)7.50 (m, 4H) 7.35 (m, 3H) 7.20 (m, 1H) 4.50 (s, 2H) 2.73 (m, 1H) 2.52 (m, 1H) 1.95 (m, 1H) 1.78 (m, 1H). MS (ESI, pos. ion) m/z: 409.1 (M + 1). 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.83-7.86 (m, 1H) 7.44-7.49 (d, J = 8.08 Hz, 1H) 7.34-7.40 (m, 2H) 7.14-7.28 (m, 3H) 7.12-7.18 (m, 2H) 3.80 (s, 3H) 2.60-2.65 (m, 1H) 2.31-2.35 (m, 1H) 1.78-1.82 (m, 1H) 1.62-1.70 (m, 1H) 1.34 (s, 6H). MS (ESI, pos. ion) m/z: 399.1 (M + 1). 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-propan-2-ol ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 12.30-12.40 (d, 1H) 7.84-7.87 (d, J = 7.83 Hz, 1H) 7.45-7.48 (d, J = 7.83 Hz, 1H) 7.29-7.40 (m, 6H) 7.17-7.23 (m, 1H) 6.96-7.10 (m, 2H) 2.60-2.67 (m, 1H) 2.38-2.43 (m, 1H) 1.81-1.86 (m, 1H) 1.62-1.68 (m, 1H) 1.20 (s, 6H). MS (ESI, pos. ion) m/z: 453.3 (M + 1). 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 12.5 (bs, 1H) 7.68-7.72 (d, J = 8.08 Hz, 2H) 7.40-7.60 (m, 7H) 7.28 (s, 1H) 7.21-7.25 (dd, J = 1.77, 8.34 Hz, 1H) 2.70-2.78 (m, 1H) 2.44-2.53 (m, 1H) 1.90-1.99 (m, 1H) 1.70-1.80 (m, 1H). MS (ESI, pos. ion) m/z: 422.2 (M + 1). 499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 12.40 (s, 1H) 8.2-8.3 (d, J = 9.34 Hz, 1H) 7.30-7.70 (m, 9H) 7.10-7.15 (m, 1H) 6.28-6.32 (m, 1H) 2.64-2.72 (m, 1H) 1.90-1.94 (m, 1H) 1.70-1.75 (m, 1H) 0.90 (s, 9H). MS (ESI, pos. ion) m/z: 514.2 (M + 1). 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)- cyclopropyl]-1H-benzimidazole ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 8.12-8.15 (dd, J = 1.26, 7.83 Hz, 1H) 7.70-7.83 (m, 6H) 7.53-7.57 (d, J = 8.08 Hz, 2H) 7.42-7.47 (ddd, J = 1.26, 7.32 Hz, 2H) 2.93-3.00 (m, 1H) 2.66-2.74 (m, 1H) 2.06-2.13 (m, 1H) 1.97-2.03 (m, 1H). MS (ESI, pos. ion) m/z: 457.1 (M + 1).

Prophetic Example 29

Using the procedures of Examples 27 or 28, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.

Cpd Name and Data 189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)- cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-propan-2-ol, 205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanone, 208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanol, 209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]- cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-benzenesulfonamide, 212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5- yl)-benzenesulfonamide, 218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- methanesulfonamide, 238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}- cyclopropyl)-phenyl]-methanesulfonamide, 239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- cyclopropyl)-phenyl]-methanesulfonamide, 241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol- 2-yl}-cyclopropyl)-phenyl]-methanesulfonamide, 245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide, 246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide, 247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, and 248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)- cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.

Example 30 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol (Cpd 489) Step A. (E)-5-bromo-2-(2-chloro-2-phenyl-vinyl)-1H-benzimidazole

A mixture of 4-bromo-benzene-1,2-diamine dihydrochloride (1.3 g, 5 mmol), phenylpropiolic acid (0.73 g, 5 mmol) in 4 mL of ethylene glycol was heated to reflux for 5 h. The mixture was cooled to rt and poured into water. The mixture was neutralized with 2N sodium hydroxide and filtered. The solid was suspended in water and extracted with ethyl acetate. The organic layers were combined, dried with anhydrous sodium sulfate, and filtered. The filtrate was concentrated to yield a red oil. The residue was purified using preparative TLC plates twice (silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes 3:7 and silica gel, 20×20 cm, 2000 microns, EtOAc: dichloromethane 3:97) to provide a mixture of cis and trans isomers of the title Compound 30a (0.345 g). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 12.59 (m, 1H), 7.86-7.78 (m, 3H), 7.64-7.56 (m, 1H), 7.54-7.49 (m, 3H), 7.46 (s, 1H), 7.40-7.34 (m, 1H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₁₆H₁₀BrClN₂: 333.0 (M+H), Found 333.1.

Step B. 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol

A mixture of Compound 30a (25 mg, 0.075 mmol), Compound 10e (18 mg, 0.113 mmol) and Pd(dppf)Cl₂CH₂Cl₂ (12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150° C. for 1 h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad of silica gel. The reaction was repeated total three times. The residues were combined and purified using preparative TLC plates twice (silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes 3:7 and then silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes: methanol 2:8:1) to provide the title Compound 489 (8.4 mg). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.78 (dd, 1H, J=8.1, 1.1 Hz, 1H), 7.62-7.60 (m, 2H), 7.52 (d, 1H, J=8.3 Hz), 7.46-7.38 (m, 4H), 7.31 (dt, 1H, J=1.5, 8.0 Hz), 7.21-7.17 (m, 2H), 7.02 (dd, J=7.5, 1.3 Hz, 1H), 1.30 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₄H₂₀N₂O: 353.2 (M+H), Found 353.3.

Example 31 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide (Cpd 490) Step A. N-tert-butyl-2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide

A mixture of Compound 30a (25 mg, 0.075 mmol), 2-(tert-butylamino)sulfonylphenyl boronic acid (29 mg, 0.113 mmol), and Pd(dppf)Cl₂.CH₂Cl₂ (12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150° C. for 1 h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad silica gel. The residue was purified by preparative TLC (silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes 3:7) to provide the title Compound 31a (12.8 mg). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₅H₂₃N₃O₂S: 430.2 (M+H), Found 430.3.

Step B. 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide

A mixture of Compound 31a (14.9 mg, 0.034 mmol) in trifluoroacetic acid and 1,2-dichloroethane (2 mL, 1:1) was heated at 90° C. for 3 h. The reaction was cooled to rt, and concentrated under reduced pressure. The residue was dissolved in dichloromethane, and washed with saturated sodium bicarbonate solution. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, dried with anhydrous magnesium sulfate, filtered, and the filtrate was removed under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes: methanol 5:5:1) to provide the title Compound 490 (12.1 mg). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.11 (dd, 1H, J=8.0, 1.2 Hz), 7.67-7.56 (m, 5H), 7.52 (ddd, 1H, J=7.6, 6.4, 1.4 Hz), 7.48-7.33 (m, 5H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₁H₁₅N₃O₂S: 374.1 (M+H), Found 374.2.

Using the procedures described in Examples 30 and 31, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:

Cpd Name and Data 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.04 (dd, 1H, J = 8.0, 1.2 Hz), 7.76 (d, J2H, = 8.2 Hz), 7.69 (d, 2H, J = 8.2 Hz), 7.58-7.53 (m, 2H), 7.54 (dt, 1H, J = 1.4, 7.5 Hz), 7.46 (dt, 1H, J = 1.4, 7.7 Hz), 7.31 (dd, 1H, J = 7.5, 1.3 Hz), 7.30 (dd, 1H, J = 8.4, 0.9 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₄F₃N₃O₂S: 442.1 (M + H), Found 442.2. 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.94 (s, 1H), 7.89 (d, 1H, J = 7.7 Hz), 7.80-7.74 (m, 2H), 7.66 (t, 1H, J = 7.8 Hz, 1H), 7.60-7.39 (m, 2H), 7.33 (m, 1H), 7.28-7.18 (m, 2H), 7.04 (dd, 1H, J = 7.5, 1.4 Hz, 1H), 1.32 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₅H₁₉F₃N₂O: 421.1 (M + H), Found 421.3. 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide ¹H NMR (400 MHz, CD₃OD δ (ppm): 8.11 (dd, 1H, J = 8.0, 1.2 Hz), 7.94 (s, 1H), 7.89 (dm, 1H, J = 7.6 Hz), 7.77 (dm, 1H, J = 7.9 Hz), 7.67-7.58 (m, 4H), 7.52 (m, 1H), 7.38 (dd, J = 7.5, 1.3 Hz, 1H), 7.37 (br s, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₂H₁₄F₃N₃O₂S: 442.1 (M + H), Found 442.2 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.83 (d, 2H, J = 8.2 Hz), 7.79 (dd, 1H, J = 8.2 1.1 Hz, 1H), 7.76 (d, 2H, J = 8.3 Hz), 7.64-7.37 (m, 2H), 7.33 (m, 1H), 7.22 (br d, 1H, J = 7.2 Hz), 7.20 (dt, 1H, J = 1.3, 7.4 Hz), 7.04 (dd, 1H, J = 7.5, 1.4 Hz), 1.32 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₅H₁₉F₃N₂O: 421.1 (M + H), Found 421.3. Preparation of (4-trifluoromethylphenyl)propynoic acid. To a solution of 4- ethynyl-α,α,α-trifluorotoluene (5 g, 29 mmol) in anhydrous THF (25 mL), was slowly added n-butyllithium 2.6M in hexanes (14.5 mL, 47 mmol). The mixture was stirred at −78° C. for 30 min and then at 0° C. for an additional 30 min. The mixture was cooled to −78° C. and transferred via a cannula to a saturated solution of carbon dioxide in anhydrous THF (25 mL) at −78° C. The mixture was stirred and allowed to warm to rt over 18 h. The mixture was quenched with saturated sodium chloride solution, and the two layers were separated. The aqueous layer was washed with hexanes and then acidified with 2N hydrochloric acid. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined and dried with anhydrous sodium sulfate and magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to yield the title Compound 31b as a white solid (5.4 g, 87%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 7.81 (s, 4H). Compound 31b was carried forward using the procedure of Example 31 to provide the title Compound 492.

Prophetic Example 32

Using the procedures of Examples 30 or 31, the corresponding bromobenzimidazole and, when not commercially available, the arylacetylenic acid precursors prepared as described in Reaction Scheme KK and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared. Alternatively, the following compounds may be prepared from their corresponding vinyl compounds by hydrogenation:

Cpd Name and Data 249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- phenyl}-methanesulfonamide, 264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}- methanesulfonamide, 298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}- phenyl)-methanesulfonamide, 299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- phenyl}-methanesulfonamide, 300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide, 306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide, 307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5- yl]-benzenesulfonamide, and 308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)- 1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.

Example 33 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol (Cpd. 449) Step A. 5-bromo-2-chloromethyl-1H-benzimidazole

A mixture of 4-bromo-benzene-1,2-diamine (200 mg, 1.07 mmol) and 2-chloroacetimidic acid ethyl ester hydrochloride salt (168 mg, 1.07 mmol; prepared according to the procedure described in J. Med. Chem. 1986, 29, 2280) in anhydrous ethanol (200 proof, 5 mL) was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure and extracted with ethyl acetate and water. The organic layer was dried over Na₂SO₄, filtered, and the filtrate was concentrated in vacuo to provide the title Compound 33a as an off-white solid (240 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.75 (d, 1H, J=1.4 Hz), 7.47 (d, 1H, J=8.6 Hz), 7.42 (dd, 1H, J=8.6 Hz, J=1.3 Hz), 4.84 (s, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₁₈H₂₀ClN₃O₂S: 247.50 (M+H), Found 247.0.

Step B. (5-bromo-1H-benzimidazol-2-ylmethyl)-triphenyl-phosphonium chloride

A mixture of Compound 33a (240 mg, 0.98 mmol) and triphenylphosphine (385 mg, 1.47 mmol), in 1,2-dichloroethane (10 mL) was heated at 140° C. for 1 h. The reaction mixture was concentrated under reduced pressure to provide the title Compound 33b, which was used in the next step without further purification.

Step C. (E)-6-[2-(5-bromo-1H-benzimidazol-2-yl)-vinyl]-quinoline

A mixture of Compound 33b (100 mg, 0.204 mmol), 6-quinolinecarboxaldehyde (32 mg, 0.29 mmol) and DBU (39.6 uL, 0.265 mmol) in ethanol:tetrahydrofuran (1:1, 2 mL) was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse phase preparative HPLC (10-100% gradient acetonitrile/water over 10 min) to provide the title Compound 33c as an off-white solid (50 mg, 72 yield). Calcd. For C₁₈H₁₂BrN₃: 350.21 (M+H), Found 350.2.

Step D. (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol

A mixture of Compound 33c (50.0 mg, 0.143 mmol), Compound 10e (46 mg, 0.29 mmol), PdCl₂(dppf) (23.4 mg, 0.029 mmol) and 1M sodium bicarbonate solution (1.15 mL, 1.15 mmol) in 1,2-dimethoxyethane (1 mL) was heated at reflux for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc) to provide the title Compound 449 as an off-white solid (11.8 mg, 20% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 9.01 (br s, 1H), 8.68 (d, 1H, J=8.1 Hz), 8.35 (m, 2H), 8.12-8.21 (m, 2H), 7.76 (m, 3H), 7.67 (s, 1H), 7.53 (m, 2H), 7.38-7.43 (m, 1H), 7.28 (m, 1H), 7.09 (m, 1H), 1.42 (s, 6H). Calcd. For C₂₇H₂₃N₃O: 406.5 (M+H), Found 406.3.

Using the procedures described in Example 33 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2- yl}-vinyl)-phenyl]-ethanone The title compound was prepared from Compound 33b (100 mg, 0.204 mmol) and 4-acetylbenzaldehyde (30.2 mg, 0.204 mmol) as an off-white solid (3.75 mg, 10% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (d, 1H, J = 8.8 Hz), 7.96 (m, 1H), 7.80 (m, 3H), 7.68 (m, 1H), 7.55 (m, 1H), 7.43 (m, 1H), 7.34 (m, 2H), 7.17-7.24 (m, 2H), 7.07 (m, 1H), 2.63 (s, 3H), 1.35 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₆H₂₄N₂O₂: 397.5 (M + H), Found 397.3. 450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2- yl]-vinyl}-benzamide The title compound was prepared from [5-(2-methylsulfamoyl-phenyl)-1H- benzimidazol-2-ylmethyl]-triphenyl-phosphonium chloride Compound 33c (90 mg, 0.15 mmol) and 4-carboxyaldehyde-N-isopropylbenzamide (24.3 mg, 0.15 mmol) as an off-white solid (10.5 mg, 15% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (dd, 1H, J = 8.1, Hz, J = 1.5 Hz), 7.87 (m, 2H), 7.55-7.74 (m, 7H), 7.43 (dd, 1H, J = 8.1 Hz, J = 1.5 Hz), 7.29 (m, 2H), 4.22 (m, 1H), 2.37 (s, 3H), 1.26 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₆H₂₆N₄O₃S: 475.5 (M + H), Found 475.2. 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 4-cyanobenzaldehyde (19.6 mg, 0.15 mmol) as an off-white solid (7.4 mg, 12% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.07 (dd, 1H, J = 8.0 Hz, J = 1.0 Hz), 7.49-7.69 (m. 8H), 7.37 (m, 2H), 7.20 (m, 2H), 2.32 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₈N₄O₂S: 415.5 (M + H), Found 415.2. 452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- phenyl)-acetamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 4-acetamidobenzaldehyde (24.3 mg, 0.15 mmol) as an off-white solid (11.3 mg, 17% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.04 (dd, 1H, J = 8.0 Hz, J = 1.3 Hz), 7.63 (td, 1H, J = 7.4 Hz, J = 1.4 Hz), 7.55 (m, 5H), 7.26-7.39 (m, 5H), 7.19 (dd, 1H, J = 8.1 Hz, J = 1.5 Hz), 2.22 (s, 3H), 2.03 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₂₂N₄O₃S: 447.5 (M + H), Found 447.2. 453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- benzoic acid The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 4-carboxybenzaldehyde (22.4 mg, 0.15 mmol) as an off-white solid (3.4 mg, 5% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.02 (m, 2H), 7.53-7.77 (m, 6H), 7.18-7.45 (m, 5H), 2.36 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₃H₁₉N₃O₄S: 434.5 (M + H), Found 434.2. 454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and indole-6-carboxaldehyde (21.6 mg, 0.15 mmol) as an off-white solid (6.5 mg, 10% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (m, 1H), 7.05-7.73 (m, 11H), 6.48 (m, 2H), 2.36 (m, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₂₀N₄O₂S: 429.5 (M + H), Found 429.2. 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 2,4-bis(trifluoromethyl)benzaldehyde (24.4 uL, 0.15 mmol) as an off-white solid (8.62 mg, 11% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.14-8.17 (m, 12H), 2.44 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₁₇F₆N₃O₂S: 526.5 (M + H), Found 526.3. 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 4-acetylbenzaldehyde (22.1 mg, 0.15 mmol) as an off-white solid (8.32 mg, 13% yield). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.06 (m, 3H), 7.56-7.79 (m, 9H), 7.44 (m, 1H), 2.62 (s, 3H), 2.37 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C₂₄H₂₁N₃O₃S: 432.5 (M + H), Found 432.2.

Example 34 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine (Cpd 486) Step A. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzonitrile

A mixture of Compound 10c (52 mg, 0.14 mmol), 2-cyanophenylboronic acid (38 mg, 0.26 mmol), Pd(dppf)Cl₂CH₂Cl₂ (36 mg, 0.044 mmol), tetrabutylammonium bromide (55 mg, 0.17 mmol), and sodium carbonate (1 mL, 1.0 M) in DME (5 mL) was heated at 90° C. for 18 h. The mixture was cooled to rt, filtered through a pad of Celite and concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 1:1 and hexanes: dichloromethane: methanol 6:14:1) to provide the title Compound 34a (20 mg, 37%). ¹H NMR (400 MHz, CD₃OD+CDCl₃) δ (ppm): 7.72-7.47 (m, 10H), 7.40-7.30 (m, 3H), 7.14 (d, 1H, J=16.55 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₃H₁₄F₃N₃:.390.1 (M+H), Found 390.3.

Step B. 2-{2-[2-(4-Trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine

A mixture of Compound 34a (20 mg, 0.051 mmol), Raney®-Nickel, ammonium hydroxide (0.1 mL) in ethanol was hydrogenated under 50 psi for 18 h. The mixture was filtered through a pad of Celite and washed with ethanol. The filtrate was concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, NH₃ in methanol: EtOAc 1:9) to provide the title Compound 486 (6.3 mg, 31%). ¹H NMR (400 MHz, CD₃OD) δ (ppm): 7.57-7.52 (m, 4H), 7.46-7.34 (m, 6H), 7.14 (dd, J=8.2, 1.5 Hz, 1H), 4.05 (s, 2H), 3.24 (s, 4H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C₂₃H₂₀F₃N₃: 396.2 (M+H), Found 396.2.

Example 35 (Z)-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 469)

A solution of Compound 18 (0.030 g, 0.07 mmol) in DMSO (5 mL) was stirred at room temperature for 5 days under a 60 W light bulb. The reaction was then applied to a 2000 micron prep TLC plate (20×20 cm) and developed using ethyl acetate:hexanes 4:6. The desired band was extracted with MeOH, filtered and concentrated to provide the title Compound 469 (0.001 g). ¹H-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.01, 8.34 Hz, 1H) 7.53 (s, 4H) 7.37-7.41 (m, 1H) 7.21-7.28 (m, 2H) 7.11 (dt, J=1.26, 7.33 Hz, 1H) 7.05 (dd, J=1.52, 8.34 Hz, 1H), 6.94-7.10 (m, 4H) 6.67 (d, 12.6 Hz, 1H) 1.23 (s, 6H). MS (ESI, pos. ion) m/z: 423.2 (M+1).

Example 36 (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 443) (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 477) Step A. (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

To a solution of sodium hydride (60% suspension in oil, 0.131 g, 3.2 mmol) in anhydrous tetrahydrofuran (10 mL) was added Compound 10c (1 g, 2.7 mmol). The solution was stirred at room temperature under an argon atmosphere. After five minutes methyl iodide was added (0.205 mL, 3.2 mmol), and the solution was stirred at room temperature for 3 h. The reaction mixture was partitioned between ethyl acetate (10 mL) and ice water (20 mL). The organic fraction was washed with brine, dried over magnesium sulfate, then filtered and concentrated to give a 1:1 mixture of the title Compound 36a and 36b (0.38 g).

Step B. (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide and (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide

Using the procedure of Example 1, Step B, the title compounds were prepared from a mixture of (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and 2-methylsulfonylaminophenyl boronic acid.

Cpd 443: ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.82-7.80 (m, 3H) 7.75 (d, J=8.1 Hz, 3H) 7.52-7.62 (m, 3H) 7.34-7.42 (m, 4H) 4.00 (s, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).

Cpd 477: ¹H-NMR (400 MHz, CD₃OD) δ (ppm) 7.88-7.95 (m, 3H) 7.72-7.77 (m, 3H) 7.56-7.67 (m, 4H) 7.40-7.44 (m, 3H) 4.10 (s, 3H) 2.73 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).

Example 37 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 311) Step A. (E)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(1-trimethylsilanyloxy-vinyl)-phenyl]-1H-benzimidazole

To a solution of Compound 15 (0.20 g, 0.492 mmol) in 16 mL 1,2-dichloroethane was added TBSOTf (0.19 mL, 1.08 mmol) and Et₃N (0.27 mL, 1.97 mmol) at 0° C. After 5 min., the mixture was warmed to 25° C. and stirred for 8 hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 4:1) to provide the title Compound 37a as a colorless oil.

Step B. (E)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(2-trimethylsilanyloxy-oxiranyl)-phenyl]-1H-benzimidazole

A mixture of Compound 37a (0.124 g, 0.238 mmol) and mCPBA (0.053 g, 0.238 mmol) in 10 mL CH₂Cl₂ was stirred for two hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 4:1) to provide the title Compound 37b as a yellow oil.

Step C. (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone

A mixture of Compound 37b (0.026 g, 0.048 mmol) and p-toluenesulfonic acid monohydrate (p-TsOHH₂O, 0.018 g, 0.0968 mmol) in 4 mL THF was stirred for four hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:2) to provide the title Compound 311 as a brown solid. ¹H-NMR (400 MHz, CD₃OD) δ (ppm): 7.85 (d, 2H, J=8.8 Hz) 7.74 (d, 2H, J=7.6 Hz) 7.71 (d, 1H, J=16.4 Hz) 7.63-7.47 (m, 6H) 7.33 (d, 1H, J=16.0 Hz) 7.25 (dd, 1H, J=1.6 and 8.4 Hz) 4.08 (s, 2H) MS (ESI, pos. ion) m/z: 423.3 (M+1).

Example 38 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 501) Step A. (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester

To a suspension of copper(I) trifluoromethanesulfonate toluene complex (31.0 mg, 0.12 mmol) in anhydrous CHCl₃ (3.0 mL) was added a solution of 2,2-bis-[(4S)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane (35 mg, 0.12 mmol) in chloroform (1.2 mL). After stirring at ambient temperature for 1 h, the resulting green solution was filtered through glass wool under argon atmosphere into a flask previously charged with a solution of 4-(trifluoromethyl)-styrene (0.887 mL, 6.00 mmol) in chloroform (0.9 mL). To this solution was added a solution of ethyl diazoacetate (1.56 mL, 15.0 mmol) in chloroform (12.0 mL) at ambient temperature through a dropping funnel over a period of 6 h. The resulting mixture was stirred for 24 h, concentrated to dryness, and purified by flash chromatography on a silica gel column (45 mm×140 mm silica gel), eluting with ethyl acetate/hexane (1, 1.5, 2%) to provide the title Compound 38a (892 mg, 58% yield, 98% ee) as a colorless liquid, and cis isomer (1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38b (128 mg, 5% yield calculated based on 34 wt % contamination of ethyl fumarate as analyzed by 1 NMR). The enantiomeric excess of the product was determined as described in Step E below.

¹H-NMR of Compound 38a (400 MHz, CDCl₃) δ (ppm): 7.53 (d, 2H, J=8.3 Hz), 7.23 (d, 2H, J=8.1 Hz), 4.18 (q, 2H, J=7.1 Hz), 2.55 (dd, 1H, J=2.6, 4.3, & 6.6 Hz), 1.94 (ddd, 1H, J=4.3, 5.6, & 9.6 Hz), 1.68-1.53 (m, 1H), 1.34 (1H, ddd, 4.8, 6.7, & 1.1 Hz), 1.29 (t, 2H, J=7.0 Hz).

1H-NMR of Compound 38b (400 MHz, CDCl₃) δ (ppm): 7.51 (d, 2H, J=7.9 Hz), 7.37 (d, 2H, J=7.8 Hz), 3.92-3.86 (m, 2H), 2.62-2.56 (m, 1H), 2.14 (ddd, 1H, J=5.8, 8.1 & 9.3 Hz), 1.73 (td, 1H, J=5.3 & 7.6 Hz), 1.39 (ddd, 1H, J=5.1, 7.8 & 8.6 Hz), 0.99 (t, 3H, J=7.1 Hz).

Step B. (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid

To a solution of Compound 38a (750 mg, 2.91 mmol) in ethanol (7.27 mL) was added a 1M aqueous solution of NaOH (7.27 mL). The resulting mixture was stirred at ambient temperature for 16 h, concentrated to about 4 g, acidified with 2M HCl to pH 3, and extracted with ethyl acetate (15 mL×2). The extracts were combined, washed with brine, dried over Na₂SO₄, concentrated to provide the title Compound 38c (611 mg, 91% yield) as a white solid. ¹H-NMR (400 MHz, CDCl₃ with a drop of CD₃OD) δ (ppm): 7.51 (d, 2H, J=8.3 Hz), 7.18 (d, 2H, J=8.1 Hz), 2.57 (ddd, 1H, J=4.2, 6.6, & 10.3 Hz), 1.90 (ddd, 1H, J=4.0, 5.3, & 8.3 Hz), 1.65 (dt, 1H, J=4.9 & 9.3 Hz), 1.35 (ddd, 1H, J=4.9, 6.4, & 11.1 Hz).

Step C: 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol

Using the procedure of Example 10, Steps B and E, the title Compound 501 was prepared from Compound 38c. ¹H-NMR (400 MHz, DMSO-d₆) δ (ppm): 12.40 (s, 0.5 H), 12.32 (s, 0.5 H), 7.87-7.84 (m, 1H), 7.66 (d, 2H, J=8.0 Hz), 7.49-7.17 (m, 6H), 7.00-6.96 (m, 2H), 4.84 (s, 1H), 2.72-2.67 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.86 (m, 1H), 1.74-1.68 (m, 1H), 1.19 (s, 3H), 1.18 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for C₂₆H₂₄F₃N₂O: 437.2. Found 437.3.

Step D: (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide

To a mixture of Compound 38c (50 mg, 0.216 mmol), N,O-dimethylhydroxylamine hydrochloride (30 mg, 0.30 mmol), BOP (134 mg, 0.30 mmol), and DMF (0.4 mL) was added DIEA (0.15 mL). The resulting mixture was stirred at ambient temperature for 48 h, concentrated to dryness, and partitioned between saturated NaHCO₃ (2 mL) and ethyl acetate (4 mL). The ethyl acetate layer was separated, and the aqueous layer was extracted with ethyl acetate (5 mL×2). All ethyl acetate layers were combined, washed with brine, dried over Na₂SO₄, concentrated, and purified by prep-TLC, developed with 10% ethyl acetate/DCM to provide Compound 38d (46 mg, 78% yield) as a white solid. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.52 (d, 2H, J=8.4 Hz), 7.23 (d, 2H, J=8.1 Hz), 3.70 (s, 3H), 3.24 (s, 3H), 2.56-2.52 (m, 1H), 2.45 (bs, 1H), 2.17-1.67 (m, 1H), 1.34 (ddd, 1H, J=4.6, 6.3, & 8.7 Hz).

Step E: Determination of ee

To a solution of Compound 38d (0.8 mg) in CDCl₃ (0.6 mL) was added (R)-(−)-2,2,2-trifluoro-1-(9-anthryl)ethanol portion-wise and the amount of addition was monitored by ¹HNMR until base line resolution of the resulting methoxy singlets was achieved. Thus, the enantiomer methoxy singlets were around 3.47 and 3.45 ppm. The integration of these singlets was 99 and 1, respectively; thus providing an ee value of 99%.

Using the procedure described in Example 38 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd Name and Data 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide Using the procedure of Example 38, the title compound was prepared from Compound 38c and 2-(t-butylamino)sulfonylphenyl boronic acid. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 12.42 (s, 0.5H), 12.40 (s, 0.5H), 8.04 (dd, 1H, J = 1.3 & 7.8 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63-7.34 (m, 7H), 7.17-7.11 (m, 1H), 7.06 (s, 1H), 7.03 (s, 1H), 2.71-2.65 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.87 (m, 1H), 1.75-1.70 (m, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd for C₂₃H₁₉F₃N₃O₂S: 458.1 (M + 1). Found 458.2. 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt Using the procedure of Example 38, the title compound was prepared from 2,2- bis-[(4R)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane and 4-(trifluoromethyl)- styrene. To a suspension of N,N′-bis-[(2R)-3,3-dimethyl-1-hydroxybutyl]-2,2-dimethyl- 1,3-propanediamide (83 mg, 0.25 mmol, prepared according to the procedure described in J. Am. Chem. Soc. 1991, 113, 726) in DCM (2.5 mL) was added (diethylamino)sulfur trifluoride (0.066 mL, 0.50 mmol, as described in J. Org. Chem. 2002, 67, 8566 for the formation of oxazoline from hydroxyamide) dropwise at ambient temperature. The resulting mixture was stirred at ambient temperature for 16 h, and poured into saturated NaHCO₃ (4.0 mL). The mixture was extracted with DCM (3 × 5 mL). The extracts were combined and dried over Na₂SO₄, then concentrated and flash chromatographed with ethyl acetate/ DCM (0, 5, 10, and 20%) to provide 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3- oxazolinyl)]propane (53 mg, 72% yield) as a white solid. ¹H-NMR was identical to the literature as reported by Evans. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.82 (dd, 1H, J = 1.5 & 8.1 Hz), 7.61 (d, 2H, J = 8.1 Hz), 7.37 (d, 2H, J = 8.1 Hz), 7.24 (dt, 1H, J = 1.8 & 7.3 Hz), 7.15-7.11 (m, 2H), 7.00 (d, 1H, J = 1.5 Hz), 6.98 (dd, 1H, J = 1.5 & 7.3 Hz), 6.52 (d, 1H, J = 7.8 Hz), 4.63 (bs, 1H), 2.52-2.47 (m, 1H), 2.33 (ddd, 1H, J = 4.1, 5.8 & 8.8 Hz), 1.75 (ddd, 1H, J = 3.7, 5.8, & 8.8 Hz), 1.45-1.40 (m, 1H), 1.22 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd for C₂₆H₂₄F₃N₂O: 437.2. Found 437.2. Analogous to Example 38, step A, both the trans isomer (1S,2S)-2-(4- trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38e and the cis isomer (1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38f were isolated. 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide Using the procedure described for Compound 503, the title compound was prepared from Compound 38e, 4-(trifluoromethyl)-styrene and 2-(t- butylamino)sulfonylphenyl boronic acid. ¹H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.41 (s, 0.5H), 12.40 (s, 0.5H), 8.04 (dd, 1H, J = 1.3 & 7.8 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63-7.34 (m, 7H), 7.17-7.11 (m, 1H), 7.06 (s, 1H), 7.03 (s, 1H), 2.71-2.65 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.87 (m, 1H), 1.75-1.70 (m, 1H). MS (ESI, pos. ion) m/z: 458.2 (M + 1). Mass Spectrum (LCMS, ESI pos.) Calcd for C₂₃H₁₉F₃N₃O₂S: 458.1 (M + 1). Found 458.2. 505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol Using the procedure described for Compound 503, the title compound was prepared from Compound 38f. 1H-NMR (400 MHz, CD₃OD) δ (ppm): 7.79 (dd, 1H, J = 1.0 & 8.1 Hz), 7.36-7.15 (m, 8H), 7.01 (t, 1H, J = 1.5 Hz), 6.99 (d, 1H, J = 1.5 Hz), 2.83-2.73 (m, 2H), 2.08-2.03 (m, 1H), 1.71 (td, 1H, J = 8.6 & 5.6 Hz), 1.23 (s, 3H), 1.22 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for C₂₆H₂₄F₃N₂O: 437.2. Found 437.3. Determination of ee: To a mixture of (1S,2R)-2-(4-trifluoromethyl-phenyl)- cyclopropanecarboxylic acid (14 mg, 0.0.061 mmol), (S)-(−)-α- methylbenzylamine (10.0 mg, 0.0609 mmol), BOP (27 mg, 0.0609 mmol), and DMF (0.2 mL) was added DIEA (0.023 mL, 0.13 mmol). The resulting solution was stirred at room temperature for 48 h, concentrated to dryness, and partitioned between saturated NaHCO₃ (1 mL) and ethyl acetate (3 mL). Ethyl acetate layer was separated, and aqueous was extracted with ethyl acetate (5 mL × 2). All ethyl acetate layers were combined, washed with brine, dried over Na₂SO₄, concentrated, and purified by prep-TLC, developed with 10% ethyl acetate/DCM to give the title compound (10.1 mg, 70% yield) as a white solid. 1H-NMR (400 MHz, C₆D₆) δ (ppm): 7.26 (d, 2H, J = 8.1 Hz), 7.03-6.95 (m, 5H), 6.68-6.65 (m, 2H), 4.96-4.89 (m, 1H), 4.79 (bd, 1H, J = 7.6 Hz), 1.80-1.73 (m, 2H), 1.23-1.17 (m, 1H), 1.00 (d, 3H, J = 6.8 Hz), 0.82-0.79 (m, 1H).). In the 1H-NMR doublet of the Me in (1R, 2S, 1′S)-N-(1′-phenethyl)-2-(4-trifluoromethyl- phenyl)-cyclopropanecarboxamide appeared at 0.85 ppm. Integration of this methyl doublet and that of the title compound was 2.5 and 97.5, respectively. 506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide Using the procedure of Example 38, the title compound was prepared from Compound 38b and 2-(t-butylamino)sulfonylphenyl boronic acid. 1H-NMR (400 MHz, CD₃OD) δ (ppm): 8.09 (dd, 1H, J = 1.3 & 7.9 Hz), 7.59 (dt, 1H, J = 1.6 & 7.6 Hz), 7.51 (dt, 1H, J = 1.5 & 7.8 Hz), 7.47 (bs, 1H), 7.42-7.29 (m, 6H), 7.19 (dd, 1H, J = 1.7 & 8.3 Hz), 2.84-2.74 (m, 2H), 2.05 (q, 1H, J = 6.3 Hz), 1.72 (td, 1H, J = 8.5 & 5.7 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd for C₂₃H₁₉F₃N₃O₂S: 458.1 (M + 1). Found 458.2. 507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol Using the procedure of Example 38, the title compound was prepared using Compound 38b. 1H-NMR (400 MHz, CD₃OD) δ (ppm): 7.79 (dd, 1H, J = 1.0 & 8.1 Hz), 7.36-7.15 (m, 8H), 7.01 (t, 1H, J = 1.5 Hz), 6.99 (d, 1H, J = 1.5 Hz), 2.83-2.73 (m, 2H), 2.08-2.03 (m, 1H), 1.71 (td, 1H, J = 8.6 & 5.6 Hz), 1.23 (s, 3H), 1.22 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for C₂₆H₂₄F₃N₂O: 437.2. Found 437.3. Determination of ee: Using the procedure described for Compound 506, the amide intermediate of Compound 507 was prepared from (1R,2S)-2-(4- trifluoromethyl-phenyl)-cyclopropanecarboxylic acid Compound 38 g and (S)-(−)- α-methylbenzylamine. 1H-NMR (400 MHz, C₆D₆) δ (ppm): 7.37 (d, 2H, J = 8.1 Hz), 7.35-7.02 (m, 5H), 6.97-6.95 (m, 2H), 4.95-4.88 (m, 1H), 4.82 (bd, 1H, J = 7.8 Hz), 1.81-1.75 (m, 1H), 1.70 (ddd, 1H, J = 4.8, 5.8 & 7.3 Hz), 1.14 (ddd, 1H, J = 5.6, 7.8 & 9.0 Hz), 0.85 (d, 3H, J = 6.6 Hz), 0.80-0.75 (m, 1H). In the 1H-NMR doublet of the Me in (1S, 2R, 1′S)-N-(1′-phenethyl)-2-(4- trifluoromethyl-phenyl)-cyclopropanecarboxamide appeared at 1.00 ppm. Integration of this methyl doublet and that of the title compound was 3 and 97, respectively. 508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide Using the procedure described for Compound 503, the title compound was prepared from Compound 38f and 2-(t-butylamino)sulfonylphenyl boronic acid. 1H-NMR (400 MHz, CD₃OD) δ (ppm): 8.09 (dd, 1H, J = 1.3 & 7.9 Hz), 7.59 (dt, 1H, J = 1.6 & 7.6 Hz), 7.51 (dt, 1H, J = 1.5 & 7.8 Hz), 7.47 (bs, 1H), 7.42-7.29 (m, 6H), 7.19 (dd, 1H, J = 1.7 & 8.3 Hz), 2.84-2.74 (m, 2H), 2.05 (q, 1H, J = 6.3 Hz), 1.72 (td, 1H, J = 8.5 & 5.7 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd for C₂₃H₁₉F₃N₃O₂S: 458.1 (M + 1). Found 458.2.

BIOLOGICAL EXAMPLES Example 1 Human VR1 (hVR1) Binding Assay

Compounds of the present invention were tested for their ability to inhibit the binding of [³H] RTX to hVR1 receptors in a [³H] RTX binding assay as previously described (Zhang, Sui-Po. Improved ligand binding assays for vanilloid receptors. PCT Int. Appl. (2002), WO 0233411 A1 20020425 AN 2002:315209, and Elfrida G. R. et al., J. Pharmacol. Exp. Ther., 2002, 300(1): 9-17.)

HEK293 cells were transfected with hVR1 vanilloid receptors and washed with Hank's balanced Salt Solution, dissociated with cell dissociation buffer (Sigma), and then centrifuged at 1000×g for 5 min. Cell pellets were homogenized in cold 20 mM HEPES buffer (pH=7.4), containing 5.8 mM NaCl, 320 mM sucrose, 2 mM MgCl₂, 0.75 CaCl₂ and 5 mM KCl and centrifuged at 1000×g for 15 min. The resultant supernatant was then centrifuged at 40,000×g for 15 min. The pelleted membranes were stored in a freezer at −80° C.

Approximately 120 μg protein/ml from membranes were incubated with indicated concentrations of [³H]RTX in 0.5 ml of the HEPES buffer (pH 7.4) containing 0.25 mg/mL fatty acid-free bovine serum albumin at 37° C. for 60 min. The reaction mixture was then cooled to 4° C., and 0.1 mg of a, acid glycoprotein was added to each sample, which was then incubated at 4° C. for 15 min. The samples were centrifuged at 18,500×g for 15 min. The tip of the microcentrifuge tube containing the pellet was cut off. Bound radioactivity was quantified by scintillation counting. Non-specific binding was measured in the presence of 200 nM unlabeled RTX.

Data were calculated according to the equation:

% inhibition=100%×[(total binding-binding)/(total binding-non specific binding)]

K_(i) values were calculated using a Prism program.

TABLE 1 Cpd Ki (nM) 1 9.7 3 20 4 31 5 17 9 0.9 14 380 15 41 17 8.7 18 6.5 27 1800 32 100 36 820 40 81 50 16 51 6.4 56 120 69 6 70 8.6 71 22 78 6.4 79 18 310 10 312 19 319 6 407 5.7 434 39

Example 2 Human VR1 (hVR1) Functional Assay

The functional activity of the test compounds was determined by measuring changes in intracellular calcium concentration using a Ca⁺⁺-sensitive fluorescent dye and FLIPR™ technology. Increases in Ca⁺⁺ concentration were readily detected upon challenge with capsaicin.

HEK293 cells expressing hVR1 were grown on poly-D-lysine coated 384 well black-walled plates (BD 354663) and 1 day later loaded with Calcium 3 Dye for 35 min at 37° C., 5% CO₂ and then for 25 min at room temperature, and subsequently tested for agonist-induced increases in intracellular Ca²⁺ levels using FLIPR™ technology. Cells were challenged with test compounds (at varying concentrations) and intracellular Ca²⁺ was measured for 5 min prior to the addition of capsaicin to all wells to achieve a final concentration of 0.030 μM eliciting about 80% maximal response. IC₅₀ values were determined from concentration-response studies, which were generated using the average of quadruplicate wells for each data point.

For those compounds tested, an IC₅₀ (nM) value and percent inhibition value is shown in Table 2. Except where indicated, the percent inhibition values were obtained at a test concentration of 1 μM; otherwise: ⁽¹⁾the test concentration was 5 μM. The percent inhibition value is provided for those compounds where an IC₅₀ value was not obtained. The term “NA” means that the data is “not available” because it was not obtained for a particular compound.

TABLE 2 Cpd % Inh IC₅₀ 1 100 27 2 100 12 3 NA 140 4 78 400 5 100 71 6 12 NA 7 10 NA 8 10 NA 9 99 2 10 94 280 11 100 210 12 100 10 13 82 310 14 49 1000 15 100 120 16 100 45 17 100 8 18 100 4 19 32 NA 20 NA 320 22 NA 18 24 8 NA 25 4 NA 26 6 NA 27 100 260 28 96 250 29 6 NA 30 10 NA 31 NA 13 32 77 380 33 NA 1700 34 ⁽¹⁾75 NA 35 100 41 36 44 NA 37 18 NA 38 89 270 39 98 200 40 99 54 41 90 280 42 100 22 43 58 890 44 95 300 45 100 16 46 100 46 47 100 20 48 33 NA 49 16 NA 50 100 100 51 100 66 52 28 NA 53 98 47 54 20 NA 55 14 NA 56 100 110 57 15 NA 58 87 95 59 80 440 60 7 NA 61 100 75 62 100 200 63 97 260 64 41 NA 65 0 NA 66 98 48 67 98 130 68 NA 329 69 98 6 70 100 7 71 99 22 77 100 76 78 99 5 79 100 7 83 NA >500 84 100 40 85 16 NA 95 81 301 101 NA >500 113 48 NA 114 99 3 129 96 34 130 100 6 131 96 31 139 98 31 145 19 NA 175 100 16 190 94 38 198 95 10 234 7 NA 250 98 19 294 101 9.1 295 100 16 309 73 NA 310 100 6 311 99 54 312 100 6 314 100 18 315 100 11 316 101 12 317 101 11 318 100 50 319 100 10 320 100 13 321 100 18 322 101 14 323 97 40 324 98 33 325 73 NA 326 89 157 327 77 343 328 99 35 329 98 27 330 85 131 331 97 43 332 98 49 333 98 27 334 94 178 335 100 47 336 89 240 337 96 14 338 96 104 339 99 27 340 98 62 341 99 6 342 98 24 343 82 243 344 101 24 345 101 13 346 87 264 347 100 44 348 86 162 349 99 59 350 100 33 351 NA >500 357 100 8 358 99 9 359 98 24 360 98 46 361 97 27 362 99 8 363 98 12 364 97 65 365 99 17 366 99 35 367 98 53 368 99 15 369 99 8 370 98 13 371 98 18 372 97 71 373 99 20 374 99 34 375 97 139 376 100 28 378 100 12 379 99 40 380 99 12 383 96 11 384 98 7 385 97 21 386 96 43 387 98 41 388 99 54 389 23 NA 390 96 7 391 95 8 392 97 10 393 98 10 394 98 6 395 99 15 396 99 13 397 99 23 398 97 3 399 97 3 402 93 38 404 94 47 405 95 20 406 97 170 407 96 9 408 64 NA 409 43 NA 410 91 156 411 85 350 412 86 190 413 82 240 414 98 140 415 95 150 416 96 120 417 100 11 418 100 18 419 93 32 420 93 15 421 95 10 422 98 7 423 99 11 424 99 11 425 2 NA 426 99 22 427 98 13 428 100 7 429 98 6 430 100 9 431 97 35 432 98 15 433 98 10 434 98 7 435 97 20 436 96 10 437 97 24 438 96 71 439 97 23 440 98 40 441 40 NA 442 96 4 444 98 28 445 96 20 446 97 76 447 98 44 448 99 17 449 100 9 450 27 NA 451 101 28 452 5 NA 453 22 NA 454 36 NA 455 100 17 456 100 45 457 22 NA 458 15 NA 459 0 NA 460 21 NA 461 99 5 462 98 97 463 100 14 464 100 3 465 75 363 466 98 71 467 86 182 468 97 8 469 99 7 470 97 45 471 100 10 472 NA >500 473 NA >500 474 NA >500 475 NA 77 476 NA 68 477 44 NA 478 NA >500 479 12 NA 480 NA >500 481 42 NA 482 100 13 483 21 NA 484 NA >500 485 NA >500 486 NA >500 487 20 NA 488 4 NA 489 96 2 490 99 26 491 NA 77 492 99 5 494 93 52 497 94 39 498 100 19 499 7 NA 500 97 19 501 99 85 502 82 190 503 93 10 504 95 22

Example 3 Chemically-Induced Models of Inflammatory Pain

Compounds of the present invention were tested in animal models of inflammation and inflammatory pain. To assess the ability of test compounds to reverse thermal hyperalgesia, baseline response latencies on a radiant heat (RH) paw stimulator were obtained before an intraplantar injection of 100 μL (1 μg/μL) CFA (1:1 CFA:saline) in male Sprague-Dawley rats. Only withdrawal responses that were quick hind paw movements (with or without licking of the hind paw) were recorded. Paw movements associated with locomotion or a shifting of weight were not considered a withdrawal response. The stimulus intensity that produced 10-15 sec baseline withdrawal latencies was used and a maximum cutoff of 20 sec was imposed. Hypersensitivity was evaluated 24 hr after CFA. Only rats that exhibited at least a 25% reduction in response latency from baseline (i.e. hyperalgesia) were included in further analysis.

Following the post-inflammogen latency assessment, rats were orally dosed (2.5 mL/kg) with test compound (10 mg/kg) or vehicle (20% hydroxypropyl beta cyclodextran). To determine the time of peak effect, latencies were redetermined 30, 60, 100, 180 and 300 min after compound administration.

Data are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:

% reversal=100%×(treatment response−post-inflammogen response)/(pre-inflammogen response−post-inflammogen response)

TABLE 3 Cpd % Reversal 17 104 18 133 22 18 23 31 31 72 47 58 70 76 78 19 114 56 310 23 464 65

Example 4 Incision-Induced Model of Postoperative Surgery

Compounds of the present invention were tested in animal models of postoperative surgery, as previously described (Brennan, T. J. et al., Pain, 1996, 64: 493-501). Male Sprague-Dawley rats were anaesthetized with 2-3 isoflurane and the plantar surface of the hindpaw was sterilized using three alternating betadine and alcohol scrubs. A 1 cm longitudinal incision through the skin of the plantar paw was made using a number 10 scalpel beginning 0.5 cm from the proximal heel and extending toward the toes. The plantaris muscle was excised using a forcep and incised longitudinally. The skin was then sutured in two locations using 5-0 silk. The wound site was then covered with antibiotic ointment and the animals were returned to their individual home cages. Changes in thermal sensitivity were evaluated before surgery and 24 hr after surgery. Vehicle (20% HPβCD) or test compound was orally administered and thermal sensitivity was re-assessed 30, 60, 100, 180 and 300 min later.

Data are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:

% reversal=100% (treatment response−post-inflammogen response)/(pre-inflammogen response−post-inflammogen response)

TABLE 4 Cpd % Reversal 18 132

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

All publications disclosed in the above specification are hereby incorporated by reference in full. 

1-14. (canceled)
 15. A method for treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of the compound of claim Formula (I):

and a salt, stereoisomer, tautomer or ester thereof, wherein: the dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond, wherein when a double bond is formed between positions 1 and 2, then R_(3b) is present, and wherein, when a double bond is formed between postions 2 and 3, then R_(3a) is present; p is 1 or 2; q is 0 or 1; r is 0, 1, 2 or 3; L is C₁₋₃alkyl, C₂₋₃alkenyl, C₂₋₃alkynyl or cyclopropyl; A₁ is selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole; R₁ is each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, C₁₋₆alkylcarbonyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₄alkyl, C₃₋₈cycloalkyl-C₁₋₄alkoxy, C₃₋₈cycloalkyl-oxy, amino, (C₁₋₆alkyl)₁₋₂-amino, (C₃₋₈cycloalkyl)₁₋₂-amino, (C₃₋₈cycloalkyl-C₁₋₄alkyl)₁₋₂-amino, aminocarbonyl, (C₁₋₆alkyl)₁₋₂-aminocarbonyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkoxycarbonylamino, aminocarbonylamino, (C₁₋₆alkyl)₁₋₂-aminocarbonylamino, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfinylamino, aminosulfonyl, (C₁₋₄alkyl)₁₋₂-aminosulfonyl, aminosulfonylamino and (C₁₋₆alkyl)₁₋₂-aminosulfonylamino, wherein alkyl is optionally substituted with C₁₋₈alkoxy, amino, (C₁₋₄alkyl)₁₋₂-amino, C₁₋₆alkylcarbonylamino, C₁₋₆alkoxycarbonylamino, aminocarbonylamino, (C₁₋₆alkyl)₁₋₂-aminocarbonylamino, C₁₋₆alkylsulfonylamino, aminosulfonylamino, (C₁₋₆alkyl)₁₋₂-aminosulfonylamino hydroxy and phenyl, wherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio and C₁₋₆alkylsulfonyl, and wherein, each instance of alkyl and alkoxy is optionally perfluorinated; R₂ is selected from the group consisting of halogen, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkylsulfonyl, nitro, amino, (C₁₋₄alkyl)₁₋₂-amino and cyano, wherein each instance of alkyl and alkoxy is optionally perfluorinated; R_(3a) and R_(3b) are each selected from the group consisting of hydrogen and optionally perfluorinated C₁₋₄alkyl; and R₄ is each selected from the group consisting of halogen, nitro, cyano, carboxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, C₁₋₆alkoxy-C₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkylthio, haloC₁₋₆alkylthio, C₁₋₆alkylsulfonyl, haloC₁₋₆alkylsulfonyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₄alkyl, C₃₋₈cycloalkyl-C₁₋₄alkoxy, C₃₋₈cycloalkyl-oxy, amino, (C₁₋₆alkyl)₁₋₂-amino, (C₃₋₈cycloalkyl)₁₋₂-amino, (C₃₋₈cycloalkyl-C₁₋₄alkyl)₁₋₂-amino, aminocarbonyl, (C₁₋₆alkyl)₁₋₂-aminocarbonyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkoxycarbonylamino, aminocarbonylamino, (C₁₋₆alkyl)₁₋₂-aminocarbonylamino, C₁₋₆alkylsulfonylamino, haloC₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfinylamino, aminosulfonyl and (C₁₋₄alkyl)₁₋₂-aminosulfonyl, wherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C₁₋₈alkoxy, amino, (C₁₋₄alkyl)₁₋₂-amino, C₁₋₆alkylcarbonylamino, C₁₋₆alkoxycarbonylamino, aminocarbonylamino, (C₁₋₆alkyl)₁₋₂-aminocarbonylamino, C₁₋₆alkylsulfonylamino, oxo and hydroxy, and wherein, each instance of alkyl and alkoxy is optionally perfluorinated.
 16. The method of claim 15, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
 17. The method of claim 15, wherein the effective amount of the compound of claim 1 is in a range of from about 0.001 mg/kg/day to about 300 mg/kg/day. 18-20. (canceled) 